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The central role of T helper 2 cells in allergic asthma
Asthma is a common, heterogeneous chronic disease of the conducting airways which is typically 
characterized by episodes of bronchoconstriction, airway hyperreactivity, mucus overproduction 
and airway inflammation. Asthma patients experience symptoms such as wheezing, shortness 
of breath and chest tightness. Asthma exacerbations are often induced by rather diverse stimuli 
including allergens (e.g. house dust mite (HDM), fungal spores, animal dander or tree or plant 
pollen), respiratory infections, irritants, exercise and change in weather. Worldwide, over 300 million 
people suffer from asthma. The majority of asthma patients responds well to standard treatment with 
inhaled corticosteroids, β2-adrenergic receptor agonists and oral leukotriene inhibitors1, 2. However, 
a subgroup of patients does not achieve disease control with these agents. Therefore, it is necessary to 
establish additional therapeutic approaches to treat asthma patients. 
Allergic asthma is the most common type of asthma which typically presents as eosinophilic 
inflammation3-5. Allergic asthma is generally thought to be induced by lung resident DCs that 
continuously sample the airway lumen for the presence of allergens. In addition to allergenic stimuli, 
DCs can become activated by epithelial-derived cytokines including thymic stromal lymphopoietin 
(TSLP), interleukin (IL)-25, IL-33 and granulocyte-macrophage colony stimulating factor (GM-CSF)6 
(Figure 1). Once activated, DCs mature and are attracted to draining lymph nodes by Chemokine (C-C 
motif) ligand 19 (CCL19), produced by reticular stromal cells, which binds to C-C chemokine receptor 
type 7 (CCR7) expressed by mature DCs and naïve T cells7. Upon antigenic stimulation by DCs, T helper 
2 (Th2) cell differentiation is initiated. After subsequent allergen exposure, allergen-specific Th2 cells 
migrate to the lungs. Th2 cells are potent producers of the cytokines IL-4, IL-5 and IL-13 that explain many 
hallmarks off allergic asthma. IL-4 induces Th2 cell differentiation as well as IgE class switching of B 
cells, development of mast cells and mucous metaplasia8. IL-5 is required for the growth, maturation and 
activation of eosinophils9. IL-13 causes smooth muscle hyperreactivity and goblet cell hyperplasia10 (Figure 1).
In addition to Th2 cells, type 2 innate lymphoid cells (ILC2) contribute to allergic asthma by producing 
IL-5 and IL-13 in response to environmental signals including TSLP, IL-25 and IL-3311, 12. IL-13, produced by 
ILC2, was shown to induce migration of activated lung dendritic cells into the draining lymph node as 
well as production of the Th2 cell-attracting chemokine CCL17 by DCs in an asthma model induced by the 
protease-allergen papain13, 14. Moreover, it was suggested that ILC2 can crosstalk with T cells since ILC2 
can, like DCs, also express major histocompatibility complex class II (MHCII), OX40L, CD80 and CD86. 
In addition, IL-2, derived from activated T cells can in combination with IL-33 lead to ILC2 stimulation15.
T helper cell differentiation
Activated migratory DCs mature and enter tissue draining lymph nodes where they activate naïve CD4+ T 
cells16. T cell activation requires three signals; (1) T cell receptor (TCR) stimulation with antigenic peptides 
in the context of MHCII, (2) co-stimulation via CD28-CD80/CD86 engagement and (3) cytokine signals17, 
18. Upon activation, T cell acquire various cell surface receptors including CD69, CD25 (IL-2 receptor alpha 
chain) and CD44. In addition, T cells downregulate expression of the L-selectin CD62L and start secreting IL-
2. Activated T cells proliferate in the lymph nodes for a maximum time of 1 week after which they migrate to 
the tissue of interest19. To migrate from the draining lymph nodes to the lungs, Th2 cells require expression 
of CCR4 which binds to its ligands CCL17 and CCL22 which are overexpressed in inflamed airways, with 
DCs being their major source20. Other chemokine receptors that have been implicated in the homing of Th2 
cells to the lungs are CCR5, CXCR3, CCR6 and CCR821. Egress of Th2 cells from the draining lymph nodes is 
mediated by Sphingosine-1-phosphate receptor 1 (S1PR1) which binds to sphingosine 1-phosphate (S1P)22.
In 1986 it was observed that CD4+ T cells can be divided into two subsets based on their cytokine production; 
Th1 cells and Th2 cells23. Today, we know at least six T cell lineages: Th1, Th2, Th9, Th17, T follicular helper 
(Tfh) and T regulatory (Treg) cells, characterized by their unique cytokine production profile, which is 
required to provide host protection against specific pathogens (Figure 2)24-26. For each T cell subset, key 
transcription factors have been identified. Additionally, T cell subsets are characterized by the expression 
of distinct members of the signaling transducer and activator (STAT) family. Moreover, depending on CD4+ 
T cell activation, polarization and differentiation, the chemokine receptor profile expressed by T helper cells 
is altered, which in part is maintained in memory T cells after the inflammatory response is resolved21. 
Therefore, the differential expression of chemokine receptors can be helpful in identifying distinct T helper 
subtypes (Figure 2).
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Figure 1. The central role of Th2 cells in allergic asthma
DCs can become activated by allergenic stimuli as well as epithelial-derived cytokines that also activate ILC2. Once activated, DCs migrate 
to draining lymph nodes which is supported by CCL19 produced by reticular stromal cells and IL-13 produced by ILC2. Antigenic stimulation 
of naïve T cells by DCs, together with cytokine signals induces Th2 cell differentiation. Th2 cells are potent producers of cytokines that 
induce IgE class switching of B cells, which induces activation of mast cells (IL-4), maturation and activation of eosinophils (IL-5) and 
smooth muscle hyperreactivity and goblet cell hyperplasia (IL-13).
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Th1
Th1 cells are associated with the elimination of intracellular pathogens. Th1 cells also help B cells in 
IgG class-switching which is required for pathogen opsonization27. Th1 polarization is driven by IL-12 
signaling via STAT4 and induction of the key Th1 transcriptional regulator T-box-containing protein 
(T-bet), encoded by Tbx21 expression. Th1 cells produce interferon gamma (IFN-γ) and Tumor Necrosis 
Factor alpha (TNF-α) which attract neutrophils and activate macrophages28, 29. 
Th2
Th2 cells have an important role in controlling helminth infections, eliminating extracellular 
microbes and for B cell help in humoral immunity30. Biased Th2 responses, on the other hand, 
can lead to allergies and asthma. Gata3 has been widely accepted as the key regulator of Th2 cell 
differentiation31, 32. Th2 differentiation is driven by IL-4 via STAT6 signaling and leads to the production 
of IL-4, IL-5 and IL-13. However, this raises the paradox that IL-4 is required to generate the cell type 
that is its major producer. The origin of the first IL-4 required for Th2 cell induction remains unclear. 
Several cell types including basophils, Tfh cells, NKT cells and type 2 innate lymphocytes (ILC2) are 
capable of producing IL-433-40. However, Th2 cell responses can still be generated when only T cells can 
make IL-4, arguing against an essential role for an external source of IL-441, 42.
Th9
Th9 cells are closely related to the Th2 lineage and provide protection against helminth infections43. 
Like Th2 cells, Th9 cells require IL-4 signaling via STAT6 to differentiate but in addition require the 
presence of transforming growth factor beta (TGF-β)44. The transcription factors PU.1 and Interferon-
regulatory factor 4 (IRF4) are required for Th9 cell differentiation and induce IL-9 production45, 46. 
Th17
Th17 cells provide protection against bacteria and fungi at mucosal surfaces but are also the main 
drivers of auto-immune diseases25. Th17 cells play a role in moderate to severe asthma47. Th17 cells are 
induced in response to IL-6, IL-23, and TGFβ48-51. Via STAT3, IL-6 induces expression of retinoic acid 
receptor-related orphan nuclear receptor gamma (Rorγt), leading to production of Th17 cytokines IL-17 
and IL-2252, 53.
T regulatory cells
Tregs can be classified into thymic-derived naturally occurring Tregs and inducible Tregs, both of 
which suppress immune responses and maintain peripheral tolerance54-57. Differentiation of Tregs 
requires high concentrations of TGF-β, with the absence of proinflammatory cytokines58. Cell-cell 
contact and IL-10 secretion is required for suppressor function, mediated through STAT5-induced 
activation of the lineage-specific transcription factor forkhead box P3 (Foxp3)59, 60. 
T follicular helper cells
Tfhs are involved in providing help for B cell class-switching for immunoglobulin production and 
germinal center formation61. Tfhs are characterized by expression of the transcription factor BCL-
662-64 and by CXCR5 by which Tfhs are attracted towards CXCL13 present in the B cell zone65. Tfh 
differentiation requires activation of the inducible costimulator (ICOS) and IL-21, IL-6 and STAT3 
signaling66. Recent studies have indicated that Tfhs, depending on the stimulus, can differentiate 
into effector cells67. In this context, it was shown that Tfhs are crucial for Th2 mediated inflammation 
and intranasal sensitization with HDM induces differentiation and expansion of IL-4 producing 
Tfh cells in the draining lymph nodes34, 68, indicating that Tfhs can be precursors of effector Th2 
cells. Apart from Th2 cells, more similarities between Tfh cells and other T helper subsets have been 
described. Depending on the inflammatory environment, Tfh cells can acquire low to intermediate 
levels of T-bet, Gata3, or Rorγt which results in a variety of Tfh cell subsets that can express low levels 
of specific cytokines capable of influencing B cell class-switching67, 69. Another Tfh subset that has 
recently been described are Foxp3+ T follicular regulatory (Tfr) cells which act on multiple levels as 
regulators of the germinal center reaction70.
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Figure 2. T helper cell differentiation
Once activated via TCR triggering by DCs, naïve T helper cells differentiate into various T helper cell lineages depending on the cytokine 
signals. Each lineage is defined by a critical transcription factor, expression of chemokine receptors and secretion of specific cytokines.
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The role of lung dendritic cell subsets during T helper cell differentiation
During steady-state, at least three DC subsets can be identified in the lungs; 2 types of conventional 
DCs (cDC1 and cDC2) and plasmacytoid DCs (pDCs)71. Depending on cytokine signals ‒ all three DC 
subsets depend on the cytokine FMS-like tyrosine kinase 3 ligand (Flt3L) ‒ and transcription factors, all 
of these subsets arise from hematopoietic stem cell (HSC) derived DC precursors and are characterized 
by expression of CD11c and MHCII72. Different functions were described for the various DC subsets 
during T cell activation, as well as during inflammatory responses. cDC1s depend on IFN-regulatory 
factor 8 (IRF8), ID2, Basic Leucine Zipper ATF-Like Transcription Factor 3 (BATF3), and Nuclear-factor 
interleukin-3 related protein (Nfil3) and are in the lungs characterized by CD103 expression. cDC1s 
are located underneath the epithelium of the large conducting airways and sense for the presence of 
antigens by protruding their dendrites into the airway lumen. cDC1s excel at cross-presenting and 
are required for the induction of CD8+ T cells in immune responses against viruses and tumors73-75. In 
contrast, cDC1s were shown to dampen Th2 and Th17 responses76-78.
cDC2 development requires various transcription factors including IRF4, v-rel avian 
reticuloendotheliosis viral oncogene homolog B (RELB), the Notch pathway nuclear effector 
Recombination Signal Binding Protein For Immunoglobulin Kappa J Region (RBPJκ; also known as 
CSL) and PU.1. Lung cDC2 typically express CD11b and are located underneath the epithelium in the 
lung lamina propria. cDC2s take up antigens efficiently, migrate to draining lymph nodes and are 
essential for both Th2 and Th17 cell priming79-82.
pDC development depends on E2-2 and these cells are involved in anti-viral responses by producing 
type I interferons83-85. In addition, pDCs were implicated in the induction of Tregs86-88 and have a 
tolerogenic role in allergic airway inflammation89, 90.
During inflammatory responses, monocytes that migrate to the site of inflammation give rise to a 
fourth DC subset, the monocyte-derived DC (moDC)91. Like cDC2, moDCs express CD11c, MHCII and 
CD11b. In addition, like macrophages, moDCs express CD64 and FcεRI on the cell surface, are poor at 
migrating but are involved in locally amplifying inflammation80.
To conclude, Th2 inflammation seems to be dependent on T cell activation and maintenance by 
cDC2 and moDCs, while cDC1s and pDCs have a more tolerogenic role. The capacity of DCs to induce 
T cell subset differentiation largely depends on the nature of DC activation, which determines the 
expression of co-stimulatory molecules and cytokines by DCs92. DCs can for example be activated 
by epithelial cell-derived cytokines including IL-33, IL-25, TSLP and GM-CSF as well as by antigenic 
triggering via pattern-recognition receptors. Co-stimulatory molecules expressed by DCs that are 
involved in Th2 cell differentiation include CD40, OX40L and the Notch ligand Jagged93-95. 
The Notch signaling pathway
The Notch signaling pathway is highly conserved and was first identified 100 years ago in fruit flies96. 
The Notch pathway mediates cell-cell contact-dependent signaling which regulates cell proliferation, 
apoptosis and a broad array of cell fate decisions and differentiation processes in neuronal, cardiac, 
endocrine and immune development and adult tissue homeostasis. Vertebrates carry four Notch 
receptors (Notch1–4) that are bound by five membrane-bound Notch ligands (Delta-like ligand (DLL) 1, 
3, and 4 and Jagged 1 and 2). Notch receptors are transmembrane proteins composed of an extracellular 
(NECD), transmembrane (TM), and intracellular (NICD) domain. Newly generated Notch receptors are 
cleaved and glycosylated in the endoplasmic reticulum and Golgi apparatus, generating a heterodimer 
composed of NECD noncovalently attached to the TM-NICD inserted in the membrane. The capacity of 
different Notch ligands to trigger Notch receptor signaling is dependent on the glycosylation status of 
NECD by Fringe proteins. Fringe is a glycosyltransferase that adds N-acetylglucosamine to O-fucose 
residues present on the receptor97, 98. When Notch receptors carry these extra sugar moieties, Jagged-
mediated Notch signaling is inhibited while the NECD preferentially signals via DLL99. Initiation of 
Notch signaling starts with ligand-receptor interaction between neighboring cells which leads to two 
consecutive proteolytic cleavages of the receptor. Notch receptors are first cleaved by metalloproteases 
from the A disintegrin and metalloproteinases (ADAM) family, which cleave the NECD external to the 
transmembrane domain. The released NECD is endocytosed by the ligand-expressing cell, which is 
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Figure 3. The Notch signaling pathway
After glycosylation by Fringe, initiation of Notch signaling starts with ligand-receptor interaction between neighboring cells, which 
leads to two consecutive proteolytic cleavages of the receptor. First the Notch extracellular domain (NECD) is cleaved by ADAM family 
metalloproteases, after which the released NECD is endocytosed by the ligand-expressing cell. This process is mediated by mindbomb 
and neuralized family E3-ubiquitin ligases, both of which are also required for the expression and function of Notch ligands. The second 
cleavage of the transmembrane domain is mediated by γ-secretase after which the Notch intracellular domain (NICD) is liberated. 
NICD subsequently translocates to the nucleus and heterodimerizes with the transcription factor RBPJκ which leads to recruitment of 
coactivators including MAML which together form a transcriptional activator complex in order to induce transcription of downstream target 
genes. Abbreviations are as follows: ADAM, A disintegrin and metalloproteinases; MAML, Mastermind-like; RBPJκ , Recombination-signal-
binding protein for immunoglobulin Jκ region.
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Delta-like ligand (DLL) and Jagged instruct Th1 and Th2 cell differentiation, respectively93. However, 
since the identification of the importance of Notch signaling in multiple T helper cell subsets, this 
bipotential instructional model will not be sufficient to fully explain the function of Notch signaling 
in Th cell differentiation. In contrast to this model, it was hypothesized that Notch signaling can 
act as a general amplifier of Th cell 
responses rather than an instructive 
director of specific T helper cell 
programs. This hypothesis was 
based on the observation that 
Notch signaling simultaneously 
induced Th1, Th2 and Th17 gene 
transcription, also under polarizing 
conditions that were described to 
favor only one of the differentiation 
outcomes135. Moreover, Notch 
signaling was shown to increase 
antigen sensitivity of CD4+ T cells 
via promoting co-stimulatory 
signals in T cells and required for 
optimal T cell expansion, CD25 
and IL-2 induction and to promote 
survival by enhancing anti-apoptotic 
signals and glucose uptake107-110, 149, 
150. Therefore, it is currently unclear 
whether Notch acts as a bipotential 
instructor or as an unbiased 
amplifier during T helper cell 
differentiation.
Next to its well described role in 
CD4+ T cells, Notch is also required 
for the differentiation and function 
of other T cell subsets including 
CD8+ T cells and NKT cells. CD8+ 
T cells are activated by MHC class 
I expressing cells and exert their 
cytotoxic function by secreting 
IFN-γ, by lysis of target cells with 
perforins and granzymes and by 
induction target cell apoptosis 
through FAS-FAS ligand binding. 
DLL1 and Notch2 have the capacity 
to induce Granzyme B production 
mediated by mono-ubiquitinylation of the cytoplasmic tail of the ligands by mindbomb and neuralized 
family E3-ubiquitin ligases. The second cleavage of the transmembrane domain is mediated by activity 
of a γ-secretase complex after which NICD is liberated. NICD subsequently translocates to the nucleus 
and heterodimerizes with the DNA binding transcription factor RBPJκ. NICD binding to RBPJκ leads to 
recruitment of other coactivators including proteins of the Mastermind-like family (MAML) to form a 
transcriptional activator complex in order to induce transcription of downstream target genes (Figure 
3)100. Notch target genes include members of the Hairy enhancer of split (Hes) or Hairy related (Hey or 
Hrt) genes101, 102, as well as many others, dependent on the tissue. Studies using genome-wide expression 
and chromatin immunoprecipitation (ChIP) arrays found a large number of genes that can be directly 
regulated by Notch103, 104. Moreover, there is emerging data suggesting that Notch can crosstalk to or 
cooperate with other signaling pathways (including mammalian target of rapamycin (mTOR), protein 
kinase PKCθ, NF-κB, hypoxia, glucose uptake, IL-2R or TGF-βR) and thereby broaden the spectrum of 
target genes that are influenced by Notch signaling105-115.
Notch signaling during T cell development and differentiation
Notch signaling drives and regulates a wide range of developmental stages of various cell types (Figure 
4)116. The importance of Notch signaling during T cell development is well studied. A Notch1 signal in 
bone marrow progenitors is required for cells to commit to the T cell lineage and to inhibit development 
of other cell types in the thymus such as myeloid cells and B cells117-123. For this, DLL4 expression by 
thymic epithelial cells is crucial124-126. Notch1 is especially required to restrict developing αβ T cells to the 
T cell lineage during early developmental stages up to the double-negative 3 (DN3) stage127. In this CD44-
CD25+ DN3 stage, first the TCRβ gene locus is rearranged and functionality of the TCRb chain is tested 
by cell surface expression of the pre-TCR, a process called β -selection. After β-selection, DN3-large and 
DN4 thymocytes proliferate before becoming CD4+CD8+ double positive (DP) cells, which subsequently 
undergo TCRα rearrangement to obtain a completely assembled TCR. Since thymocytes immediately 
downregulate Notch1 expression after successfully passing β-selection, double-positive (CD4+CD8+) 
thymocytes have very low levels of Notch signaling128. 
An accumulating number of studies suggest that the Notch signaling pathway is essential for CD4+ T cell 
differentiation. Notch signaling is able to induce Th2 cell differentiation by direct activation of (1) a 3’ 
enhancer of the Il4 gene, and (2) an upstream promoter of Gata339, 93, 129, 130. 
Moreover, Notch signaling is essential for Th2 cell-mediated responses in vivo93, 130-134. The role of Notch 
signaling in Th1 cell differentiation remains poorly understood. The signature Th1 genes Ifng and 
Tbx21 were identified as direct Notch targets135, 136. However, while some research groups found that 
Notch1 and Notch2 are required for Th1 cell function, others demonstrated that Th1 cell function was 
unaffected when components of the Notch signaling were deleted129-131, 135-137. Notch signaling cooperates 
with TGF-β to induce Th9 cell differentiation and IL-9 expression via Jagged2 ligation138. Also, Th17 cell 
differentiation is decreased when Notch signaling is blocked and the Rorc, Il17 and Il23r gene promoters 
are identified as direct Notch targets139-143. In addition, the key Treg transcription factor Foxp3 is a 
direct Notch target differentiation and Treg function requires Notch signaling in T cells105, 144-146. Lastly, 
Notch signaling is required for the differentiation of Tfh cells147, 148. In summary, Notch signaling is 
essential for the differentiation of multiple T helper cell subsets.It was suggested that Notch ligands 
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Figure 4. The function of Notch signaling during T cell development, 
differentiation and function 
Scheme of T cell development and differentiation, showing the main lineage 
decisions during T cell development and T helper subset differentiation. Notch 
receptors or ligands that are required (if known) during these processes are 
indicated in red. Abbreviations are as follows: CLP, common lymphoid progenitor; 
CMP, common myeloid progenitor; DLL, Delta-like ligand; DN, double-negative; 
DP, double-positive; HSC, hematopoietic stem cell; Jag, Jagged; MPP, multipotent 
progenitor; NK, Natural killer.
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and to improve cytotoxic activity of CD8+ T cells151, 152. NKT cells contribute to host immunity by rapidly 
producing cytokines including IL-4, IFN-γ and IL-17 upon antigen recognition33, 153. It was shown in 
mice with a conditional deletion for Notch1 and Notch2 or RBPJκ that Notch signaling coordinates NKT 
cell differentiation and function by positively regulating IFN-γ and IL-4 expression, and impairing 
IL-17 secretion39, 154.
Collectively, an increasing number of studies showed a role for Notch in the development and 
function of a range of T cell subsets. Still, there is many contradicting data. Therefore, more in vivo 
loss-of-function experiments would help to exactly elucidate the role of Notch signaling in T cell 
development, differentiation and function.
Notch signaling during other cell-fate decisions
Next to the well-established role for Notch signaling during T cell development, Notch directs development 
of many other cell types including ILCs, B cells, DCs and lung structural cells (Figure 5). Like T cells, ILCs 
develop from common lymphoid progenitors (CLPs) and can be subdivided in three major subclasses 
based on their cytokine expression155. In contrast to T cells, ILCs lack antigen-specific receptors. ILC2 
are dependent on RORα and Gata3 and secrete IL-5 and IL-13 during inflammation. In vitro studies have 
suggested a role for Notch signaling in ILC2 differentiation via DLL1156-158. This has however not yet been 
confirmed in vivo. Natural killer (NK) cells belong to the group 1 ILCs and have cytotoxic activity and 
functions155. While the role of Notch signaling in ILC1 remains unclear, NK cells do need Notch signals to 
develop since Notch1 and the ligands Jagged2, DLL1 and DLL4 were shown to promote NK cell differentiation 
and to increase IFN-γ production and cytolytic activity by NK cells159-165. Notch signaling has also been 
implicated in the differentiation and function of ILC3. The development of lymphoid tissue-inducer (LTi) 
cells (a type of group 3 ILC that is essential for the development and generation of secondary lymphoid 
organs) is dependent on RORγt155. Notch1 and Notch2 are required for the generation of fetal α4β7+ LTi cell 
progenitors before upregulation of RORγt. However, Notch signaling has to be subsequently downregulated 
again to allow the expression of RORγt and the final maturation of LTi cells166. IL-22 producing NKp46+ ILC3 
are, like LTi cells, dependent on RORγt155. The differentiation of NKp46- ILC3 into NKp46+ ILC3 was shown to 
depend on DLL1 signals167-169. In addition, conditional inactivation of RBPJ led to a reduction in NKp46+ ILCs 
numbers in the lamina propria of the intestine but not in Peyer’s patches170. 
B cells originate from B cell progenitors in the bone marrow, after which they migrate to secondary 
lymphoid organs where they further mature after which they become either mature follicular B cells or 
marginal zone cells. In this context, the development of marginal zone B cells is dependent on Notch2 
signaling via DLL1 ligation148, 171, 172.
Although Notch signaling inhibits the differentiation of hematopoietic stem cells to myeloid progenitor 
cells or erythroid cells173-176, Notch is required for the differentiation of mature myeloid cells. Notch2, but 
not Notch1 is specifically required for the development of a subset of cDC2 that is required for immune 
responses to bacterial pathogens177-181. In addition, Notch signaling via DLL1 is required for optimal DC 
maturation and activation since RBPJκ deletion in DCs led to decreased dendrite outgrowth and reduced 
expression of MHCII and CXCR4 in response to lipopolysaccharide (LPS)182. Furthermore, deletion of 
ADAM10 or Notch1 in DCs led to a decrease in type 2 inflammation in mice models for allergic asthma183. 
During macrophage activation, Notch signaling was shown to induce transcription of proinflammatory 
cytokines including IL-1β, IL-6, TNF-α and IL-12184-186. Lastly, in vitro studies have implied functions for Notch 
in the differentiation of granulocytes187 and Notch signaling is required for in vitro survival, differentiation 
and cytokine production by basophils188. 
In addition to its role in immune cell differentiation, Notch also drives lung organogenesis and 
alveologenesis189. Basal cells are progenitors of airway epithelial cells that can differentiate into 
secretory and ciliated cells. In this context, jagged1 expression on basal cells was shown to enhance their 
differentiation into secretory cells190. While some studies describe that Notch signaling induces goblet cell 
differentiation191, others found an inhibitory role for Notch in the differentiation of secretory cells into 
goblet cells192.
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Figure 5. The role of Notch signaling during lymphoid and myeloid cell development and function 
Overview of hematopoiesis, showing the main steps during lymphoid and myeloid cell development. Notch receptors or ligands that are 
required (if known) during these processes are indicated in red. Abbreviations are as follows: cDC, Conventional dendritic cell; CLP, common 
lymphoid progenitor; CMP, common myeloid progenitor; DLL, Delta-like ligand; HSC, hematopoietic stem cell; ILC, Innate lymphoid cell; 
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Taken together, Notch drives and regulates developmental programs and functions of a large range of 
cell types (Figure 5). Therefore, it is not surprising that mutations in Notch genes can result in diseases 
such as T cell acute lymphoblastic leukemia (T-ALL). Aberrant expression of NICD in bone marrow 
progenitors led to an induction of T-ALL in mice193. Moreover, in samples from patients with T-ALL 
tumors, constitutive active mutations were found in the Notch1 gene194, 195. Although it is unclear how 
Notch signaling induces T-ALL in detail, data suggests that Notch induces T-ALL via interfering with 
several signaling pathways that are required for cell proliferation, growth metabolism and survival 
including c-Myc, mTOR, NF-κB and NFAT196. In addition, since Notch drives differentiation of CD4+ T 
cell subsets, Notch signaling is thought to contribute to many immune-mediated diseases including 
auto-immune diseases and allergies197. Therefore Notch signaling might serve as a therapeutic target 
in those diseases. Most studies investigating Notch therapies have used γ-secretase inhibitors (GSI). 
However, interpretation of these findings is complicated, since GSI are not limited to Notch signaling 
and for example also target HLA-A2 expression and cadherins198. Synthetic, cell-permeable stabilized 
peptides that specifically target the Notch transactivation complex199-201, as well as specific antibodies 
targeting Notch receptors202-204 or Notch ligands205, 206 have been designed. Therefore, it is crucial to 
elucidate what the exact role is of Notch signaling in T cell-mediated diseases and whether cell-
permeable stabilized peptides or antibodies that block Notch signaling are beneficial for patients with 
autoimmune disease or allergies such as allergic asthma.
Aims and outline of this thesis
Notch signaling is essential for the development as well as the subset differentiation of CD4+ T cells. In 
this thesis, we aimed to investigate what the role is of the Notch signaling pathway in Th2 cell-mediated 
inflammation in allergic asthma. Notch signaling has the capacity to initiate Th2 cell differentiation by 
direct activation of an upstream promoter of Gata3129, 130, which is the key transcription factor that controls 
Th2 differentiation. In chapter 2, we will further elaborate on how Gata3 controls differentiation and 
function of T cells and ILCs. 
Several research groups have found that Notch ligands Jagged and DLL instruct Th2 and Th1 cell 
differentiation, respectively93, 207. Jagged1, but not Jagged2, expressed on the cell surface of antigen 
presenting cells stimulated Th2 effector generation93, 208-210 while surface DLL expression was shown to 
promote generation of Th1 cells152, 211-213. In addition, the expression of Jagged ligands on DCs was linked to 
Th2-associated stimuli while DLL ligands were upregulated in response to Th1 cell promoting stimuli93, 
205, 208, 211, 214-230 200. In chapter 3 we investigate the role of Notch signaling and Jagged ligands in allergic 
asthma. To this end, we exposed mice lacking Jagged ligands on DCs or RBPJκ specifically in T cells to a 
HDM-mediated model for allergic airway inflammation (AAI). We used HDM since HDM is the cause of 
chronic allergic sensitization in ~50% to ~85% of the asthmatic patients. HDM derives its allergenic nature 
from mite-derived fecal proteins which contain Toll-like receptor ligands and crude extracts of entire 
Dermatophagoides organisms. Inhalation of mite fecal pellets activates both epithelial cells and DCs of 
the lung, leading to Th2 priming in the absence of adjuvant addition231-233.
The finding that canonical Notch signaling is required for the induction of AAI, suggested that blocking 
the Notch signaling pathway can serve as a potential therapeutic target in allergic asthma. Interestingly, 
others have shown that administration of γ-secretase inhibitors (GSI) during only the challenge in 
asthma models was sufficient to decrease Th2 cytokine production132, 133. Effects 
of GSI are not limited to Notch signaling and can induce unwanted side-effects 
including gastrointestinal toxicity234. Therefore, we aimed to investigate whether 
cell-permeable stabilized peptides that more specifically block Notch signaling 
can be used to alleviate AAI. In chapter 4, we treated mice that were exposed to our 
acute HDM-driven model for AAI with the synthetic, cell-permeable stabilized 
peptide SAHM1199-201 to target protein-protein interfaces in the Notch transactivation 
complex. In addition, we investigated whether blocking Notch signaling is essential 
during the sensitization or during the challenge phase.
In chapter 5, we further investigated the role of the Notch receptors in Th2 cell 
inflammation. Therefore we exposed mice lacking either Notch1 or Notch2 or both 
receptors on T cells to acute and chronic HDM-driven models for AAI. We specifically 
questioned which Notch receptor (Notch1 or Notch2) is required for the induction of 
AAI and whether the lack of these receptors can be overcome by enforced expression 
of Gata3. In addition, we investigated whether Notch signaling is required for the 
priming of T cells or during the challenge phase. Finally, in this chapter we aimed 
to identify the role of Notch signaling in Th2 cells and investigated whether Notch is 
required for proliferation, differentiation or migration of Th2 cells.
We found in chapter 3 that Jagged expression on dendritic cells is dispensable for Th2 
cell mediated inflammation in AAI. In chapter 6 we therefore investigated the role 
and function of the expression of the Jagged1 and jagged2 Notch ligands on B cells, 
follicular reticular cells and T cells. 
A subgroup of asthma patients is unable to control their disease using 
corticosteroids. Therefore, it is necessary to obtain knowledge about the 
immunological differences between steroid-controlled and uncontrolled asthmatic 
patients to develop additional therapeutic approaches to treat uncontrolled asthma 
patients. Because of the evidence that Notch signaling is required during Th2 
inflammation in AAI in mice, we questioned whether Notch expression is altered 
on Th2 cells in allergic asthma patients. Therefore, in chapter 7, we compared 
Notch protein expression and gene expression profiles in T helper subsets from 
steroid-controlled and uncontrolled asthmatic patients with healthy individuals. 
We measured this using flow cytometry and genome-wide RNA sequencing and 
investigated whether our RNA and protein expression profiles correlated with 
clinical parameters or with circulating immune cells including eosinophils and 
neutrophils.
The role of Notch signaling in the differentiation of T helper cells are described in 
chapter 8. Implications of our work and potential future directions in the field of 
asthma research are described in chapter 9.
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GATA-3 function in innate 
and adaptive immunity
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Genome-wide analyses have identified a large number of GATA-3-binding sites in both active and 
silent genes in thymocytes and various mature T cell subsets259-261, suggesting that GATA-3 can both 
activate and/or repress gene expression. In contrast to the detailed knowledge of GATA-3 function 
in transcriptional regulation of Th2 cytokine genes, little is known about mechanisms of GATA-
3-dependent gene regulation in developing T cells and ILCs. As GATA-3 has crucial roles in a broad 
variety of cell types, it is logical to assume that GATA-3 function is context-dependent. As such, the 
regulatory output of GATA-3 will be dictated by its distinct protein-protein interactions in a given 
cell type. In this review, we highlight recent reports describing functional roles for GATA-3 in several 
hematopoietic cell types and discuss how genome-wide identification of binding sites support a model 
in which GATA-3 is recruited to distinct subsets of its potential binding sites, in a dose-dependent, 
developmental stage-specific and cell-lineage specific fashion.
GATA-3 and its family members 
In mammals the GATA family of transcription factors consists of six members, GATA-1 to GATA-6. 
GATA proteins contain two N-terminal transactivation domains and two characteristic Cys₄ DNA-
binding zinc finger domains, each of which is followed by a conserved basic region. The zinc finger 
closest to the C-terminus mediates binding to the consensus DNA sequence (A/T)-GATA-(A/G), while 
the N-terminal zinc finger stabilizes this binding and physically interacts with the zinc finger co-
regulator protein friend of GATA (Fog)262 (Table 1 and discussed below).
GATA factors have pivotal roles during development, as disruption of each of the GATA genes (except GATA-
5) in mice results in embryonic lethality. Most GATA factors show a tissue- and cell-restricted pattern 
of expression. GATA-1 and GATA-2 are primarily expressed in the hematopoietic system, while GATA-4, 
GATA-5, and GATA-6 are mostly expressed in the cardiac, pulmonary and digestive systems263, 264, although 
GATA-6 is also expressed in peritoneal macrophages in which it is required for proliferative renewal during 
homeostasis and in response to inflammation265, 266 (Figure 1). The broad expression of GATA-3 in multiple 
cell types is an exception to the rule. There is a functional overlap among GATA family members: GATA-3 
can partially restore erythroid development in GATA-1-deficient embryos267 and GATA-1, -2, -3 and -4 all 
have the ability to enhance IL-4 and IL-5 and to inhibit IFN-γ production in differentiated T cells268.
GATA-1 is critically involved in the development of erythrocytes, megakaryocytes, mast cells, 
dendritic cells (DC), basophils and eosinophils (Figure 1). GATA-2 is indispensible for efficient 
hematopoiesis, both for the production and expansion of HSCs in the embryonic 
aorta-gonad-mesonephros (AGM) region and for the proliferation of HSCs in adult bone marrow269. 
During erythroid differentiation GATA-1 and GATA-2 manifest dynamic reciprocal changes in their 
expression profiles (see for review: REF 270). In addition, a key role for GATA-2 has been demonstrated 
in basophil development and mast cell generation (Figure 1). Surprisingly, GATA-3 overexpression in 
early double negative (DN1) and DN2 but not DN3 fetal thymocytes that were cultured in the absence 
of Notch ligands rapidly and efficiently induced mast cell specification271. Mast cell development 
usually occurs independent of GATA-3, however as GATA proteins can induce their own expression, 
it is likely that the ability of GATA-3 to up-regulate Gata2 gene expression accounts for the observed 
reprogramming of thymocytes into mast cells. 
Summary
The zinc-finger transcription factor GATA-3 has received much attention as a master regulator of T helper 
2 (Th2) cell differentiation, during which it controls IL-4, IL-5 and IL-13 expression. More recently, GATA-3 
was shown to contribute to type 2 immunity through regulation of group 2 innate lymphoid cell (ILC2) 
development and function. Furthermore, during thymopoiesis GATA-3 represses B cell potential in early 
T cell precursors, activates TCR signaling in pre-T cells and promotes the CD4+ T cell lineage after positive 
selection. GATA-3 also functions outside the thymus in hematopoietic stem cells, regulatory T cells, CD8+ 
T cells, thymic NK cells and ILC precursors. Here we discuss the varied functions of GATA-3 in innate and 
adaptive immune cells, with emphasis on its activity in T cells and ILCs, and examine the mechanistic basis 
for the dose-dependent, developmental stage- and cell-lineage-specific activity of this transcription factor.
Introduction 
Shortly after its identification in 1990, the zinc-finger transcription factor GATA-3 was found to be 
required for both early T cell development in the thymus and for differentiation of naïve CD4+ T cells 
into committed T helper type 2 (Th2) cells31, 32, 235, 236. The molecular function of GATA-3 has been most 
extensively studied in the context of transcriptional regulation of genes encoding the Th2 signature 
cytokines interleukin-4 (IL-4), IL-5 and IL-13, which are tightly clustered to form the Th2 cytokine 
locus. Within this locus, GATA-3 has a complex role: not only does it bind to the Il5 and Il13 promoter 
regions, but also to Th2-specific DNAse I hypersensitive sites (DHS) that engage chromatin remodeling 
machinery allowing GATA-3 to orchestrate a three-dimensional topography of type II cytokine 
transcription237. GATA-3 can repress expression of other genes, for example Ifng encoding the Th1 
signature cytokine interferon-γ (IFN-γ), although the mechanism for this repression remains less clearly 
understood.
The paradigm of GATA-3 as a central mediator of type II inflammation was recently extended by the 
finding that GATA-3 is also essential for group 2 innate lymphoid cell (ILC2) development and Th2 cell 
cytokine production238-241. ILC2 are innate non-T and non-B lymphoid cells that produce large amounts 
of IL-5 and IL-13 upon activation by epithelial-derived pro-inflammatory cytokines242-244. However, it has 
become clear that GATA-3 function is not limited to innate and adaptive lymphocytes that mediate type 
II immunity. GATA-3 is also required in several mature T cell populations as well as in developmental 
cell-fate decisions during lymphoid development. For example, in addition to controlling Th2 cell 
differentiation, GATA-3 controls survival and proliferation of CD8+ T cells and is essential for regulatory 
T (Treg) cell function245-247. Beyond the T cell lineage, GATA-3 is also involved in hematopoietic stem cell 
(HSC) self-renewal and maintenance248-250 and repression of B cell commitment in lymphoid precursors251, 
252. GATA-3 is not needed for classical NK cell development and function, but is important for several 
specialized subsets of NK cells253. In an analogous fashion to its critical role in early T lymphopoiesis, 
recent evidence shows that GATA-3 functions not only in mature ILC2 but also in ILC precursor cells241, 
254-256 that give rise to various ILC populations (reviewed in REF 257, 258). Thus GATA-3 is essential in the 
differentiation and function of multiple innate and adaptive lymphocytes.
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Members of the GATA family have a highly conserved gene organization. Two distinct promoters 
drive lineage and tissue-specific expression and alternative first exon usage generates a series of 
GATA mRNA isoforms. Regulation of Gata3 gene expression is particularly complex and is dictated by 
individual tissue-specific enhancers. For example, a kidney enhancer element has been identified ~113 
kb 5’ to the Gata3 structural gene277, while a cis-acting element located ~280 kb 3’ to the Gata3 structural 
gene regulates GATA-3 expression in the T and NK cell lineage in vivo278.
The GATA-3 protein contains a classical nuclear localization signal motif and its localization between 
cytoplasm and nucleus is dependent on phosphorylation of critical serine residues by mitogen-
activated protein kinase (MAPK) p38. MAPK is activated by T cell receptor (TCR) and IL-33R signaling in 
T cells and ILC2, respectively, which facilitates binding to the nuclear transporter protein importin-α 
resulting in nuclear carriage250, 279, 280. Corticosteroids, which are highly effective in suppressing 
allergic airway inflammation, have the capacity to suppress GATA-3 nuclear import by competing for 
importin-α and by inducing MAPK phosphatase-1, an inhibitor of MAPK p38281. Finally, it is known 
that the acetylation status of GATA-3 affects is transactivation ability. The GATA-3 mutant KRR-
GATA-3 is hypoacetylated and shows hypomorphic functions, resulting in reduced T cell survival and 
altered lymphocyte homing282. 
In the hematopoietic system, expression of GATA-3 is confined to specific lymphocyte populations 
(Figure 1), as will be discussed below. GATA-3 is also expressed in various non-hematopoietic tissues, 
including adrenal glands, kidneys, central nervous system, inner ear, hair follicles, skin and 
mammary gland. GATA-3-deficient embryos die between embryonic day 11 and 12 and display internal 
bleeding, growth retardation, severe brain and spinal cord deformation and aberrations in fetal liver 
hematopoiesis272. The embryonic lethality is secondary to noradrenalin deficiency of the sympathetic 
nervous system, and GATA-3 mutation-induced lethality is partially averted by feeding catechol 
intermediates to pregnant dams273. Haploinsufficiency of GATA3 in man results in an autosomal 
dominant developmental disorder, referred to as hypoparathyroidism-deafness-renal (HDR) 
dysplasia, associated with various heterozygous germline GATA-3 abnormalities, including nonsense, 
frameshift and missense mutations274. Mutations in the GATA3 gene are commonly found in human 
breast cancers and low GATA-3 expression is associated with poor prognosis. GATA-3 is required for 
luminal epithelial cell differentiation and commitment in the mammary gland. Whereas GATA-3 
expression suppresses lung metastasis, loss of GATA-3 triggers fibroblastic transformation 
and cell invasion (See for review: REF 275). Loss of GATA-3 is also observed in high-grade invasive 
bladder cancer276. 
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Figure 1. Function of GATA factors in hematopoietic development.
Overview of hematopoiesis, showing the main lineage commitment steps from HSC to fully maturated and functional blood cells. GATA 
transcription factors that are required for these processes are indicated in red: GATA-1 and GATA-2 are important for the development of 
the erythroid and myeloid cell lineages. In contrast, GATA-3 is only involved in the lymphoid cell lineage, whereby GATA-3 is crucial for NK 
cell maturation, for the development of ILCs and T cells and for the repression of B cell potential. Abbreviations: CLP, common lymphoid 
progenitor; CMP, common myeloid progenitor; HSC, hematopoietic stem cell; ILC, innate lymphoid cell ; NK, natural killer.
Table 1. Interacting partners of GATA-3 
Protein Function Cell type Reference
CHD4 Chromodomain-helicase-DNA-binding protein 4, ATP-dependent chromatin remodeler, 
subunit of the repressive NuRD complex
Th2 363 
CBP-p300 Histone acetyltransferease (HAT) complex – transcriptional activation Th2 363
NuRD Nucleosome remodeling histone deacetylase repression complex – transcriptional 
repression 
Th2 363
Fog1 Friend of GATA-1; zinc-finger transcription factor that inhibits GATA-3 auto-activation 
and represses Il5 gene transcription and Th2 differentiation
Naïve 
T cells
381 
Rog Repressor of GATA (also known as Zbtb32); lymphoid-specific transcription factor 
that is rapidly induced in activated T cells and that represses GATA-3-induced 
transactivation
Activated 
T cells 
382
T-bet T-box protein; master regulator of Th1 differentiation, essential regulator of IFN-γ  
expression
Th1 364
Eomes T-box protein eomesodermin, highly homologous to T-bet and expressed in NK cells and 
inactivated CD8+ T cells, Th1 and Th2 cells
Th1 365
Runx3 Transcription factor that represses CD4 and activates CD8 expression and promotes 
Th1 differentiation in naïve T cells and induces IFN-γ 
Th1/Th2 383
FoxP3 Master regulator of Treg differentiation and function Treg 245
Smad3 Intracellular signal transducer of TGF-β Th2 384
YY1 Yin Yang 1, ubiquitously expressed zinc-finger transcription factor implicated in long-
distance DNA interactions
Th2 308
Fli1 Member of the ETS transcription factor family also known as ERGB T cells 260
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GATA-3 in Th2 cell differentiation 
The role of GATA-3 in transcriptional regulation of the murine Th2 cytokine locus is well understood (Figure 
2). This ~150 kb region contains the Il4, Il5 and Il13 genes, as well as a locus control region (LCR) that is crucial 
for appropriate Th2-specific cytokine expression and is located at the 5’ end of the interspersed Rad50 gene, 
encoding a ubiquitously expressed DNA repair protein283. GATA-3-mediated gene regulation and chromatin 
remodeling in the Th2 cytokine locus represents a model for understanding the molecular mechanisms of 
type II immune responses. 
Initiation of Th2 differentiation and inhibition of Th1 differentiation 
Multiple distinct Th cell subsets (Th1, Th2, Th9, Th17, Th22, follicular T helper (Tfh) and Treg cells), 
characterized by unique cytokine production and transcription factor profiles have been described (see for 
recent review: REF 284). 
Th2 cells control helminth infections and allergic immune responses and are characterized by the 
expression of the proinflammatory cytokines IL-4, IL-5 and IL-13. The initiating signals that drive Th2 
differentiation have been the subject of intense investigation and include IL-4 that induces phosphorylation 
and activation of STAT6, which in turn enhances GATA-3 expression via distal and proximal Gata3 
promoters and an upstream conserved regulatory region285. GATA-3 is necessary and sufficient for Th2 
cytokine gene expression in T helper cells31, 32. Once induced, GATA-3 upregulates its own expression, either 
directly286 or via the transcription factor Dec2287. GATA-3 is essential for the differentiation of naïve T cells 
to Th2 cells, as well as for the activation of already established Th2 cells288, 289. The induction of GATA-3 by 
the IL-4-STAT6 axis in differentiating Th2 cells however raises the paradox that IL-4 is essential for the 
generation of the cell type that is its major producer. The initial source of IL-4 that directs the Th2 response 
remains unclear. While a range of cell types can produce IL-4, Th2 responses can be generated when IL-4 is 
exclusively produced by T cells or when mice lack functional IL-4R signaling, arguing against a requisite 
role for an external source of IL-441, 42.
Other pathways have been implicated in the initial production of IL-4. TCR triggering in naïve T cells 
induces GATA-3 and IL-4 upregulation290, 291 and IL-2 secretion that in turn activates STAT5a in T cells292. 
STAT5a can bind to the DNase hypersensitive sites (DHS) HSII and HSIII in the Il4 locus (Figure 2), and high 
STAT5a activity can cooperate with GATA-3 to induce Th2 cell differentiation293. Several studies showed that 
GATA-3 and IL-4 expression can be directly regulated by Notch signaling in activated T cells129, 130. The role 
of Notch signaling in the innate and adaptive immune system has recently been reviewed116. Differentially 
expressed Notch ligands on DCs are able to instruct differentiation of naïve CD4+ T helper cells: Delta-like 
(DLL) and Jagged ligands induce Th1 and Th2 differentiation, respectively93. Notch signaling induces Th2 
differentiation by: (1) directly activating the upstream Gata3 gene promoter; and (2) by regulating Il4 gene 
transcription through activation of a 3’ enhancer. Both of these events are dependent on a nuclear complex 
that contains recombination-signal-binding protein for immunoglobulin Jκ region (RBPjκ). In the absence 
of GATA-3, Notch no longer induces Th2 cells but instead induces Th1 cell differentiation. Mice lacking 
RBPjκ or the Notch1 and Notch2 receptors fail to generate robust Th2 responses to parasite antigens129. 
Therefore, it can be concluded that the Notch signaling pathway is a STAT6-independent pathway that is 
crucial for Th2 induction via GATA-3. Although high amounts of exogenous IL-4 can induce normal Th2 
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Figure 2. GATA-3-mediated regulation of the Th2 cytokine locus.
(A) GATA-3 binds to the Il5 and Il13 promoter regions and to the Il13 HS1-CGRE region302, 373, 374. GATA-3 can also bind to a regulatory element in 
the first intron of the Il4 gene375. GATA-3 helps establish long-range chromatin changes in the cytokine locus during Th2 cell differentiation, 
including the acquisition of four specific DHS sites: the HSII-intronic enhancer (IE), HSIII, HSVa and HSV, whereby HSII-IE is crucial in GATA-3 
mediated activation of the Il4 gene298, 303, 376, 377. HSII, controlled by GATA-3, is strongest of the known Il4 enhancers in Th2 cells302, 373, 374. In 
the intergenic regulatory region CNS-1 located between the Il4 and Il13 genes, two additional Th2 cell-specific DHS sites HSS1 and HSS2 
are occupied by GATA-3 in vitro378. GATA-3 also binds to RHS5 and RHS7 in the LCR located within the Rad50 gene379 in a STAT6-dependent 
manner305. Additional nuclear factors that have been shown to bind in the Th2 locus are indicated (see text). 
(B) Schematic representation of the Th2 locus in naïve T cells (left) and in polarized Th2 cells (right). In naïve T cells, the promoters for 
the Th2 cytokines genes are in close spatial proximity. During Th2 differentiation, activated STAT6 and Notch signaling induce GATA-3 
up-regulation, leading to the participation of the LCR and CNS1 elements in this “poised” chromatin core configuration, allowing for high 
transcription of IL-4, IL-5 and IL-13, which is dependent on the presence of CTCF380. Abbreviations: CGRE, conserved GATA-3 response 
element; CNS1, conserved non-coding region; CTCF, CCCTC-binding factor; DHS, DNaseI hypersensitive site; Il, interleukin; IRF4, interferon 
regulatory factor 4; LCR, locus control region; RBPjκ , recombination-signal-binding protein for immunoglobulin Jκ region; Runx3, Runt-
related transcription factor 3; Satb1, special AT-rich sequence-binding protein-1; STAT, Signal Transducer and Activator of Transcription; 
YY1, Yin Yang 1.
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Chromosome conformation capture (3C) studies show that the promoters for the Th2 cytokines genes are 
in close spatial proximity in various cell types, and in CD4+ T cells specifically the LCR participates in this 
“poised” chromatin core configuration283. GATA-3 and STAT6 have the capacity to directly remodel the LCR305 
and are essential for the establishment or maintenance of these long-range interactions, but additional 
nuclear factors have been implicated in the 3D organization of the Th2 locus. These include Th2-specific 
transcription factors involved in Il4 gene regulation, such as interferon regulatory factor 4 (IRF4), nuclear 
factor of activated T cells NFATc2 and c-Maf, but also general chromatin organizers, such as special AT-rich 
binding protein 1 (SATB1), Yin Yang1 (YY1), CCCTC-binding factor (CTCF) and cohesin306-309 (Figure 2). Further 
studies are required to elucidate the exact mechanisms by which GATA-3 contributes to the formation of 
chromatin loops in the Th2 cytokine locus. 
In addition to Th2 cells, diverse myeloid cells, including mast cells, basophils and eosinophils, are potent 
producers of IL-4, IL-5 and IL-13 in vivo. The finding that GATA-1 and GATA-2 bind HSII in the Il4 locus in mast 
cells310, indicates that in type II immunity GATA-3 function in lymphoid cells is, at least partly, substituted 
by GATA-1 and/or GATA-2 in myeloid cells. 
GATA-3 in T cell development
As GATA-3 plays critical roles in several tissues and deletion of Gata3 results in embryonic lethality in 
mice272, analysis of GATA-3 function in immune development has been challenging. However, the use of 
diverse technical approaches (including blastocyst complementation, fetal liver hematopoietic stem cell 
reconstitution and conditional gene targeting) has provided important clues as to how GATA-3 functions 
during the various stages of T cell development.
One dramatic result of GATA-3 deletion is the complete absence of T cell development236, 311, 312. In the thymus, 
the T cell program is initiated by differentiation of early thymic progenitors (ETP) derived from multipotent 
hematopoietic precursors in the bone marrow313. Thymopoiesis requires several regulatory pathways for 
early thymocyte differentiation, including activation of the Notch1 receptor117, 119 by its ligand delta-like 4 
expressed on thymic epithelial cells124, 125. Notch1 triggering initiates and sustains the T cell program via 
activation of its transcription factor targets Tcf1 and Bcl11b314. GATA-3 is also up-regulated at this stage, 
although it is not clear whether this event is Notch-dependent. As such, the interrelationship between 
Notch1 and GATA-3 pathways remains unclear. Without Notch1 signals, ETPs do not develop and thymic 
progenitors can be diverted into the B cell pathway120, 123, 315. This Notch1-mediated repression of B cell 
development also involves GATA-3, as GATA-3-deficient pro-T cells retain a latent B cell potential despite 
active Notch1 triggering252 (Figure 3). This is not the case with pro-T cells deficient for the Notch1 targets Tcf1 
or Bcl11b316, 317, and thus GATA-3 appears unique in its ability to “seal” Notch1-induced T cell commitment318. 
The mechanism by which GATA-3 represses the B cell program is unknown, but it is striking that repression 
of GATA-3 by the transcription factor early B cell factor-1 (Ebf1) is a critical component of normal B cell 
development251. In the absence of Ebf1, lymphoid progenitors exhibit increased T cell lineage potential 
associated with increased Gata3 gene transcription251. Ebf1 ablation can divert lymphoid precursors into 
the ILC pathway as well319. As such, the relative balance between GATA-3 and Ebf1 pathways critically 
determines the B versus T cell or ILC cell fate decision. 
differentiation in the absence of Notch signaling66, 129, 131, it is likely that under physiological conditions, 
Notch signaling and IL-4R signaling synergize to promote Th2 cell responses via the activation of GATA-3.
GATA-3 and Notch signaling are also required for efficient Th9 cell development. Th9 cells produce IL-9 and 
can differentiate from naïve T cells or Th2 cells under the influence of IL-4, IL-9 and TGF-β294. It has been 
shown that IL-9R expression is regulated by GATA-3260. Conditional deletion of Notch1 and Notch2 led to 
decreased IL-9 production in Th9 cultures and the Notch ligand Jagged2 - but not Delta-like 1- induced IL-9 
in cells cultured with TGFβ alone138.
Whereas Th2 cells substantially up-regulate GATA-3 levels during development, Th1 cells express very low 
amounts of GATA-331, 32, 295, 296. During Th2 cell differentiation, GATA-3 inhibits T-bet function and IFN-γ 
expression. Moreover, GATA-3 suppresses Th1 cell development by down-regulating STAT4 and IL-12Rβ2 
chain expression295, 296. This was supported by genome-wide analyses demonstrating that GATA-3-deficient 
Th2 cells have increased expression of STAT4 and IL-12Rβ2 mRNA260. Nevertheless, recent data shows that 
Th1 and Th2 cell differentiation is not mutually exclusive (as previously thought), as stable and functional 
GATA-3+T-bet+ T cells that produce both IL-4 and IFN-γ are generated in vitro and in vivo in parasite and 
lymphocytic choriomeningitis virus (LCMV) infection297-300. These GATA-3+T-bet+ T cells support both Th1 
and Th2 cell-mediated immune responses but cause less immunopathology compared with committed 
T-bet+ Th1 or GATA-3+ Th2 cells, suggesting a regulatory role for these GATA-3+T-bet+ T cells. These studies 
are consistent with the notion of T helper cell flexibility and adaption depending on the characteristics of 
invading pathogens. Moreover, evidence is now emerging for frequent co-expression of the Th signature 
transcription factors GATA-3, T-bet, RORγt, Bcl6 or FoxP3 in specialized CD4+ T cell subtypes, challenging 
the paradigm of stable T helper subsets defined by the expression of a single “master regulator”301. As such, 
T helper cell differentiation appears quite diverse and perhaps less stable compared with developmental 
cell-fate decisions that accompany lineage commitment, e.g. to the B or T lymphocyte lineage.
GATA-3 and the Th2 cytokine locus 
GATA-3 binds directly to the Il5 and Il13 promoters, as well as to a binding site in the first intron of the Il4 
gene (Figure 2). In addition, GATA-3 plays a crucial role in establishing long-range chromatin interactions, 
as it binds to almost all DHS in the locus that Th2 cells acquire during their differentiation from naïve T 
cells, including DHS in the LCR, as well as four DHS crucial for activation of the Il4 gene302. GATA-3 can 
induce the latter DHS in Th1 cells, which clearly demonstrates that GATA-3 is associated with chromatin 
remodeling activity303. More recently, chromatin immunoprecipitation coupled with next generation 
sequencing (ChIP-Seq) experiments showed that in Th2 cells genomic regions surrounding the GATA-3 
binding sites in the Il4 and Il13 genes are associated with activating H3K4 methylation, but lack extensive 
repressive H3K27 trimethylation. In contrast, GATA-3 binding sites in the Tbx21 and Ifng loci are associated 
with H3K27 trimethylation in Th2 cells260, 304. The finding that deletion of Gata3 resulted in decreased H3K4 
dimethylation at specific sites in the Th2 cytokine locus and decreased H3K27 trimethylation around its 
binding sites in the Tbx21 and Ifng loci showed that GATA-3 mediates gene activation and repression by 
chromatin remodeling260. While T-bet is not expressed by Th2 cells, T-bet and GATA-3 are co-expressed in 
polarized human and mouse Th1 cells. Interestingly, ChIP-Seq experiments showed that many of the T-bet 
and GATA-3 binding sites in the Ifng locus in Th1 cells were coincident259, 261, as discussed below. 
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and Notch 2, TCR components and the RAG enhancer. Because in DN thymocytes GATA-3 occupancy 
of regulatory elements in Cd3d, Rag1, Rag2 and Zbtb7b loci preceded their expression, GATA-3-mediated 
chromatin remodeling may function to prepare loci for interactions with nuclear factors at later stages of 
T cell development. 
Conditional ablation of GATA-3 at later stages of T cell development (at the DP stage, using CD4-
Cre transgenic Gata3-floxed mice) demonstrates the necessity of GATA-3 for promoting CD4+ lineage 
choice320. In the absence of GATA-3 differentiation of the CD4+ lineage is blocked before CD4/CD8 
commitment, because MHC class II-restricted GATA-3-deficient thymocytes are redirected to the 
CD8+ T cell lineage, albeit inefficiently324. In this context, GATA-3 is required for the expression 
of the transcription factor ThPOK, which promotes CD4+ lineage differentiation325, 326. The finding 
that enforced ThPOK expression does not rescue CD4+ lineage differentiation of GATA-3-deficient 
thymocytes, indicates that GATA-3 also acts as a key CD4+ lineage differentiation factor, independently 
of its capacity to induce ThPOK324. Expression of GATA-3 is induced by TCR signaling during positive 
selection at the DP stage and as GATA-3 enhances TCR upregulation, it is likely that GATA-3 establishes 
a positive feedback loop that increases TCR surface expression in developing CD4-lineage cells327, 328. 
Accordingly, GATA-3 binds strongly to the Tcra, Tcrb, Cd3d and Cd3g loci and expression of CD3δ and CD3ε 
mRNA is decreased in GATA-3-deleted CD69+ DP cells. Although it has been suggested that Notch 
activity directly influences CD4/CD8 lineage commitment, it now seems that DP have very low levels of 
Notch signaling and that Notch does not play a direct role in lineage commitment116, 329. 
Development of CD8+ SP thymocytes is not affected by lack of GATA-3. However, peripheral mature naïve 
CD8+ T cells constitutively express GATA-3, albeit to lower levels than found in CD4+ T cells, and expression 
is upregulated by TCR activation and cytokine signaling. GATA-3 is important in CD8+ T cells as it controls 
proliferation by regulating c-Myc, but it is dispensable for IFN-γ production246 (Figure 3). GATA-3-deficient 
CD8+ T cells manifest defective long-term maintenance, which is attributed to lower IL-7R expression. By 
contrast, GATA-3 expression does not appear to be critical for the response to IL-7 in thymocytes. This is 
inferred from the finding that in GATA-3-deficient mice CD8+ SP thymocytes develop normally, although 
IL-7R signaling is essential for positively selected thymocytes to express the transcription factor Runx3 to 
specify CD8 lineage choice and promote CD8+ SP differentiation330. 
While GATA-3 is required for multiple stages of T lineage development (Figure 3), an additional role for 
GATA-3 in pre-thymic lympho-hematopoietic progenitor cells is as yet unclear. HSC express GATA-
3248, although early reports found that absence of GATA-3 did not affect the generation, maintenance 
or self-renewal of HSC in fetal and adult mice261, 312, 331. In contrast, it was recently shown that Gata3 
deletion enhances expansion of long term-multipotent HSC, consistent with a role for GATA-3 as an 
autonomous regulator of the balance between HSC self-renewal and differentiation250. Although in 
the absence of Gata3 the production of functional definitive HSCs in the embryonic AGM region is 
impaired, this is largely independent of a cell-intrinsic role of GATA-3 and secondary to abnormalities 
in the developing sympathetic nervous system249.
Using Lck-Cre transgenic Gata3-floxed mice to ablate GATA-3 expression in early DN cells, it was 
established that GATA-3 is critical for β-selection (Figure 3), and thus for the generation of T cell 
receptor (TCRβ)-expressing DN4 thymocytes320. This is consistent with findings in GATA-3 reporter 
mice that demonstrate up-regulation of GATA-3 during pre-TCR-mediated β-selection311. Continued 
Notch1 triggering is also required for this transition321, 322, which again suggests a close relationship 
between Notch1 and GATA-3 pathways at this juncture. 
Using Chip-Seq technology and expression profiling in developing thymocytes, GATA-3 binding was 
detected at 1,500 loci with marked differences in GATA-3 occupancy between early and later stages of T cell 
development260, 323. In fact, GATA-3 binding sites did not show significant similarities between DN1 and 
DP cells, but rather binding was particularly enriched at “stemness” genes and “T cell identity” genes, 
in these respective stages323. These analyses suggest that GATA-3 is involved in control the expression of 
many genes that play a crucial role in T cell development, including key transcription factors, Notch1 
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Figure 3. GATA-3 has multiple roles in ILC and T cell development and function
HSC-derived CLPs give rise to both adaptive and innate lymphoid cells. ILC development (top) mirrors T cell development (bottom). 
Developmental steps or cellular functions that absolutely require GATA-3 are indicated. These include the generation of a common ILC 
precursor, the differentiation into thymic NK cells and ILC2, as well as for NK cell maturation. GATA-3 represses B cell potential and in 
crucial in various stages of T cell development. In addition, GATA-3 is important for the function of CD8+ T cells, Treg cells and Th2 cells, as 
indicated. T effector and ILC subsets are grouped according to their ability to produce different cytokines. Abbreviations: CLP, common 
lymphoid progenitor; CTL, cytotoxic T lymphocyte; HSC, hematopoietic stem cell; IFN, interferon; IL, interleukin; ILC, innate lymphoid cell; 
iNK, immature NK cell; mNK, mature NK cell; NK, natural killer cell; NKT, natural killer T cell; P, progenitor; TGF, transforming growth factor; 
Th, T helper cell; Treg, regulatory T cell. 
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ILC2 development from CLP in vitro240, suggesting that GATA-3 transcriptional activity is a major 
determinant of ILC2 cell fate in uncommitted lymphoid precursors. Accordingly, bone marrow and 
lung ILC2 homeostasis in naïve mice correlates in vivo with Gata3 gene copy number240. The transition 
from CLP to ILC2 is associated with up-regulation of the transcription factors inhibitor of DNA-
binding 2 (Id2) and RORα, both of which are essential for ILC2 differentiation156, 342. Although the 
gene encoding Id2, which is involved in the development of all known ILC lineages242, 343, is occupied 
by GATA-3 in early thymocyte precursors323, inactivation of GATA-3 in mature ILC2 did not affect the 
expression of Id2 or RORα241. In vitro generation of ILC2 from CLP is dependent on Notch signaling156, 157, 
although it remains to be demonstrated whether ILC2 development in vivo requires canonical Notch 
signaling. Nevertheless, certain parallels between ILC2 development and early T cell are striking: 
Notch1, GATA-3 and Tcf1 are critical for ILC2 and T cell development344, with Tcf1 being a Notch1-
induced target for T cell specification316 that likely serves a similar role in ILC2 generation. 
In mature ILC2, GATA-3 controls cell activation and function, including IL-5 and IL-13 cytokine 
secretion, cytokine responsiveness (IL-25 and IL-33 receptors) and production of amphiregulin, an 
epidermal growth factor family protein essential for airway epithelium integrity238-241, 345. The finding 
that ILC2 effector function directly correlates with Gata3 gene expression suggests that GATA-3 
modulation impacts pathological conditions that involve dysregulation of type II immunity. This 
notion gains support from genome-wide association studies showing a significant association of 
the Il33 and Il1Rl1 (encoding the IL-33R subunit T1ST2) loci with asthma in human and the increases 
susceptibility to allergic airway inflammation observed in mice with enforced expression of GATA-3 
in T cells and ILC2346. In mouse models of allergic lung inflammation, ILC2 along with classical Th2 
cells are major producers of IL-5 and IL-13 that orchestrate and amplify allergic inflammatory events 
in asthma347. Moreover, ILC2-derived IL-13 can promote migration of activated lung DCs that drive 
differentiation of naïve T cells into Th2 cells13. 
Thus, GATA-3 plays a crucial role in the induction of IL-5 and IL-13 cytokine production both in ILC2 and 
in Th2 cells, which synergize in type II immunity and are activated through different mechanisms 
and with different kinetics. 
ILC3
ILC3 are a heterogeneous population and include CCR6+ lymphoid tissue inducer (LTi) cells that are 
needed for lymphoid tissue organogenesis in lymph nodes and Peyer’s patches during fetal life and for 
postnatal formation of intestinal lymphoid clusters348. Moreover, adult CD4+ ILC3 that can be found 
in secondary lymphoid tissues and in mucosal sites produce IL-17A and IL-22 that can contribute to 
immune defense349. Another subset of ILC3 that express the NK cell receptor NKp46 is non-cytotoxic 
and produces IL-22 but not IFN-γ350-352. NKp46+ ILC3 are CCR6-, are found primarily in the intestinal 
lamina propria, and cross-talk with epithelial cells to stimulate cell proliferation and production of 
anti-microbial peptides that regulate communities of commensal bacteria351, 353. Heterogeneous CD4-
NKp46- ‘double negative’ ILC3 have also been described and produce IL-17A, IL-22, IFN-γ and TNF-α and 
are involved in intestinal inflammation354-356. Both NKp46+ and a subset of double negative ILC3 express 
the transcription factor T-bet, which is critical for their development168, 354, 357. 
GATA-3 in ILC development and function 
Recent work has demonstrated that GATA-3 serves as a central regulator of ILC development and 
function (Figure 3). ILCs contribute to the first-line immune defense against invading pathogens 
and have the capacity to promptly produce large amounts of pro-inflammatory cytokines, prior to 
the generation of adaptive immunity. ILCs have been categorized into three major groups, based 
on transcription factor dependency and cytokine production profiles, which strikingly mirror the 
various T helper cell subsets257. Group 1 ILCs (or ILC1) consist of NK cells and other IFN-γ-producing 
innate lymphocytes that express T-bet. ILC1 have been shown to play a major role in the defense 
against viruses, intracellular bacteria and protozoa256, 332, 333. ILC2 secrete IL-5 and IL-13 in response 
to stimulation with the cytokines IL-25, IL-33 or thymic stromal lymphopoietin (TSLP). ILC2 are 
important in the immune response against helminths, but are also associated with allergic airway 
inflammation and hyperreactivity and maintenance of epithelial barrier integrity during influenza 
infection (see for review: REF 11). Group 3 ILCs (ILC3) include several phenotypically distinct cells that 
express and require the transcription factor Rorγt for their development and for production of IL-17A 
and IL-22. ILC3 are enriched at mucosal sites and appear to regulate barrier function and epithelial cell 
homeostasis258. 
ILC1 
Several transcription factors drive bone marrow and tissue-resident NK cell development from 
lymphoid precursors, including the T-box factors T-bet (encoded by Tbx21) and eomesodermin (Eomes), 
nuclear-factor interleukin-3 related (Nfil3) and GATA-3 (reviewed in REF 334). Gata3 ablation affects the 
development of mature CD11b+ splenic NK cells and reduces their capacity to produce IFN-γ335. In the 
thymus, GATA-3 deletion ablates the generation of IL-7Rα+ NK cells253 and more recent results show 
that GATA-3 is also critical for the development of a peculiar subset of CD49a+Eomes-NKp46+NK1.1+ 
ILC1 in the gut256, but not in the liver336. This differential impact of GATA-3 deletion on diverse NK cell 
subsets suggests distinct developmental pathways for conventional and tissue-resident NK cells256, 337, 
338 (Figure 3). Consistent with this hypothesis, a bone marrow PLFZ+GATA-3+ ILC precursor was described 
that can develop into CD49a+ hepatic but not conventional NK cells254. The signals that generate these 
apparently distinct ILC precursors from CLP and their capacity to promote NK cell development in the 
bone marrow versus tissue-specific sites remains an area of active research. 
Recent work has demonstrated that other IFN-γ-producing NK1.1+ cells are present in mucosal sites in 
humans339 and in mice256, 340. These ILC1 subsets require the transcription factors T-bet, Nfil3 and GATA-
3 for their generation and are phenotypically distinct from conventional NK cells that express NKp46, 
CD49a, IL-7Rα, CD27 but not CD11b. These ILC1 subsets seem to be an important source of IFN-γ and 
TNF-α in both the intestinal epithelial layer and the lamina propria under steady state conditions and 
during intestinal inflammation256, 340. The molecular mechanism through which GATA-3 contributes 
to ILC1 development or if its maintained expression is needed for functional attributes is unclear. 
ILC2
GATA-3 plays an essential role in ILC2 development in mice239-241, 280 and man341 (Figure 3). ILC2 are 
generated from CLP in vivo156, 157 and alterations in Gata3 gene dosage positively correlates with 
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GATA-3 cofactors and target genes 
GATA-3 and its interacting partners 
As GATA factors are expressed in a variety of cell types and can act as transcriptional activators 
or repressors, it was expected that their functional outcome would depend on their interactions 
with other transcriptional regulators. Indeed, using a biotinylation tagging/proteomics approach 
in erythroid cells, the association of specific interacting partners were linked to activating versus 
repressive functions of GATA-1362. Likewise, it was recently shown that GATA-3 and chromodomain 
helicase DNA binding protein 4 (Chd4) complex form functionally distinct activating and repressive 
assemblies with histone acetyltransferease (HAT) and histone deacetylase (HDAC) activity, 
respectively363. Many other proteins are known to interact with GATA-3 (Table 1). Genome-wide 
identification of GATA-3 binding sites in thymocytes and various effector T cell populations using 
Chip-Seq technology showed that in addition to the primary 5’-(A/T)GATA(A/G)-3’motif they contained 
several secondary motifs, including binding sites for the Ets, Runx, AP1 and TCF11 transcription 
factors, or even contained only secondary motifs260. Therefore, GATA-3 can be recruited through 
physical interactions with another transcription factor, or protein interactions may stabilize binding 
of GATA-3 to non-canonical target sequences. 
T-bet represses Th2 lineage commitment through a physical interaction with GATA-3 that is enhanced 
by T-bet tyrosine phosphorylation and interferes with GATA-3 binding to its target DNA364. However, 
recent genome-wide comparison of T-bet and GATA-3 binding sites revealed that many of the Th1-
specific GATA-3 binding sites overlapped with T-bet binding motifs259, 261. As in Th1 cells, GATA-3 binds 
to T-box motifs and not to cognate GATA-3 sites, GATA-3 occupancy is mediated through association 
with T-bet and T-box motifs261. On the other hand, the T-box factor Eomes interacts with GATA-3 and 
suppresses the transcriptional activity of GATA-3 (and IL-5 expression) in memory T cells365. Interaction 
of GATA-3 and the transcription factor Runx3 actively represses production of IFN-γ in Th1 cells. These 
examples demonstrate how GATA-3 targets repression and can be the target of repression.
FoxP3 forms a complex with GATA-3 specifically in activated Treg cells. Under inflammatory settings, 
GATA-3 limits Rorγt expression and thus restrains excessive polarization and inflammatory cytokine 
production by Treg cells247, 366. GATA-3 is induced upon TCR and IL-2 stimulation and is required for 
the accumulation of Treg cells at inflamed sites. In Treg cells, GATA-3 specifically binds to regulatory 
elements of the Foxp3 locus and thereby directly controls FoxP3 expression245. Conversely, FoxP3 binds 
to the promoter and intronic regions of the Gata3 locus, and thus FoxP3 and GATA-3 proteins not only 
physically interact, but also reciprocally control each other’s expression. Because FoxP3-GATA-3 
complex formation is dependent on TCR stimulation, GATA-3+ Treg cells are subject to immune control 
in response to environmental changes.
YY1 occupies regulatory elements in the Th2 locus and is required for subsequent GATA-3 binding308. 
Thus, cooperation of YY1 with GATA-3 is essential for regulation of the Th2 cytokine locus and Th2 cell 
differentiation. The Ets-family member Fli1 binds to ~70% of all GATA-3-bound sites in Th2 cells260. 
Upon Gata3 deletion, Fli1 occupancy at the majority of shared GATA-3 and Fli1 binding sites is lost 
(including binding to the IL13 and Rad50 loci) indicating mutualistic binding of these two factors. 
More recently, GATA-3 was shown to be crucial for development of both LTi cells and T-bet+ ILC3241, 
255. ILC3 express abundant GATA-3 protein, albeit in lower amounts than observed in mature ILC2. 
Hematopoietic chimeric mice derived from GATA-3-deficient fetal liver cells failed to generate 
intestinal ILC3 subsets and showed defective IL-22 production and maintenance of mucosal barrier 
homeostasis upon infection23. Conditional Gata3 ablation using Vav1-Cre generates a similar defect 
in ILC3 development241. Moreover, in the fetus GATA-3 is critical for differentiation of CD135+α4β7+ 
CLP-like cells and cell-intrinsic GATA-3 expression is essential to generate fetal liver RORγthiIL7Rαhi 
precursor cells255. While the GATA-3-dependent transcriptional pathways that drive ILC3 development 
remain unclear, RNA-seq analyses revealed that GATA-3 ablation does not modify Rorc, Runx1, Runx3, 
AhR, Id2 or Tcf7 expression in mature ILC3241. This result probably reflects the context-dependent role 
for GATA-3 in early ILC development that is not recapitulated in mature ILC3, as previous reports 
demonstrate that GATA-3 expression in mature Id2+ ILC3 is not essential for their homeostasis239.
GATA-3 as a central regulator of ILC development 
The observation that GATA-3 ablation severely affects development of several distinct ILC subsets (ILC2, 
ILC3, intestinal CD49a+NK1.1+ ILC1, thymic NK cells) suggests that GATA-3 could operate at an early stage 
of ILC differentiation and perhaps via the generation of common ILC precursors (Figure 3). In the fetus, a 
subset of α4β7+ fetal liver precursor (Lin− IL-7Rα+ Sca-1intc-Kitlo) cells have been described that fail to give rise 
to B and T cells but retain NK cell and ILC3 potential356, 358. A similar α4β7+Lin-IL-7Rα+ bone marrow subset 
exists, although it includes more mature ILC2239, 240. Recently, two reports identified that this α4β7+ subset 
contains committed ILC progenitors254, 256. Both groups used GFP reporter mice (in either the Zbtb16 (PLZF) 
or Id2 loci) to show that putative fetal and adult BM ILC precursors could give rise to ILC1-3 subsets in vivo 
and in vitro at the single cell level. These ILC precursors gave rise to ILC2, ILC3 (especially NKp46+ ILC3) and 
the peculiar CD49a+NKp46+ ILC1 subset that has been identified in the liver and gut. Interestingly, these 
ILC precursors had reduced capacity to generate conventional NK cells. As such, these ILC precursors had 
the developmental potential for the same ILC subsets that require GATA-3 for their development168, 254, 255, 
335, 354. Accordingly, one group found that PLZF+ α4β7+ cells co-expressed GATA-3 protein, suggesting a link 
between GATA-3 expression in these ILC precursors and their cell fate potential254.
As CLP are GATA-3- Id2- and PLZF-240, 254, identifying the signals that allow for the emergence of 
Id2+PLZF+GATA-3+ ILC precursors from CLP will be of considerable interest. Soluble factors (such as IL-7) 
and cell-intrinsic transcription factors (including Notch1, Tox, Runx1) are important for the normal 
development of distinct ILC subsets166, 168, 170, 359-361. One possibility is that GATA-3 up-regulation is an early 
event in CLP that effectively restricts B lineage fate and thereby generates T and ILC precursors (Figure 3). 
Such ‘bi-potent’ precursors would then further differentiate to more restricted T lineage precursors (ETP) 
or ILC precursors; up-regulation of Id2 would be a dominant factor in promoting the development of the 
latter. This model is consistent with the existing data and would clearly distinguish the developmental 
pathway of conventional NK cells (GATA-3-independent) from other ILC subsets (GATA-3-dependent).
Although GATA-3 function in ILC precursors and ETP may be partly overlapping, e.g. to repress B cell 
potential, it is conceivable that collaboration of GATA-3 with other transcription factors, such as RBPjκ, 
Id2, Tcf1, Nfil3, T-bet or RORg may enforce differentiation into the distinct ILC subsets or the T cell lineage.
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Concluding remarks 
Over two decades of research on GATA-3 biology has demonstrated that within the hematopoietic stem, 
GATA-3 has multiple and diverse roles that are mediated in a complex, dose-dependent, developmental 
stage-specific and cell-lineage specific fashion. Context-dependent activating or repressive functions of 
GATA-3 are provided by differential cooperative binding of GATA-3 with several different transcription 
factors, whereby related T cell or ILC subsets exhibit very different genome-wide GATA-3 occupancy. 
Highly-sensitive approaches to examine genome-wide GATA-3 binding sites in small populations of ILC 
subsets and their precursors may help to elucidate the critical GATA-3-dependent developmental pathways 
from CLPs to individual lymphocyte precursors. Moreover, such analyses should identify crucial GATA-3 
targets as well as the complex relationships between GATA-3, Notch signaling and key transcription factors 
such as Id2, RORα, RORγ, Tcf1 and Nfil3 in lymphocyte cell-fate decisions. 
Parallels exist between ILC in the bone marrow and T cell development in the thymus, as they both 
require – in addition to GATA-3 - similar transcription factors (e.g. Tcf-1) and Notch signaling. Obviously, 
instructive signals from the micro-environment such as cytokines, Notch ligands or Wnt signaling are 
different between bone marrow and thymus, but also ETP and ILC precursors will have different intrinsic 
developmental capacities. Therefore, future experiments should show common and unique GATA-3 targets 
and their epigenetic configurations in ILC precursors and ETP. 
In mice, GATA-3 functions in a dose-dependent fashion in both ILC2 and T cells240, 346, 369. Whereas human 
GATA-3 haploinsufficiency affects T cell function, its effects on ILC subsets are not known. Enforced 
expression of GATA-3 during T cell development induces DP T cell lymphoma, whereby malignant 
transformation involves cooperation with c-Myc and the induction of activating Notch1 mutations370. 
Likewise, recent genome-wide germline SNP analysis identified GATA3 gene variants that influence 
susceptibility to Philadelphia chromosome-positive acute lymphoblastic leukemia and risk of relapse371. 
It will be important to understand how dysregulated GATA-3 influences neoplastic transformation in 
hematopoietic cells and non-hematopoietic lineages275.
Although to date the role of GATA-3 in the regulation of Th2 cytokine expression is known in molecular 
detail, one of the unresolved questions that remains is how signals from the micro-environment cooperate 
to induce GATA-3 expression in activated T cells. Next to TCR, IL-4R and Notch signaling, very recent 
studies indicate that also nucleic acids (NA) released from dead cells and complexes with antimicrobial 
peptides or histones can upregulate GATA-3 expression, independently of known NA sensors372. GATA-3 
expression is sufficient and required for development and function of Th2 cells and ILC2 that play a central 
role in allergic inflammation. Therefore, inhibiting GATA-3 function, e.g. by inhibition of its translocation 
to the nucleus49, could be an excellent starting point for drug discovery strategies. 
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The differential complex formation provides a mechanism by which GATA-3 can be directed to a distinct 
subset of its potential binding sites in a cell type-specific fashion, and can help explain GATA-3 function 
as a transcriptional activator or repressor. Moreover, context-dependent cooperative binding of GATA-
3 with different transcription factors dramatically increases the regulatory complexity. Indeed, even 
closely related T cell subsets (e.g. DN2 and DP thymocytes or Th1 and Th17 effector cells) exhibited different 
GATA-3 binding patterns, despite nearly identical amounts of total GATA-3 protein present260, 323. 
GATA-3 target genes
To identify GATA-3 target genes genome-wide, GATA-binding sites have been identified by Chip-Seq 
and changes in gene expression upon Gata3 deletion were evaluated in various thymocyte and mature 
T cell subsets260, 261, 323. In these studies, >7,000 and >14,000 GATA-3 binding sites were identified 
genome-wide in murine and human Th2 cells, respectively. Although GATA-3 binding was enriched in 
gene regions just upstream of transcription start sites and 5’UTR, a majority of binding sites was >2kb 
distal to known gene promoters. These distal sites were frequently at conserved sequences, coinciding 
with DHS, and enriched for both activating H3K4 methylation marks, indicative for cis-regulatory 
elements261. Gene Ontology analysis revealed that genes harboring distal GATA-3 binding sites - but 
not genes bound by GATA-3 only at their promoter region - were enriched for immune response 
functions. Upon deletion of Gata3 only a minority of GATA-3 bound genes (<10%) showed a significant 
increase or decrease in expression, but ~46% of its bound genes manifested a significantly changes in 
H3K4 or H3K27 histone methylation marks. Therefore, the observed epigenetic modifications are most 
likely regulated by GATA-3 activity and not a consequence of transcriptional activation or silencing.
In addition to GATA-3 targets in the Th2 locus, these genome-wide studies identified several 
other complex loci controlled by GATA-3 in Th2 cells. These include the ~145-kb cytokine cluster 
containing the Il10 gene and the homologues Il19, Il20 and Il24367. Consequently, Gata3 deletion resulted 
in significantly decreased expression of IL-10 and IL-24. Furthermore, the large genomic regions 
encompassing the chemokine receptor genes (CCR9, CXCR6, XCR1, CCR1, CCR3, CCR2, CCR5, CCRL2) or the 
Il1r1, Il1rl2, Il1l1 (encoding IL-33R or T1ST2), Il18r1 and Il18rap genes contains many GATA-binding sites, 
whereby GATA-3 binds to sites in the Il18r1 gene in both Th1, Th2, Th17 and iTreg cells260, 261. As described 
above, expression of IL-33R is crucial for ILC2 activation and enforced expression of GATA-3 in 
transgenic mice induced the formation of Th2 memory cells expressing high amounts of IL-33R368. 
To date, the identification of GATA-3 targets in the various mature ILC subsets and in developing ILCs is 
not only hampered by the low cell numbers of the individual ILC subsets and their precursors, but also 
by the fact that ILC precursors are still poorly defined. Nevertheless, comparison of genes expressed in 
Th2 cells and mature ILC2 showed that only 55 genes were positively or negatively regulated by GATA-3 
both in Th2 and ILC2, including Il5, Il13, Areg, (encoding amphiregulin) and Il1rl1241. In contrast, 281 unique 
targets were regulated by GATA-3 in ILC2 (e.g. Icos, Il2ra and Kit), while 568 targets were regulated in Th2 
cells (e.g. Il4 and Maf). Although these may represent both direct and indirect targets of GATA-3, these 
findings indicate that GATA-3 has mostly unique functions in these two functionally related cell types. 
In a similar fashion, less than 4% of genes regulated by GATA-3 in ILC2 were also regulated by GATA-3 in 
ILC3.
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challenges with HDM, DC-specific Jagged1, Jagged2 single or double-deficient mice developed an 
eosinophilic airway inflammation and Th2 cell activation phenotype that was not different from 
that in control littermates. In contrast, RBPJκ-deficient mice failed to develop AAI and airway 
hyperreactivity. 
Conclusion: Our results show that the Notch signaling pathway in T cells is crucial for the 
induction of Th2-mediated AAI in a HDM-driven asthma model, but that expression of Jagged1 or 
Jagged2 on DCs is not required. 
Clinical Implications: The Notch signaling pathway in T cells is critical for development of 
house-dust mite driven allergic airway inflammation in mice, indicating it could be a potential 
therapeutic target in asthma.
Introduction
Allergic asthma is a T helper 2 (Th2) cell-mediated disease characterized by chronic airway 
inflammation, airway hyperreactivity and episodes of bronchoconstriction. Inflammatory dendritic 
cells (DCs) are necessary for induction of Th2 immunity to inhaled house dust mite (HDM) allergen 
in mice, as was shown in CD11c-diphtheria toxin receptor (DTR) mice in which DCs were specifically 
depleted by DT exposure385. Lung resident DCs continuously sample the airway lumen for the presence 
of allergens such as HDM and once activated, these cells mature and migrate to draining lymph 
nodes to activate naïve T cells (reviewed in REF 386). Upon antigenic stimulation by DCs, Th2 cell 
differentiation is initiated whereby the polarizing cytokine IL-4, which induces phosphorylation and 
activation of STAT6, enhances expression of the key Th2 transcriptional regulator Gata3285. Th2 cells 
are potent producers of cytokines that induce IgE synthesis (IL-4), recruit eosinophils (IL-5) and cause 
smooth muscle hyperreactivity and goblet cell hyperplasia (IL-13). 
Therefore, the initiation of Th2 cell differentiation via the IL-4/STAT6 axis is suggestive of an autocrine 
loop that leads to the expansion of IL-4 producing T cells. However, the primary origin of IL-4 that 
induces the Th2 response remains unclear. One of the pathways that has been implicated in the 
initiation of Th2 cell differentiation is the Notch signaling pathway. It has been demonstrated that 
Notch signaling has the capacity to induce Th2 cell differentiation by (I) directly activating the 
upstream Gata3 gene promoter and by (II) regulating Il4 gene transcription through activation of a 
3’ enhancer93, 129, 130. Both of these are dependent on a nuclear complex that includes recombination-
signal-binding protein for immunoglobulin Jκ region (RBPjκ) and the co-activator Mastermind-like 
1 (MAML1). Notch signaling in CD4+ T cells is required for physiological Th2 responses to parasite 
antigens, as was shown in mice deficient for RBPjκ or the Notch1 and Notch2 receptors129 and in 
mice expressing dominant-negative MAML131. Moreover, pharmacological inhibition of γ-secretase, 
the enzyme that liberates the intracellular Notch domain from the plasma membrane allowing it 
to function as a transcription factor in the nucleus, led to decreased Th2 cytokine production after 
immunization with ovalbumin in an asthma model133. 
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Background: Allergic asthma is characterized by a T helper 2 (Th2) response induced by dendritic 
cells (DCs) that present inhaled allergen. Although the mechanisms by which they instruct Th2 
differentiation are still poorly understood, expression of the Notch ligand Jagged on DCs has been 
implicated in this process. 
Objective: To establish whether Notch signaling, induced by DCs, is critical for house-dust mite 
(HDM) driven allergic airway inflammation (AAI) in vivo.
Methods: The induction of Notch ligand expression on DC subsets by HDM was quantified by qRT-
PCR. We used a HDM-driven asthma mouse model to compare the capacity of Jagged1 and Jagged2 
single and double-deficient DCs to induce AAI. In addition, we studied AAI in mice with a T cell-
specific deletion of RBPJκ, a downstream effector of Notch signaling. 
Results: HDM exposure promoted the expression of Jagged1, but not Jagged2, on DCs. In agreement 
with published findings, in vitro differentiated and HDM-pulsed Jagged1 and Jagged2 double-deficient 
DCs lacked the capacity to induce AAI. However, following in vivo intranasal sensitization and 
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Bone marrow-derived dendritic cell cultures
GM-CSF bmDCs were generated as described393. Briefly, to prepare single cell suspensions from bone marrow 
(BM), femurs and tibias from mice were cleaned with 70% ethanol and mechanically disrupted in RPMI 
1640 containing GlutaMAX-I (Invitrogen, Carlsbad, CA, USA) after which cells were separated from bones 
using a 100 μm cell strainer (BD Falcon, Bedford, MA, USA). 2 ∙ 106 bone marrow (BM) cells/ml were cultured 
in 6-well plates in 2 ml of complete medium with 20 ng/ml GM-CSF (kindly provided by Dr. K. Thielemans, 
Belgium). 2 ml new medium supplemented with GM-CSF was added at day 3. At day 6, 2 ml of culture 
medium was discarded and replaced by 2 ml fresh medium with GM-CSF. Cells were harvested at day 10.
DC subset sorting
DCs were sorted using a FACS Aria equipped with BD FACS Diva software (BD Biosciences, San Jose, CA, 
USA). Cells were selected on negativity for DAPI (invitrogen). Doublets were depleted using side scatter- and 
forward scatter width and height and cells were further gated as indicated in the figure legends. A list of all 
used fluorochrome labeled antibodies can be found in Supplementary table 1.
Sorted DCs were collected in FCS and stimulated overnight with 10μg/ml house-dust mite (HDM) extract 
(Greer, Lenoir, NC, USA)(endotoxin; 1397.5 EU/vial, protein; 5.59 mg/vial), 10 ng/ml LPS (Enzo life sciences, 
Farmingdale, NY, USA) or a similar volume of PBS (invitrogen) after which cells were stored in RNA 
lysisbuffer (Qiagen, Venlo, the Netherlands) containing 2-mercaptoethanol.
To activate in vivo DCs from draining lymph nodes, WT mice and Jag1fl/flJag2fl/fl CD11c-cre+ (Jg1Jg2ΔCD11c/ΔCD11c) mice 
were treated intranasally (i.n.) with 50 μg HDM in 40 μl PBS or with 40 μl PBS under isoflurane anesthesia 
72 hrs prior to sacrifice. To obtain sufficient numbers of cells, MedLN from 6 mice were pooled per sample. 
After sorting, cells were collected in RNA lysis buffer containing 2-mercaptoethanol.
RNA extraction and quantitative real-time PCR
RNA was extracted using RNeasy Micro Kit (Qiagen) according to manufactures’ protocol. RNA from 
cultured DCs was synthesized into cDNA using RevertAid H Minus Reverse Transcriptase and random 
hexamer primers in the presence of RiboLock RNase inhibitor (Thermo scientific, Waltham, MA, USA). 
Amplified cDNA from sorted ex vivo DC RNA was prepared using Ovation PicoSL WTA System V2 (Nugen, San 
Carlos, CA, USA).
For qRT-PCR reactions, probes from the Universal ProbeLibrary Set (Roche Applied Science) and 
Taqman Universal Mastermix were used (Applied Biosystems, Foster City, CA, USA). qRT-PCR 
reactions were performed by an Applied Biosystems Prism 7300 Sequence Detection System (Applied 
Biosystems). Primers were designed using transcript sequences obtained from www.ensembl.org 
and were specific for Jag1 (forward: 5’-accagaacggcaacaaaact-3’, reverse: 5’-gacccatgcttgggactg-3’, 
probe 97), Jag2 (forward: 5’-cgtcattccctttcagttcg-3’, reverse: 5’-cctcatctggagtggtgtca-3’, probe 95), 
Dll1 (forward: 5’-gggcttctctggcttcaac-3’, reverse: 5’-taagagttgccgaggtccac-3’, probe 103) and Dll4 
(forward: 5’-gaggaacgagtgtgtgattgc-3’, reverse: 5’-gtcccatacaggatgcaatgt-3’, probe 3). mRNA 
levels of genes of interest were normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) 
(forward: 5’-TTCACCACCATGGAGAAGGC-3’, reverse: 5’-GGCATGGACTGTGGTCATGA-3’, probe 
TGCATCCTGCACCACCAACTG). Primers were checked for specificity and efficacy using standard criteria. 
Several lines of research support that Notch ligands Delta-like ligand (DLL) and Jagged instruct Th1 and 
Th2 cell differentiation, respectively207. Surface DLL expression was shown to promote generation of Th1 
cells and to reduce Th2 responses, whereas Jagged expressing antigen presenting cells stimulated Th2 
effector generation93. Jagged1 can be upregulated on DCs by stimuli that promote Th2 cell responses. 
For instance, via thymic stromal lymphopoietin, produced by diesel exhaust particle-treated human 
bronchial epithelial cells220, and upon stimulation with T. brucei-derived antigens as well as TNF, 
Dermatophagoides pteronyssinus group 7 allergen (Derp7) and low-dose LPS214, 219, 387. Jagged1 was 
shown to be crucial in the induction of a Th2 response in a model of airway hyperresponsiveness 
using ovalbumin-pulsed in vitro cultured granulocyte-macrophage colony-stimulating factor (GM-
CSF) bone marrow-derived (bm)DCs208. Although evidence was provided that Jagged2 is dispensable 
for the induction of Th2 cells in vivo209, 210, Jagged2 was shown to have the capacity to induce Th2 cell 
differentiation in vitro209. Correspondingly, DLL1 and DLL4 ligands are induced on DCs by stimuli that 
elicit Th1 responses and have the capacity to induce Th1 differentiation in vitro225, 388. 
In contrast to this model, it has been hypothesized that Notch signaling acts as a general amplifier of 
T helper cell responses rather than an instructive director of specific cell fates. This could either be by 
enhancing proliferation, cytokine production and anti-apoptotic signals135, 149, 150 or by boosting antigen 
sensitivity via promoting co-stimulatory signals in T cells107, 108. 
Therefore, in this report we aimed to determine whether Notch signaling is critical for HDM-driven 
allergic airway inflammation (AAI) in vivo. In particular, we questioned whether Jagged1 and Jagged2 
on DCs are required for the induction of polarization of naïve T cells into Th2 cells. We found that the 
expression of Jagged1 or Jagged2 on DCs is not required while T cells do need Notch signals, specifically to 
differentiate into Th2 cells.
Methods
Mice
Wild-type (WT) mice were purchased from Harlan (Zeist, the Netherlands). Jag1fl/fl mice389, Jag2fl/fl mice390 
and Rosa26-stop-EYFP reporter (ROSAEYFP) (Jackson Laboratories, Bar Harbor, ME, USA) mice were bred 
with CD11c-cre transgenic mice177. RBPJκfl/fl mice391 were crossed with CD4-cre transgenic mice392. All mice 
were bred on a C57BL/6 background in the Erasmus MC animal facility under specific-pathogen free 
conditions and genotyped by PCR as described177, 389-392. In experiments, both male and female 6-14-week-
old mice were used. Mice were given ad libitum access to food and water. All experiments involving 
animals were approved by the Erasmus MC Animal Ethics Committee.
Single cell suspension preparation
Single cell suspensions were obtained as previously described347. Briefly, directly after harvest, spleen 
and lymph nodes were mechanically disrupted in a cell strainer. Lungs were digested using 20 μg/ml 
liberase (Roche Applied Science, Almere, the Netherlands) and 2 μg/ml DNase I (Sigma-Aldrich, St. 
Louis, MO, USA) for 30 minutes at 37°C while shaking. Erythrocytes in BM, lung and spleen were lysed 
with osmotic lysis buffer for 1 minute.
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Data was acquired by a LSR II flow cytometer and FACS Diva software 6.1 (BD biosciences) and analyzed 
using Flowjo 9.8.5 (tree Star Inc., Ashland, OR, USA).
Cytokine and immunoglobulin measurements
Cytokines were quantified by commercial enzyme-linked immunoasorbent assay (ELISA) for IL-5, IL-
12, TNF-α (eBioscience), IgE, IL-6 (BD biosciences) and KC (R&D, Minneapolis, MN, USA) according to 
manufactures’ protocol.
HDM-specific IgE and IgG1 (antibodies from BD biosciences) were measured as described398. 
Levels of TNP-KLH specific IgM, IgG1 and IgG2a were determined as described399. To discriminate high- 
versus total affinity anti–TNP-KLH IgG1 Abs, plates were coated with TNP (13)-KLH and TNP (29)-KLH, 
respectively.
Statistical analysis
Reported values are shown as mean + SEM. For statistical analysis, a Mann-Whitney U-test was 
performed with GraphPad Prism software (version 5.01, La Jolla, USA). P values were considered 
significant when values were <0.05.
Results 
Jagged1 is upregulated on in vitro GM-CSF bmDCs upon exposure to HDM
Because several research groups have shown a role for Jagged in the orchestration of T cell responses 
by employing GM-CSF bmDCs93, 208-210, 387, we first investigated the expression of Notch ligands on 
bmDCs upon stimulation with the pro-Th2 stimulus HDM and the pro-Th1 stimulus LPS. GM-CSF 
bmDCs were cultured from WT mice and sorted at day 9 into CD11c+MHCIIintF4/80-CD115+ GM-moDCs, 
CD11c+MHCIIhighF4/80-CD115- GM-DCs and CD11c+MHCIIintF4/80+CD115+ GM-Macs (Figure 1A), based on 
the study by Helft et al.400. Upon HDM stimulation, Jagged1 mRNA was upregulated on GM-moDCs 
and GM-DCs, whereas LPS stimulation induced upregulation of DLL4 mRNA on GM-moDCs and GM-
Macs. Expression of Jagged2 and DLL1 was not altered on GM-CSF bmDCs upon stimulation (Figure 1A). 
Thus, Jagged1 mRNA is substantially upregulated on in vitro GM-CSF bmDCs after HDM stimulation. 
Jagged is crucial during the sensitization phase in a model that employs GM-
CSF bmDCs to induce AAI
To delete Jag1 and Jag2 specifically in DCs, we employed Jag1fl/fl and Jag2fl/fl mice, in which the Jag loci 
contain loxP sites, as well as CD11c-cre transgenic mice, expressing Cre recombinase under the 
control of the DC-specific CD11c promoter. Efficiency of CD11c-cre mediated-deletion was confirmed 
in CD11c-cre transgenic ROSAEYFP mice with cre-mediated excision of a loxP-flanked transcriptional 
STOP sequence. GM-CSF bmDCs were cultured from CD11c-cre×ROSAEYFP mice and WT×ROSAEYFP mice 
with GM-CSF. Analysis of EYFP expression by flow cytometry indicated that GM-CSF bmDC subsets 
manifested Cre-mediated deletion in 70-74% of the cells (Supplementary figure 1A). 
Mouse studies
To induce AAI with DCs, mice were sensitized with 30.000 unsorted GM-CSF bmDCs from Jg1Jg2ΔCD11c/
ΔCD11c or Jg1Jg2+/+ mice (stimulated overnight with 5 μg/ml HDM or with an equal volume of PBS as a 
control) intratracheally (i.t.) while anesthetized with ketamine 75 mg/kg and medetomidine 1.0 mg/
kg as previously described80. From day 7, mice were challenged with 10 μg HDM in 40 μl PBS for 5 
consecutive days. During HDM treatments, mice were anesthetized with isoflurane. 1 day after the 
last challenge, mice were sacrificed and analyzed. 
HDM-mediated AAI was induced as described before394. Briefly, mice were sensitized with 1 or 10 
μg HDM (as indicated in the figures) i.n. in 40 μl or with PBS. At day 7-10, mice were i.n. exposed 
to 10 μg HDM (40 μl) for 5 consecutive days. During HDM/PBS treatments, mice were anesthetized 
with isoflurane. Mice were sacrificed and analyzed 4 days after the last challenge, or at 1 day when 
bronchial hyperreactivity (BHR) measurements were performed. 
To study Th1 responses, mice were injected subcutaneously in the tail base with 100 μl of a mixture of 
2 mg/ml OVA and Incomplete Freund’s Adjuvant (IFA, BD biosciences) or PBS with IFA as a control. At 
day 7, mice were sacrificed and inguinal- and axillary lymph nodes were collected and restimulated in 
vitro with 100 μg/ml OVA for 72 hrs. 
Mice were immunized i.p. with TNP-KLH(29) (Biosearch Technologies, Petaluma, CA, USA)   day 0 (in 
combination with alum) and day 35 (without alum), as described395. For immunoglobulin analysis, 
blood was drawn from the tail vain at day 0 (baseline), 7, 35 and 42. Mice were sacrificed at day 42. 
Bronchial hyperreactivity measurement
BHR was analyzed 24 hrs after the last challenge with HDM using flexiVent invasive measurement 
of dynamic resistance (SCIREQ Scientific Respiratory Equipment Inc., Montreal, Canada) as 
described previously396. Mice were anesthetized with urethane, paralyzed using d-tubocurarine 
and tracheotomized with an 18-gauge catheter, followed by mechanical ventilation with a flexiVent 
apparatus (SCIREQ). Respiratory frequency was set at 120 breaths per min with a tidal volume of 
0.2 ml and a positive end-expiratory pressure of 2 ml H2O. Increasing concentrations of metacholine 
(0–100 mg/ml) (Sigma-Aldrich) were administered via the jugular vein. Dynamic resistance and 
compliance were recorded after a standardized inhalation maneuver given every 10 s for 2 min. 
Baseline resistance was restored before administering the subsequent doses of metacholine.
Flow cytometry
Single cell suspensions were stained with a mixture of fluorochrome labeled antibodies in FACS 
buffer containing 0.25% BSA, 0.5 mM EDTA, 0.05% NaN3 in PBS as described previously397. A list 
of all fluorochrome labeled antibodies that were used can be found in Supplementary table 1. For 
intracellular cytokine measurements, cells were restimulated with a mixture of 50 ng/ml PMA, 500 
ng/ml ionomycin (both Sigma-Aldrich) and protein transport inhibitor (golgistop, BD biosciences) in 
complete medium. Next, cells were fixed and permeabilized with paraformaldehyde and 0.5% saponin 
in FACS buffer prior to intracellular staining. For staining of transcription factors, cells were fixed and 
permeabilized with Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego, CA, USA). 
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required during the challenge phase of AAI induction, Jg1Jg2ΔCD11c/ΔCD11c or Jg1Jg2+/+ mice were sensitized with WT 
GM-CSF bmDCs and challenged with HDM. We found comparable AAI induction in Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ 
mice (not shown), indicating that for AAI induction Jagged expression is only required on GM-CSF bmDCs 
during the sensitization phase and not during HDM challenge. 
Taken together, these findings confirm that expression of Jagged1 and Jagged2 is crucial during the 
sensitization phase in a model where GM-CSF bmDCs are used to induce HDM driven AAI.
Next, we analyzed Jagged mRNA expression in DCs from CD11c-Cre transgenic Jag1fl/flJag2fl/fl mice (Jg1Jg2ΔCD11c/
ΔCD11c) and Jg1Jg2+/+ control mice (Figure 1B). We found reduced expression of Jagged1 and Jagged2 compared to 
WT DCs in all GM-CSF bmDC subsets. Finally, recombination of Jag1 and Jag2 was confirmed on genomic 
DNA of GM-CSF bmDCs from Jg1Jg2ΔCD11c/ΔCD11c, compared with Jg1Jg2+/+ mice (Supplementary figure 1B). 
To confirm that Jagged expression on DCs is essential for 
allergic airway inflammation (AAI) induction by intratrachael 
transfer of allergen-pulsed GM-CSF bmDC, we sensitized WT 
mice with HDM-pulsed total GM-CSF bmDCs from Jg1Jg2ΔCD11c/
ΔCD11c or Jg1Jg2+/+ mice and challenged the mice with HDM (Figure 
2A). HDM stimulated Jg1Jg2+/+ GM-CSF bmDCs induced AAI, as 
evidenced by a significant increase in numbers of eosinophils, 
macrophages, neutrophils, B cells, T cells and DCs in BAL, 
compared with mice that were sensitized with PBS treated 
GM-CSF bmDCs (Figure 2B). In contrast, GM-CSF bmDCs from 
Jg1Jg2ΔCD11c/ΔCD11c mice lacked the capacity to induce AAI (Figure 
2B). Accordingly, IL-4+, IL-5+, IL-13+, IFN-γ+ and IL-17A+ T cells in 
BAL (Figure 2C) or Gata3+ Th2 cells in mediastinal lymph nodes 
(MedLN) (Figure 2D and 2E), were reduced, when mice were 
sensitized with Jg1Jg2ΔCD11c/ΔCD11c GM-CSF bmDCs compared with 
control DCs. Numbers of Rorγt+ Th17 cells or Foxp3+ Tregs in 
MedLN were not different between the two groups of mice, and 
T-bet expression was not detected (not shown).
The defective capacity of Jg1Jg2ΔCD11c/ΔCD11c GM-CSF bmDCs 
(Supplementary figure 2A) to induce Th2 polarization in vivo 
was likely not due to cell-intrinsic defects, because these 
DCs expressed similar levels of co-stimulatory molecules 
(Supplementary figure 2B), DLL1 and DLL4 (Supplementary figure 
2C) and produced similar amounts of pro-inflammatory 
cytokines (Supplementary figure 2D) as control DCs did upon in 
vitro activation with a variety of stimuli. Finally, to investigate 
whether expression of Jagged1 and Jagged2 is perhaps also 
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Figure 1. Jagged1 is upregulated on bmDCs upon HDM exposure and 
CD11c-cre is effective in GM-CSF bmDCs
(A) Flow cytometric gating strategy for bmDC subsets from C57BL/6 mice. Live 
cells were analyzed for CD11c and MHCII and gated as indicated (top). mRNA 
expression of the indicated Notch ligands, quantified by qRT-PCR, in GM-moDCs, 
GM-DCs and GM-Macrophages and stimulated overnight in the presence or 
absence of HDM or LPS, as indicated (bottom).
(B) Quantification of relative Jagged1 and Jagged2 expression by qRT-PCR in 
bmDC subsets that were FACS sorted from Jg1Jg2ΔCD11c/ΔCD11c mice compared to 
WT C57BL/6 mice, which were set to 100%. Data are shown as mean + SEM of four 
mice per group in one experiment, except for HDM stimulated GM-DCs (n=2 in 
panel 1A; n=1 in panel 1B). * p < 0.05 using Mann-Whitney U-test.
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Figure 2. Jagged1 and Jagged2 are crucial during the sensitization phase when using GM-CSF bmDCs to induce AAI
(A) Sensitization and challenge scheme of HDM-driven AAI in mice, using cultured total bmDCs.
(B) Numbers of macrophages (FSChighSSChighautofluorescent+CD11c+Siglec-F+), eosinophils (FSCintSSChighSiglec-F+), neutrophils (Ly-6G+), 
B cells (CD19+), T cells (CD3+), DCs (CD11c+MHCIIhi) in BAL in mice treated with either PBS-pulsed or HDM-pulsed bmDCs from Jg1Jg2ΔCD11c/
ΔCD11c or Jg1Jg2+/+ mice. 
(C) Numbers of IL-4+, IL-5+, IL-13+, IFN-γ+ and IL-17A+ CD3+CD4+ T cells in BAL in mice treated with either PBS-pulsed or HDM-pulsed bmDCs.  
(D) Flow cytometry profile of Gata3/Rorγt expression in CD3+CD4+ T cells in mice treated with HDM-pulsed bmDCs from Jg1Jg2ΔCD11c/ΔCD11c 
or Jg1Jg2+/+ mice. (E) Total numbers of Gata3+, Rorγt+ and Foxp3+CD25+ CD3+CD4+ T cells in MedLN from mice treated with PBS-pulsed or 
HDM-pulsed bmDCs from Jg1Jg2ΔCD11c/ΔCD11c or Jg1Jg2+/+ mice, as indicated.  
Data are shown as mean + SEM of four mice (PBS) or six mice (HDM) per group, in one experiment. * p < 0.05, ** < 0.01, using Mann-Whitney U-test.
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Jagged1 is highly upregulated on in vivo migratory CD11b+ cDCs upon HDM 
exposure 
To analyze the role of Jagged expression in a more physiological HDM-driven airway inflammation 
model, we first aimed to establish which in vivo DC subsets expresses crucial Notch ligands during 
HDM exposure. In this context, CD11b+ conventional DCs (cDCs) were shown to be the main DC 
subset involved in the induction of Th2 cells in draining lymph nodes, whereas monocyte-derived 
DCs (moDCs) play a crucial role during the challenge phase80. We sorted resident moDCs, migratory 
moDCs, resident CD11b+ cDCs and migratory CD11b+ cDCs from MedLN from WT mice intranasally 
(i.n.) treated with HDM or PBS for 72 hrs. In migratory CD11b+ cDCs, both Jagged1 and DLL4 were 
expressed at baseline and significantly upregulated upon exposure to HDM, whereas Jagged2 and DLL1 
were not detected (Figure 3A). Resident moDCs, migratory moDCs and resident CD11b+ cDCs expressed 
very low levels of Jagged1 mRNA and expression of other Notch ligands was not detected (not shown).
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Figure 3. Jagged1 is upregulated on migratory CD11b+ cDCs upon HDM exposure and CD11c-cre is effective in in vivo DCs 
(A) Gating strategy of ex vivo sorted DC subsets from C57BL/6 mice that were i.n. treated with 50 μg HDM or PBS (top). mRNA expression of 
the indicated Notch ligands, as determined by qRT-PCR, in DAPI-MHCIIhiCD11b+CD103-CD64- (migratory) DCs from MedLN after 72 hrs of in 
vivo stimulation (bottom). 6 mice were pooled per sample. Data are shown as mean + SEM of three samples per group, in one experiment.  
(B) EYFP expression in CD11c+MHCIIhi DCs in the indicated tissues from WT×ROSAEYFP and CD11c-cre×ROSAEYFP mice after 72 hrs of in 
vivo stimulation with 50 μg HDM or PBS. Data are shown as histogram overlays of EYFP expression in the indicated mice. Samples were 
concatenated, data are shown as mean + SD of four mice (CD11c-cre X ROSAEYFP) or 2-3 mice (WT X ROSAEYFP) per group, in one experiment. 
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Jag1 and Jag2 are effectively deleted in DCs from Jg1Jg2ΔCD11c/ΔCD11c mice 
To check the efficacy of CD11c-cre-mediated in vivo gene deletion, we analyzed DCs from CD11c-
cre×ROSAEYFP mice and control mice. EYFP was expressed in 88-97% of CD11c+MHCIIhigh DCs in lungs, 
bronchoalveolar lavage (BAL), MedLN and spleen and was unaltered when mice were challenged with 
50 mg of HDM 72 prior to analysis (Figure 3B; see Supplementary Table 2 for a detailed analysis of EYFP 
expression in DC subsets and other immune cells). In accordance with the EYFP data, Jagged1 and 
Jagged2 mRNA expression was not detected in migratory CD11b+ cDCs sorted from MLN from Jg1Jg2ΔCD11c/
ΔCD11c mice (data not shown). 
Together, these data show that Jagged1, but not Jagged2, is substantially upregulated on migratory 
CD11b+ cDCs upon stimulation with HDM. In addition, DCs from Jg1Jg2ΔCD11c/ΔCD11c mice show almost 
complete in vivo deletion of both Jagged1 and Jagged2.
Mice lacking Jagged expression on DCs develop AAI similar to WT animals
Next, we used an acute AAI model by sensitizing and challenging Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice with 
HDM. Four days after the last challenge, mice were analyzed (Figure 4A). Surprisingly, following 
HDM exposure both Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice developed similar AAI inflammation characterized 
by increased macrophages, eosinophils, neutrophils, B cells and T cells in BAL, compared to PBS-
sensitized mice (Figure 4B). Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice showed similar increases in IL-4, IL-5, IL-13 
and IL-9 expressing CD4+ T cells and also the numbers of IFN-γ or IL-17A T helper cells were similar 
(Figure 4C and 4D). Accordingly, restimulated MedLN cells from Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice showed no 
differences in production of HDM-induced IL-5 (Figure 4E). In addition, numbers of Gata3+ T cells were 
higher in HDM-treated Jg1Jg2ΔCD11c/ΔCD11c mice, compared with Jg1Jg2+/+ control mice. In these experiments 
the numbers of Rorγt+ and Foxp3+ T cells were not different between the two groups. (Figure 4F). T-bet+ 
T cells were not detected (not shown). Whereas total serum IgE levels were higher in Jg1Jg2ΔCD11c/ΔCD11c 
mice, compared with Jg1Jg2+/+ mice, HDM specific IgE and IgG1 in serum were similar in the two HDM-
treated mouse groups (Figure 4G). When we analyzed single gene conditional knockouts, we found, 
as expected, that Jg1ΔCD11c/ΔCD11c and Jg2ΔCD11c/ΔCD11c mice developed AAI similar to WT littermates upon HDM 
exposure (Figure 4H). 
To verify that the DC migration and responsiveness was comparable between Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ 
mice, the DC response to HDM was analyzed 24 hr after intranasal administration of either PBS, 10 
μg HDM or 50 μg HDM (Supplementary figure 3A). We did not detect differences in the numbers of cells of 
individual DC subsets (Supplementary figure 3B and 3C) nor in the expression of co-stimulatory molecules 
on total DCs (Supplementary figure 3D) or separate DC subsets (not shown) in the MedLN or lungs between 
Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice. We noticed a small but significant increase in DLL4 expression on DCs in 
the MedLN of Jg1Jg2ΔCD11c/ΔCD11c mice, compared with Jg1Jg2+/+ mice. 
Taken together, our analysis demonstrates that in the HDM-driven asthma model, there is no 
evidence for a role for Jagged1 or Jagged2 expression on DCs. 
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Conditional Jagged1 and Jagged2 knockout mice develop normal Th1 
responses in vivo
Although Th2 responses still developed in the HDM model in mice with Jagged-deficient DCs, it 
remained possible that these mice had a shift in the Th1/Th2 balance. However, when we analyzed 
in vitro recall responses to OVA, there was no difference in T cell activation, Th1 cells or Th2 cells 
(Supplementary figure 4A-4D), or IL-4+ and IFN-γ+ T cells (not shown) between in vitro OVA-restimulated 
lymph node cells from Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice. Likewise, no differences were found in T cell-
dependent B cell responses, because total or high affine TNP-KLH-specific IgM, Th2-driven IgG1 and 
Th1-driven IgG2c levels were similar in Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice (Supplementary figure 4F and 4G). 
Therefore, the absence of Jagged expression on DCs does not affect the Th1/Th2 balance in vivo. 
Canonical Notch signaling via RBPJκ in CD4+ T cells is required for the 
development of AAI
To establish whether Notch signaling in T cells is critical for the induction of Th2 differentiation, mice 
with T cell-specific conditional deletion of the downstream transcription factor RBPJκ93 were studied. 
We exposed CD4-Cre transgenic RBPJκfl/fl mice (termed RBPJκΔCD4/ΔCD4) and non CD4-Cre expressing RBPJκfl/
fl littermates (termed RBPJκ+/+) to our HDM-driven AAI model (Figure 5A). Strikingly, in the absence of 
RBPJκ in T cells, mice displayed a significant decrease in the number of macrophages, eosinophils, 
neutrophils, B cells, T cells and DCs in BAL compared to WT littermates (Figure 5B). Also, the numbers 
and percentages of IL-4+, IL-5+ and IL-13+ T cells were lower in RBPJκΔCD4/ΔCD4 than in RBPJκ+/+ mice, whereas 
we found similar numbers and increased percentages of IFN-γ+ and IL-17A+ T cells in BAL, MedLN and 
lungs (Figure 5C and 5D and data not shown). Moreover, the ratio of cytokine-producing T cells, shifted 
from a predominant Th2-phenotype to a more equal Th1/Th2/Th17 phenotype in the absence of RBPJκ in 
T cells (Figure 5E). In addition, induction of Gata3 was particularly impaired in RBPJκΔCD4/ΔCD4 mice in CD4+ 
cells in BAL, MedLN and lungs (Figure 5F, 5G and data not shown), Furthermore, serum IgE levels (Figure 
5H) and airway resistance to methacholine were significantly lower in RBPJκΔCD4/ΔCD4 mice, compared 
with RBPJκ+/+ mice (Figure 5I).
In summary, these results demonstrate that canonical RBPJκ-mediated Notch signaling in CD4+ T cells 
is crucial for the induction of AAI and airway hyperreactivity in vivo. 
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Figure 4. Jagged1 and Jagged2 expression on DCs is dispensable for the development of AAI in vivo
(A) Scheme of HDM-mediated AAI induction in mice.  
(B) Total numbers of the indicated cell populations in BAL from PBS- or HDM-treated Jg1Jg2ΔCD11c/ΔCD11c or Jg1Jg2+/+ mice.
(C) Intracellular flow cytrometric analysis of cytokine production by CD3+CD4+ T cells in BAL from the indicated mice and (D) quantification 
of the total numbers of cytokine-positive CD3+CD4+ T cells in BAL.  
(E) Quantification of IL-5 production in vitro by MedLN cells that were restimulated with 15 μg/ml HDM for 7 days, as quantified by ELISA.  
(F) Numbers of Gata3+, Rorγt+ and Foxp3+CD25+ CD3+CD4+ T cells in BAL from PBS- or HDM-treated Jg1Jg2ΔCD11c/ΔCD11c or Jg1Jg2+/+ mice. 
(G) Total IgE levels and levels of HDM-specific IgE and IgG1 in serum of the indicated mice. 
(H) Cell counts of eosinophils and IL-5+ CD3+CD4+ T cells in BAL from PBS- or HDM-treated in Jg1ΔCD11c and Jg2ΔCD11c mice with WT littermates. 
Data are shown as mean + SEM of 6-7 mice per group and are representative of three independent experiments. * p < 0.05, ** < 0.01, using 
Mann-Whitney U-test.
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Discussion 
To induce a Th2 response, Notch signaling in T cells is crucial. This was shown earlier in mouse models 
using parasite antigens129, 131 and in asthma models using OVA133. In line with these reports, we found 
that mice with T cell-specific RBPJκ-deficiency did not mount a Th2 response in a HDM-induced mouse 
AAI model. However, the role of the Notch ligands Jagged1 and Jagged2 in Th2 induction remains more 
elusive. Here we show that upon HDM exposure, Jagged1 is specifically upregulated on migratory 
CD11b+ cDC in medLN, but expression of Jagged1 and Jagged2 on DCs is dispensable for the induction of 
HDM induced AAI in vivo. 
 Whereas we found a substantial increase of Jagged1 expression upon HDM stimulation in vivo and 
in vitro, Jagged2 expression was low and remained unaltered. In addition, Jagged1 was shown to be 
crucial in the induction of a Th2 response in a AAI model using OVA-pulsed in vitro cultured GM-CSF 
bmDCs208, whereas Jagged2 is not required for Th2 induction in vivo209, 210. Therefore, we hypothesized 
that Jagged1, but not Jagged2, would be critical in the induction of AAI in vivo. However, in our 
physiological model using HDM to sensitize and challenge mice, we found that expression of Jagged1 
and Jagged2 on DCs was dispensable. Nevertheless, our data based on transfer of in vitro HDM-
activated GM-CSF bmDCs confirmed earlier literature showing that Jagged-deficient GM-CSF bmDCs 
are incapable of inducing AAI in vivo208 in an OVA-based model. Thus, the requirement for Jagged 
expression on GM-CSF bmDCs for their capacity to induce AAI does not appear to be dependent on the 
nature of the allergen (HDM or OVA), but is likely related to the use of GM-CSF bmDCs to sensitize 
the mice. In particular, it was recently shown that GM-CSF bmDCs comprise a heterogeneous cell 
population consisting of both conventional DC-like cells and monocyte-derived macrophages400. 
These findings indicate that data obtained employing in vivo transfers of GM-CSF bmDCs should be 
interpreted with care. 
While there is no doubt that Notch is required to induce proper effector T cell responses, it is currently 
under debate whether Notch ligands have an instructive role in T helper cell differentiation or 
whether Notch signaling acts as an amplifier of T helper cell responses207. The results obtained after 
instillation of Jagged deficient DCs would appear to support a general role for Notch in promoting 
T helper cell responses. In contrast, in RBPJκ deficient mice treated with HDM, we clearly observed 
a selective defect in Th2 cell responses, while numbers of Th1 and Th17 cells were similar to those in 
wild type mice, arguing for a role for Notch as a Th2 instructive signal. We speculate that Notch can 
perform both roles, enhance general T cell activation and function as a more specific promoter of Th2 
responses, depending on the repertoire of signals mobilized. Thus, when HDM treated DCs are used to 
prime the response, the repertoire of additional T cell activating signals may be limited. In that case, 
T cell activation would become more dependent on activation of Notch. When, on the other hand, 
HDM is inhaled, many cell types (innate lymphocytes, epithelial cells, tissue resident myeloid cells) 
will contribute to the generation of activating signals that may override the requirement for Notch in 
priming of the T cells. In this latter scenario, only the Th2-promoting function of Notch would then be 
critical.
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Figure 5. Notch signaling in CD4+ T cells is crucial for the induction of AAI
(A) Scheme of HDM-mediated AAI induction in RBPJκΔCD4/ΔCD4 and RBPJκ+/+ mice. 
(B) Total numbers of the indicated cell populations in BAL from PBS- or HDM-treated mice.
(C-E) Intracellular flow cytrometric analysis of cytokine production by CD3+CD4+ T cells in BAL from the indicated mice and 
(D) quantification of the total numbers of cytokine-positive CD3+CD4+ T cells in BAL and 
(E) distribution of Th1, Th2 and Th17 cells, as signified by their key cytokines IL-5, IFN-γ and IL-17A, in BAL of the indicated mice. 
(F) Flow cytometry profile of transcription factor expression in CD3+CD4+ T cells in mice treated with HDM.
(G) Quantification of Gata3+, Rorγt+, Foxp3+ CD4+ T cells and CD49b+ CD4+ NKT cells in BAL.  
(H) Total IgE levels in serum, as determined by ELISA. 
(I) Airway resistance, measured directly after administration of increasing doses of methacholine, using Flexivent, in the indicated mouse groups. 
Data are shown as mean + SEM of 4-6 mice per group (B-I) and are representative of 6 independent experiments (B-H). * p<0.05, **p <0.01, using 
Mann-Whitney U-test.
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Supplementary figures and tables 
Supplementary figure 1. Generation of Jagged deficient bmDCs
(A) Scheme of bmDCs culture and stimulation. 
(B) EYFP expression in bmDC subsets from WT×ROSAEYFP and from CD11c-cre×ROSAEYFP mice, stimulated with 
10 μg/ml HDM. Data are shown as mean + SD of 2-4 mice per group.
(C) PCR analysis of genomic DNA from total bmDCs for the presence of the CD11c-cre transgene and for the 
presence of loxP-mediated deletion of Jag1 and Jag2 in GM-CSF bmDCs (shown for 2 mice per genotype) 
from the indicated mice. 
It has previously been suggested that Notch ligands DLL and Jagged instruct Th1 and Th2 responses, 
respectively93. However, we found that mice with a conditional deletion for Jagged1 and Jagged2 in 
DCs developed Th2 responses to HDM to a similar extent as their WT littermates. These findings 
indicate either (I) a critical role for other Jagged-expressing cells, implying an instructive role for 
Notch signaling or (II) redundancy between various Notch ligands (Jagged1, Jagged2, DLL1 and DLL4) 
on DCs during the induction of Th2 responses, which would argue for a role for Notch as an unbiased 
amplifier. 
One explanation for the induction of a Th2 response in the absence of Jagged1 and Jagged2 on DCs could 
be that there is a redundancy of other Jagged expressing cells. It is not likely that Jagged expression on 
alveolar macrophages is required for Th2 priming. Firstly, although macrophages can take up HDM, 
they have been reported to lack the capacity to induce T cell proliferation80. Secondly, our finding of 
>94% EYFP expression in alveolar macrophages from CD11c-cre×ROSAEYFP mice (Supplementary figure 
2B), would indicate that in the Jg1Jg2ΔCD11c/ΔCD11c also these cells are Jagged-deficient. Another candidate 
would be B cells which have been implicated in the induction of Th2 mediated AAI34, 401, 402. Also, B cells 
are important in the development and maintenance of T follicular helper (Tfh) cells403, which play an 
important role in AAI by secreting IL-4 and IL-2134, 68, 404, 405. However, in FACS-sorted activated and non-
activated B cells from HDM treated- and control mice Jagged1 was not detected and levels of Jagged2 
were very low (I.T., unpublished findings), inconsistent with a role for Jagged expression on B cells in 
Th2 cell induction.
We found that upon stimulation with HDM, DLL4 was increased on migratory CD11b+ cDCs in vivo 
(Figure 1B). In the absence of Jagged1 and Jagged2 on DCs, DLL4 expression was increased (Supplementary 
figure 4D), raising the possibility that DLL4 compensates for the absence of Jagged1 and Jagged2. 
DLL4 signaling was originally thought to be associated with the induction of Th1 responses93, 225. 
Indeed, DLL4 is upregulated on DCs in response to Th1 stimuli, including bacterial LPS, respiratory 
syncytial virus (RSV) and dengue virus223, 225, 229. Later studies however showed that it is also induced by 
certain Th2 stimuli, including cockroach allergen, low doses LPS and RSV-mediated allergic asthma 
exacerbations214, 217, 406. Furthermore, a regulatory role for DLL4 was demonstrated in Th2 responses 
to cockroach allergen217, and when DLL4-pretreated bmDCs stimulated with OVA were adoptively 
transferred to induce AAI218. On the other hand, Th2 responses were decreased when DLL4 was 
neutralized in vivo in a mouse model for RSV-mediated allergic asthma exacerbations406. It is therefore 
unclear if DLL4 compensates for the absence of Jagged molecules on DC or if DLL4 has a regulatory role 
in this setting. Further studies targeting both Jagged1 and DLL4 Notch ligands are required to resolve 
this question.
In summary, we showed that Notch signaling is crucial for the induction of HDM-mediated 
eosinophilia, Th2 responses and airway hyperreactivity in vivo, indicating that Notch on T cells could be 
a potential therapeutic target in allergic asthma patients. In addition, our data indicate that there is 
redundancy, either between various Jagged-expressing cells or between Jagged and Delta-like ligands 
on DCs. Therefore, further studies are required to identify which cells and which ligands provide the 
Notch signals that are essential for Th2-induction in allergic asthma. 
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Supplementary figure 3. DCs from Jg1Jg2+/+ and Jg1Jg2ΔCD11c/ΔCD11c mice are similar in numbers and expression of co-
stimulatory factors in an innate response to HDM
(A) Scheme of innate DC activation: Jg1Jg2+/+ and Jg1Jg2ΔCD11c/ΔCD11c mice were i.n. challenged with the indicated amounts of HDM and analyzed 
one day later by flow cytometry.
(B) Numbers of total DCs, CD11b+ cDCs (CD11b+CD103-CD64-FcεRI-), moDCs (CD11b+CD103-CD64+FcεRI+) and CD103+ DCs (CD11b-
CD103+CD64-FcεRI-) in lungs (CD11c|+MHCII+), migratory DCs (CD11c+MHCIIhi) in MedLN and resident DCs (CD11c+MHCII+) in MedLN, upon 
stimulation with the indicated amounts of HDM. 
(C) Numbers of plasmacytoid DCs (pDCs; SSClowFSClowCD11cintMHCIIintCD11b-Ly6Chi) in lungs and MedLN, upon stimulation with the indicated 
amounts of HDM. 
(D) Expression levels of CD80, CD86, OX40L, CCR7, DLL1 and DLL4 gated on total DCs (CD11c+MHCII+) in lungs and MedLN, expressed as MFI 
values determined by flow cytometry. 
Data are shown as mean values + SEM of 3-6 mice per group. Statistical evaluations were performed, whereby side-by-side comparisons 
were done between Jg1Jg2+/+ and Jg1Jg2ΔCD11c/ΔCD11c mice. Differences were not significant unless indicated; * p < 0.05, using Mann-Whitney 
U-test.
Supplementary figure 2. BmDCs from 
Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice are 
similar in expression of co-stimulatory 
molecules, DLL ligands and  
pro-inflammatory cytokines 
(A) Flow cytometric gating strategy for bmDC subsets 
from Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice. Live cells 
were analyzed for CD11c, MHCII and F4/80. Gated cells 
were analyzed for expression of CD115 and MHCII.
(B, C) Mean fluorescent intensity (MFI) values of the 
indicated co-stimulatory molecules (B) and Notch 
ligands (C) on CD11c+MHCII+ bmDCs, stimulated with 
PBS, 10 ng/ml LPS, 10 μg/ml HDM, 0.1 μg/ml IL-33 or 1 
μg/ml HDM and 0.1 μg/ml IL-33. 
(D) Protein concentrations of IL-6, IL-12, TNF-α 
and KC (CXCL1), determined in bmDC culture 
supernatants, measured by ELISA.  
Data are shown as mean values + SEM of 3-4 mice per 
group. No significant differences were found between 
Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ bmDCs, using Mann-
Whitney U-tests.
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Supplementary Table 1. Antibodies used for flow cytometry
Target Conjugate Company Clone
120G8 FITC Own production
B220 Biotin BD biosciences RA3-6B2
B220 PE eBioscience RA3-6B2
B220 PE-Cy7 eBioscience RA3-6B2
CCR7 PE eBioscience 4B12
CD3 APC-ef780 eBioscience 17A2
CD3 PE eBioscience 145-2c11
CD3 PE-CF594 BD biosciences 145-2C11
CD4 AF700 eBioscience GK1.5
CD4 APC-H7 BD biosciences GK1,5
CD4 BV605 BD biosciences RM4-5
CD4 PerCP-Cy5.5 eBioscience RM4-5
CD8a FITC eBioscience Ly-2
CD8a PE-Cy7 eBioscience 53-6.7
CD8a PerCP BD biosciences 53-6.7
CD11b ef450 eBioscience M1/70
CD11b PerCP-Cy5.5 BD biosciences M1/70
CD11c APC-ef780 eBioscience N418
CD11c BV786 BD biosciences HL3
CD11c PE-Cy7 eBioscience N418
CD11c PE-Texas Red Invitrogen N418
CD19 AF700 eBioscience eBio1D3
CD19 APC-ef780 eBioscience 1D3
CD24 Biotin BD biosciences M1/69
CD24 PE BD biosciences M1/69
CD25 PE-Cy7 eBioscience PC61.5
CD25 PerCP-Cy5.5 eBioscience PC61.5
CD49b AF647 BD biosciences HMa2
CD64 AF647 BD biosciences X54-5/7.1
CD64 BV711 biolegend X54-5/7.1
CD69 PE eBioscience H1.2F3
CD80 PerCP-Cy5.5 BD biosciences 16-10A1
CD86 PE-Cy7 BD biosciences GL1
CD103 ef450 eBioscience 2E7
CD103 PE eBioscience 2E7
CD115 PE eBioscience AFS98
DLL1 AF488 eBioscience HMD1-5
DLL4 APC Biolegend HMD4-1
F4/80 APC-ef780 eBioscience BM8
F4/80 Biotin eBioscience BM8
F4/80 FITC eBioscience BM8
Supplementary figure 4. Jagged1 and Jagged2 molecules on DCs are not required for the development of a Th1 
response in vivo
(A) In vivo immunization scheme and in vitro restimulation of inguinal lymph node cells. 
(B-D) Total cells in inguinal lymph nodes (B), MFI of CD69 expression on CD3+CD4+ T cells (C) and proportions of Gata3+ and T-bet+ CD3+CD4+ T 
cells (D) in Jg1Jg2ΔCD11c/ΔCD11c and Jg1Jg2+/+ mice.  
(E) Scheme of TNP-KLH immunization and analysis. 
(F,G) Total TNP-KLH-specific IgM, IgG1 and IgG2c and high-affine TNP-KLH-specific IgM, IgG1 and IgG2c in the serum of Jg1Jg2ΔCD11c/ΔCD11c and 
Jg1Jg2+/+ mice at different time points, as measured by ELISA.
Data are shown as mean + SEM of 4-8 mice per group. ns, not significant, using Mann-Whitney U-test.
IFA, incomplete Freund’s adjuvant; TNP-KLH, tri-nitrophenol keyhole limpet hemagglutinin. 
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Supplementary Table 2. CD11c-cre activity in in vivo DCs 
Cell type Lungs BAL MedLN Spleen
CD11b+ moDCs1) 89,88 ± 4,542) 97,48 ± 3,36  87,85 ± 9,08 82,85 ± 11,71
CD103+/CD8+ DCs 95,70 ± 3,03 99,50 ± 1,00 74,28 ± 2,00 83,78 ± 2,29
Resident CD11b+ cDCs  3)    67,85 ± 12,18  
Resident moDCs1)      68,63 ± 10,40  
Resident CD103+ DCs      39,20 ± 9,53  
CD8+ moDCs       84,88 ± 4,77
CD11b-CD4+ DCs       43,03 ± 9,99
CD11b-CD4+ moDCs1)       56,45 ± 12,71
pDCs 35,78 ± 4,94   57,05 ± 7,36 11,98 ± 2,38
(Alveolar) macrophages 93,70 ± 1,15 98,28 ± 0,43 9,86 ± 4,17 74,23 ± 9,27
Interstitial macrophages 13,05 ± 0,79      
B cells 5,03 ± 1,39 18,15 ± 9,75   5,75 ± 1,63 
T cells4) 11,89 ± 4,45 16,07 ± 7,32   12,18 ± 4,34
NK cells 10,40 ± 1,18 10,38 ± 7,47   11,47 ± 1,35 
1) moDCs were characterized as CD64+FcεRI+CD4+ in the spleen and CD64+FcεRI+ in other organs.
2) Proportions of EYFP+ cells in DC subsets and other immune cells in lungs, BAL, medLN and spleen from 
CD11c-cre×ROSAEYFP mice, stimulated with 50 μg HDM 72 hrs prior to sacrifice. Proportions of EYFP+ basophils, 
eosinophils and granulocytes were <10%. Shown is cells in HDM stimulated mice. Percentages of EYFP positivity 
were similar in PBS treated mice. Data are shown as mean + SD of 2-4 mice per group.
3) Grey, Not determined.
4) EYFP expression in CD3+ T cells was comparable to CD4+ and CD8+ T cells in all organs. 
FcεRI-α Biotin eBioscience MAR-1
Foxp3 AF488 eBioscience FJK-16s
Foxp3 PE-Cy7 eBioscience FJK-16s
Gata3 ef660 eBioscience TWAJ-14
IFN-γ BV650 BD biosciences XMG1.2
IFN-γ PE-Cy7 eBioscience XMG1.2
IL-4 PE BD biosciences 11B11
IL-4 BV711 BD biosciences 11B11
IL-5 APC BD biosciences TRFK-5
IL-5 Biotin BD biosciences TRFK4
IL-9 PE BD biosciences D9302C12
IL-13 ef450 eBioscience eBio13A
IL-13 ef660 eBioscience eBio13A
IL-17A AF700 BD biosciences TC11-18H10.1
Live/Dead Amcyan Invitrogen
Ly-6C BV605 BD biosciences AL-21
Ly-6G PE BD biosciences 1A8
Ly-6G PE-Cy7 BD biosciences 1A8
MHC class II AF700 eBioscience M5/114.15.3
MHC class II APC eBioscience M5/114.15.2
MHC class II APC-Cy7 Biolegend M5/114.15.2
MHC class II BV650 BD biosciences M5/114.15.2
OX40L PE eBioscience RM134L
Rorγt PE BD biosciences Q31-378
Siglec-F PE BD biosciences E50-2440
Siglec-F PE-CF594 BD biosciences E50-2440
Streptavidin APC-ef780 eBioscience
Streptavidin BV650 BD biosciences
Streptavidin PE-Cy7 eBioscience
T-bet BV421 BD biosciences O4-46
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Intriguingly, the induction of Gata3 by the IL-4/Stat6 axis in differentiating Th2 cells raises the paradox 
that IL-4 is required for the generation of the cell type that is its major producer. However, in this context 
it was demonstrated that antigen presenting dendritic cells (DCs) use the Notch signaling pathway to 
instruct T cell differentiation, independently of IL-493. In this model, expression of Jagged Notch ligands 
on DCs constitutes an instructive signal for Th2 differentiation, whereby Notch signaling regulates Gata3 
gene transcription from an upstream promoter, as well as Il4 gene transcription in parallel with Gata3129, 
130. Conversely, expression of the Notch Delta-like ligands on DCs, which is induced by stimulation 
with microbial products, promotes Th1 cell differentiation225, 388, 410. Supporting a critical role for Notch 
signaling in Th2 differentiation, we recently found that house dust mite (HDM)-driven allergic airway 
inflammation (AAI), Th2 activation and BHR were diminished in mice lacking the canonical Notch 
signaling mediator recombination signal-binding protein for IgJκ region (RBPj) in T cells108. However, in 
this HDM-driven asthma model, expression of the Jagged Notch ligands on DCs was dispensable. 
Notch signaling also sensitizes T cells to exogenous cytokines135, potentiates T cell receptor and CD28 
signaling, and stimulates metabolic reprogramming and IL-2 secretion during priming of naïve T cells108. 
Moreover, Notch is required to maintain Th1 and Th2 programs, controls memory Th cell survival by 
regulating glucose uptake109, 135, and acts as a general amplifier of T cells108. RBPj in T cells affected the 
ability of Th17 cells to adequately respond to IL-23141. 
In addition to its role in T cell differentiation, Notch is also important during lung organogenesis, 
alveologenesis, and differentiation189, 190. In addition, Notch signaling has been implicated in other 
immune cells and is also involved, for example, in DC differentiation and maturation411. 
Ligand binding to the Notch heterodimeric cell-surface receptor initiates its intramolecular cleavage 
mediated by a γ-secretase complex, resulting in the release of the Notch intracellular domain (NICD), 
which thereby translocates from the cytosol into the nucleus116, 207. There, NICD forms a transactivation 
complex with mastermind-like (MAML) proteins and RBPj, resulting in the activation of target genes. 
Binding of RBPj to DNA in the absence of NICD prevents target gene transcription by recruiting co-
repressors. Interaction of NICD with RBPj removes co-repressors and recruits co-activators, including 
MAML, which in turn recruit DNA modification enzymes and induce Notch target gene transcription.
Interestingly, blocking Notch signaling by means of intranasal administration of γ-secretase inhibitors 
(GSIs) reduced allergic lung inflammation in a mouse asthma model133. Because GSIs are associated with 
severe, on-target gastrointestinal toxicity, other Notch inhibitors are being developed. For example, 
it has been demonstrated that therapeutic antibodies blocking Notch signaling prevent immune 
activation200, 201 and activation of AKT downstream of Notch can be inhibited by the phosphatidylinositol 
3-kinase inhibitor PI-103412. Assembly of the NICD-MAML-RBPj nuclear complex can be prevented 
by the synthetic, cell-permeable inhibitor stapled α-helical peptide derived from mastermind-like 1 
(SAHM1)199, 413. SAHM1 proved to be effective in a murine model of T cell acute lymphoblastic leukemia 
caused by inappropriate Notch activation and outside the cancer field199, 414, 415. Importantly, this inhibitor 
can be more specific for Notch than the commonly used GSIs, which also affect cleavage of many 
other substrates of this enzyme complex199, 416, or might preferentially affect certain tissues because of 
pharmacologic differences. 
Abstract
Background: The Notch signaling pathway has been implicated in the pathogenesis of allergic 
airway inflammation (AAI). Targeting the active Notch transactivation complex by using the cell-
permeable, hydrocarbon-stapled synthetic peptide stapled α-helical peptide derived from mastermind-
like 1 (SAHM1) resulted in genome-wide suppression of Notch-activated genes in leukemic cells and 
other models. However, the efficacy of SAHM1 in allergic asthma models has remained unexplored.
Objective: We aimed to investigate the therapeutic efficacy of SAHM1 in a house dust mite (HDM)-
driven asthma model. 
Methods: Topical therapeutic intervention with SAHM1 or a control peptide was performed during 
sensitization, challenge or both with HDM in mice. Airway inflammation was assessed by using 
multicolor flow cytometry, and bronchial hyperreactivity (BHR) was studied. Additionally, SAHM1 
therapy was investigated in mice with established AAI and in a model in which we neutralized IFN-γ 
during HDM challenge to support the Th2 response and exacerbate asthma. 
Results: SAHM1 treatment during the challenge phase led to a marked reduction of eosinophil 
and T cell numbers in bronchoalveolar lavage, compared with those in diluent-treated or control 
peptide-treated mice. Likewise, T cell cytokine content and bronchial hyperreactivity were reduced. 
SAHM1 treatment dampened Th2-inflammation during ongoing HDM challenge and enhanced 
recovery after following established asthma. Additionally, in the presence of anti-IFN-γ antibodies, 
SAHM1 downregulated expression of the key Th2 transcription factor Gata3 and intracellular IL-4 in 
bronchoalveolar lavage T cells, but expression of the Th17 transcription factor retinoic-actid-related 
orphan receptor gt or intracellular IL-17 was not affected. SAHM1 therapy also reduced serum IgE levels. 
Conclusions: Therapeutic intervention of Notch signaling by SAHM1 inhibits AAI in mice and is 
therefore an interesting new topical treatment opportunity in asthmatic patients.
Clinical Implications: We show that targeting the Notch transactivation complex with SAHM1, 
a synthetic cell-permeable peptide, inhibits allergic airway inflammation in mice, indicating that 
SAHM1 is an interesting novel treatment opportunity in asthma.
Introduction 
Allergic asthma is characterized by bronchial hyperreactivity (BHR), eosinophilic airway 
inflammation and increased IgE levels407, 408. The hallmarks of asthma are the direct consequences of 
enhanced activation of T helper 2 (Th2) cells producing the cytokines IL-4, IL-5 and IL-13, expression of 
which is controlled by the key Th2 transcription factor (TF) Gata331, 32, 409. Central to the initiation of the 
differentiation of naïve T cells into the Th2 direction is IL-4, which induces Gata3 through IL-4 receptor 
(IL-4R) and signal transducer and activator of transcription 6 (STAT6). 
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Results
SAHM1 abrogates eosinophilic airway inflammation
To evaluate the efficacy of SAHM1, we used an acute airway inflammation model, sensitizing and 
challenging C57bl/6 mice with HDM, and mice were analyzed 4 days after the last challenge (Figure 
1A). In this model mice had AAI characterized by increased eosinophil, neutrophil, macrophage, 
DC, T cell, B cell and type 2 innate lymphocyte cell (ILC2) counts in BAL, compared with those in 
PBS-sensitized mice (Figure 1B and 1C). Treatment with an optimal dose range of 0.3 to 3 mg of SAHM1 
during HDM sensitization and challenge abrogated eosinophilic airway inflammation in lung tissue 
and BAL fluid (Figure 1A-C). 
Next, we used intracellular flow cytometry to analyze cytokine-producing T cells in BAL fluid and 
observed that although the proportions of Th2 cytokine-positive cells were not affected, SAHM1 
treatment reduced significantly the total numbers of CD4 T cells positive for IL-5, IL-13, IL-17 and 
IFN-γ (see Figure E2 in this article’s Online Repository at www.jacionline.org). Thus SAHM1 treatment 
during both sensitization and challenge reduced Th2 cell differentiation and eosinophilic airway 
inflammation. 
SAHM1 treatment is effective during challenge
Because Notch signaling has been implicated in both the induction and in maintenance of Th2 
differentiation93, 135, we compared the effects of SAHM1 (1mg) treatment administered during either 
sensitization or challenge (Figure 1D). We found that SAHM1 treatment effectively reduced eosinophilic 
and T cell accumulation in BAL fluid only when given during the challenge phase (Figure 1E). SAHM1 
treatment during sensitization only did not show any effects. IL-4 is not only important for the 
initiation of Th2 differentiation, but also induces serum IgE (see the Results section in this article’s 
Online Repository), another hallmark of asthma. We observed that the levels of total serum IgE 
were reduced to control levels when mice were treated with SAHM1 during challenge, showing the 
effectiveness of SAHM1 treatment (Figure 1F). 
No effects of SAHM1 treatment were observed in an innate response to a single dose of 100 mg HDM 
regarding BAL differentiation, DC subset cell numbers and CD86 expression (see Figures E3-E5 in this 
article’s Online Repository at www.jacionline.org), indicating that in this context Notch signaling is 
not important for DC activation. Next, when we investigated IL-33-driven alveolar inflammation (see 
Figure E6 in this article’s Online Repository at www.jacionline.org), we noticed that SAHM1 treatment 
did not impair the IL-33-driven eosinophilic inflammation. Therefore SAHM1 does not have a direct 
effect on recruitment and accumulation of eosinophils. 
Next, we adoptively transferred OVA-specific (OTII) T cells in mice that received SAHM1 therapy or D1 
or diluent. No difference in OTII cell division was seen in the presence of SAHM1 therapy during this 
primary response. OVA restimulation of the adoptively transferred OVA-specific OTII T cells obtained 
from lung draining mediastinal lymph nodes (MedLNs) indicates a reduced level of IFN-γ (see Figure E7 
in this article’s Online Repository at www.jacionline.org). 
Given the prominent role of Notch signaling in type 2 immunity, we investigated the capacity of 
the SAHM1 peptide to mitigate pathology in eosinophilic lung inflammation in an HDM-driven 
asthma model. We found SAHM1 therapy to be beneficial because it reduced all hallmarks of asthma, 
including eosinophilic airway inflammation, Th2 differentiation and BHR. 
Methods
Mice 
C57bl/6 mice (Envigo, Zeist, The Netherlands) and OTII (C57bl/6; Erasmus MC, Rotterdam, 
The Netherlands) mice were kept under specific pathogen free conditions, provided with water and 
food ad libitum, and were used at the age of 6 to 11 weeks. All experiments were approved by the 
Erasmus MC Animal Ethics Committee. 
House dust mite allergic airway inflammation model and therapy
Isoflurane-anesthetized mice were sensitized intratracheally (i.t.) with 10 µg of HDM (Greer 
Laboratories, Lenoir, NC) extract in 80 µL of PBS, or PBS only was used to induce AAI on day 0346. 
Ten days later, anesthetized mice were challenged with 10 µg of HDM in 50µL of PBS intranasally 
(i.n.) for 5 consecutive days. In the first set of experiments, treatment with HDM or control PBS was 
admixed with diluent (dimethylsulfoxide (DMSO)); 0.3, 1.0 or 3 mg SAHM1; or D1 (stock solution, 25 
mg/L in DMSO; see the Methods section in this article’s Online Repository at www.jacionline.org for 
supplementary data). The treatment preparation was made just before use. Four days after the last 
challenge, mice were killed and bronchoalveolar lavage (BAL) was performed by flushing the lungs 
3 times with 1 ml PBS containing EDTA (Sigma-Aldrich, St Louis, Mo). The Lungs were snap-frozen 
in liquid nitrogen and stored at -80°C until further processing for histological analysis. In some 
mice, lung function was measured after increasing doses of nebulized methacholine (for details, 
see the Methods section in this article’s Online Repository). Innate immune responses were studied 
with HDM or IL-33 (for details, see the Methods section in this article’s Online Repository at www.
jacionline.org).
Flow cytometric analysis and immunohistochemistry
BAL fluid cells were collected for cellular differentiation by using flow cytometry, as previously 
described346. For details of flow cytometry, see Figure E1 in this article’s Online Repository at www.
jacionline.org. Immunohistochemical staining was performed in a half-automatic stainer (Sequenza, 
Milan, Italy) as previously described417. Sections were stained with rat anti-Siglec-F (clone E50-2440; 
BD Biosciences, San Jose, Calif).
Statistical analysis
Reported values are shown as means + SEMs. Statistical analyses were performed with SPSS software 
(SPSS, Chicago, Ill) by using the Kruskal Wallis test followed by a Mann-Whitney U-test. Resulting p 
values of less than 0.05, 0.01 and 0.001 are indicated and considered significant. Test results that did 
not reach significance (p > 0.05) are not indicated. 
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Figure 1. SAHM1 abrogates eosinophilic airway inflammation.
(A) Experimental HDM-driven asthma design, showing intratracheal sensitization (s) and challenge (c) of 10 µg of HDM admixed with 
diluent, 0.3 and 3 mg SAHM1 (t), or PBS admixed with diluent or 3 mg SAHM1 as a control. Arrows indicated PBS or HDM treatment and 
SAHM1 or diluent therapy (↑). Analyses (a) were performed 4  days after the last challenge. (B) Immunohistochemical  Siglec-F staining 
(red) to identify eosinophils in indicated representative lung samples. (C) Quantification of flow cytometric analyses of the indicated 
populations of BAL cells. The results shown represent one of 2 independent experiments with 3 to 6 animals per group and are expressed 
as means + SEMs. *p<0.05, **p<0.01. (D) Experimental HDM-driven asthma design, showing SAHM1 treatment either during sensitization 
(s) or challenge (c) with 10 µg of HDM admixed with diluent or 1 mg SAHM1 treatment (t), including PBS exposures admixed with diluent or 
1 mg SAHM1 as controls. Analyses (a) were performed 4 days after the last challenge. (E) Quantification of flow cytometric analyses of the 
indicated populations of BAL fluid cells. (F) Total serum IgE levels were measured by means of ELISA. Results are from one experiment with 
3 to 6 animals per group and shown as means + SEMs. *p<0.05, **p<0.01.
SAHM1, but not the mutant control D1, abrogates eosinophilic airway 
inflammation 
Next, we investigated whether a control mutant peptide affected airway inflammation when given 
during HDM challenge (Figure 2A). In contrast to the active SAHM1 inhibitor, the mutant peptide D1199 did 
not abrogate eosinophilic airway inflammation (Figure 2B). When we investigated intracellular cytokine 
content of CD4+ T cells using flow cytometry, we observed a significant reduction in total numbers of Th2 
cells producing IL-5 or IL-13 in BAL fluid when HDM SAHM1-treated mice were compared with HDM D1-
treated mice (Figure 2C and 2D). 
SAHM1 targets the nuclear complex downstream of the Notch signaling pathway by preventing the 
binding of MAML in the RBPj complex, which is important for transcription of Notch target genes, 
which include Gata3, which has an RBPJ-binding site in its upstream promoter129, 130. Intracellular flow 
cytometric analyses were performed to investigate the effect of SAHM1 on key T cell subset TFs, which 
showed that SAHM1 treatment induced a significant reduction in the numbers of Gata3+, retinoic 
acid-related orphan receptor γt (Rorγt)+ and forkhead box P3 (Foxp3)+ T cells in BAL fluid (Figure 3). For Rorγt 
and Foxp3, the reduction was explained mostly by the lower number of T cells found in SAHM1-treated 
animals. In contrast, numbers of Gata3+ CD4+ T cells were also reduced as a proportion of the total T cells, 
suggesting that inhibition of Notch specifically affected Gata3 expression, independent from diminishing 
T cell numbers. And therefore both the proportions (Figure 3A) and absolute numbers of Gata3+ T cells (Figure 
3B) were reduced markedly. In agreement with the limited involvement of Th1 cells in HDM-driven airway 
inflammation in mice, the key Th1 TF T box-containing protein was not induced and not affected by 
SAHM1 treatment. Taken together, these findings demonstrate that SAHM1 is able to reduce the numbers 
of key inflammatory cells in mice with AAI and particularly the Th2 inflammatory response.
SAHM1 abrogates airway BHR
BHR is another hallmark of asthma that we investigated in our HDM-driven asthma model, in which 
PBS control mice and HDM-exposed mice were treated only during allergen challenge with either 1 mg of 
SAHM1 or control diluent (Figure 4A). No differences were observed between the 4 groups of mice in baseline 
airway responsiveness, as measured based on lung resistance. BHR to increasing doses of methacholine 
was significantly increased in HDM-challenged mice treated with diluent, compared with diluent-treated 
PBS control mice (Figure 4B). Importantly, treatment with SAHM1 was potent enough to abrogate BHR in 
HDM-challenged mice. 
SAHM1 improves recovery from AAI
Because asthmatic patients present with clinical symptoms only after airway hypersensitivity has already 
developed fully, we investigated whether SAHM1 treatment would improve airway inflammation in mice 
with already established asthma. To this end, we investigated 5 different groups of mice (Figure 5A). Two 
control groups consisted of PBS/diluent or PBS/SAHM1 controls through sensitization and challenge only. 
Three other groups were sensitized with HDM, followed on day 10 to 14 and thereafter by 5 additional 
HDM challenges. These HDM-exposed mice were then challenged again on 5 successive days (days 15-19) 
with either HDM in the presence of diluent (group 3) or PBS with either diluent or SAHM1 (group 4 and 5, 
respectively; Figure 5A). This setup allowed us to investigate wether SAHM1 enhances the recovery after 
establishment of asthma. 
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When analyzed at day 23, the PBS controls showed no signs of allergic inflammation in BAL fluid. 
The group that was HDM-sensitized and then HDM exposed from days 10 to 19 exhibited significantly 
increased numbers of total cells, eosinophils and T cells, indicating an allergic response (Figure 5B). 
Importantly, when SAHM1 treatment was started 5 days after HDM challenges, the SAHM1-treated 
mice (HDM PBS SAHM1, Figure 5) still showed a strong reduction in eosinophil and T cell numbers, 
compared with the mice receiving diluent (HDM PBS diluent, Figure 5). This showed that SAHM1 
treatment was able to enhance recovery from AAI. Moreover, SAHM1 treatment reduced the numbers 
of Th2 cytokine-producing T cells, which reached significance for IL-5 and IL-13 (Figure 5A), as well as 
the numbers of neutrophils and DCs, in the BAL fluid (data not shown). Therefore SAHM1 treatment 
improves the recovery of already established AAI in an HDM-driven asthma mouse model. 
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Figure 3. SAHM1, but not D1, reduces key T cell subset TF expression. 
(A) TF expression profiles of gated BAL fluid CD3+CD4+ T cells. (B) Quantification of intracellular flow cytometric analyses of the indicated 
populations of BAL fluid T cells. Results are from one experiment with 3 (PBS) or 6 (HDM-exposed) mice per group and shown as as means + 
SEMs. *p<0.05, **p<0.01.
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Figure 2. SAHM1, but not the control peptide D1, abrogates eosinophilic airway inflammation. 
(A) Experimental HDM-driven asthma design, showing intratracheal sensitization (s) and challenge (c) with 10 µg of HDM admixed with 
diluents, 3 mg of D1 control peptide, or 3mg of SAHM1. PBS admixed with diluents, 3mg of D1, or 3 mg of SAHM1 were included as controls. 
Analysis (a) were performed 4 days after the last challenge. (B) Quantification of flow cytometric analyses of the indicated populations of 
BAL fluid cells. (C) Cytokine expression profiles of gated BAL CD3+CD4+ T cells upon 4 hrs of phorbol 12-myristate 13-acetate/ionomycin 
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animals per group and shown as as means + SEMs. *p<0.05, **p<0.01. 
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SAHM1 treatment suppresses α-IFN-γ-induced asthma exacerbation
A previous study showed that inhibition of Notch resulted in loss of Th2 responses to a helminth 
parasite, but that Th2 responses could be restored by blocking IFN-γ135. This result suggested the 
possibility that a main function of Notch is to counteract the inhibitory activity of IFN-γ towards 
development of Th2 type responses. The imbalance between Th1- and Th2-type cytokines in favor of Th2 
cytokines is a major cause of allergic diseases in human patients. If the primary function of Notch 
is indeed to counteract the inhibitory function of IFN-γ on Th2 responses, a prediction would be that 
neutralization of IFN-γ would also obviate the ability of Notch inhibition to mitigate the development 
of allergic asthma.
Therefore we tested whether SAHM1 treatment could suppress development of eosinophilic airway 
inflammation when mice are injected with neutralizing antibodies to IFN-γ-induced exacerbation. 
To this end, we investigated eosinophilic airway inflammation in HDM-exposed mice in the presence 
of α-IFN-γ or control rat immunoglobulin (Ig) treated with either diluent or SAHM1 (Figure 6A). On 
the basis of previous reports showing an increased Th2 response when Th1 activity is suppressed by 
binding of free IFN-γ135, 418, we expected that the presence of α-IFN-γ during the challenge phase would 
exacerbate the AAI. Indeed, eosinophilic airway inflammation was more severe in the presence of 
α-IFN-γ , as evidenced by increased induction of focal dense infiltrates (Figure 6B). Importantly, the 
inflammation was less severe when mice were treated with SAHM1 (Figure 6B). Likewise, numbers of 
eosinophils, neutrophils, macrophages and T cells were significantly increased by treatment with 
Figure 4. SAHM1 treatment abrogates airway BHR.
(A) Experimental HDM-driven asthma design, showing intratracheal sensitization (s) and challenge (c) with of 10 µg HDM admixed with 
either diluent or 1 mg SAHM1. PBS admixed with either diluent or 1 mg of SAHM1 served as controls. Analyses (a) were performed 4 days 
after the last challenge in the indicated mouse groups. (B) Bronchial hyperresponsiveness measurement (Lr, lung resistance) with Buxco in 
the indicated mouse groups. Results are from one experiment with 4 (PBS) or 8 (HDM-exposed) mice per group and expressed as as means 
+ SEMs. *p<0.05, **p<0.01. 
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Figure 5. SAHM1 improves recovery from AAI
(A) Experimental HDM-driven asthma design, showing intratracheal sensitization (s) and challenge (c) with HDM during the first interval 
(day 10-14) to induce asthma. During the second interval (day 15-19), HDM (ongoing inflammation) or PBS (resolution phase) was given 
with either 1 mg of SAHM1 treatment (t) or diluent as a control. Analyzes (a) were performed four days after the last challenge in the 
indicated mouse groups. (B) Quantification of flow cytometric analyses of the indicated populations of BAL fluid cells during ongoing 
inflammation and resolution. Results are from one experiment with 3 to 6 animals per group and are shown as as means + SEMs. *p<0.05. 
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Figure 6. SAHM1 treatment suppresses α-IFN-γ induced asthma exacerbation
Figure 6. SAHM1 treatment suppresses α-IFN-γ induced asthma exacerbation
(A) Experimental HDM-driven asthma design, showing intratracheal sensitization (s) and challenge (c). During challenge, HDM was 
admixed either with 150 mg control rat immunoglobulin or α-IFN-γ (to exacerbate asthma) and diluent or 3mg of SAHM1. Analyses (a) 
were performed 4 days after the last challenge in the indicated mouse groups. (B) Immunohistochemical Siglec-F staining (red) to identify 
eosinophils in the indicated representative lung samples. (C) Quantification of flow cytometric analyses of the indicated populations of 
BAL fluid. Cell numbers were significantly less for PBS (statistics not indicated in figure). (D) Total CD4+ T cell numbers in BAL fluid (left) 
and pie charts of CD4+ T cells classified as Th2 (IL-4), Th1 (IFN-γ) and Th17 (IL-17) cells (right). (E) TF expression profiles of gated BAL 
fluid CD3+CD4+ T cells. (F) Quantification of flow cytometric analyses of the indicated populations of TF-expressing BAL fluid T cells in 
the indicated experimental mouse groups. (G) Total serum IgE levels were measured by means of ELISA. Results shown are from one 
experiment with 3 to 6 animals per group and are shown as as means + SEMs. *p<0.05.
α-IFN-γ (Figure 6C). Asthma exacerbation by α-IFN-γ during HDM challenge was associated with 
increased numbers of eosinophils, neutrophils, macrophages and T cells in BAL fluid, but additional 
treatment with SAHM1 restored these numbers to those observed in HDM and control rat Ig-exposed, 
diluent-treated mice (Figure 6C).
Intracellular flow cytometry showed that the numbers of Th2 (IL-4), Th1 (IFN-γ) and Th17 (IL-17) cells 
in BAL fluid were significantly increased in the presence of α-IFN-γ compared with those in mice that 
received control rat Ig, but only a limited effect of SAHM1 on the relative proportions of cells producing 
these cytokines content could be detected (Figure 6D). Therefore, we investigated TF expression in 
BAL fluid Th cells and saw that blocking IFN-γ resulted in reduced proportions of Gata3+CD4+ T cells 
and increased proportions of Rorγt+CD4+ T cells in BAL fluid (Figure 6E). Importantly, in the presence 
of α-IFN-γ , SAHM1 treatment still reduced the proportions of Gata3-expressing CD4+ T cells in BAL 
fluid compared with diluent treatment (Figure 6E). This reduction was greater than the reduction of 
the CD4 T cell number by SAHM1 (Figure 6D), suggesting that Notch inhibition specifically reduced 
Th2 responses in this model, even when IFN-γ was neutralized (Figure 6E). Quantification of absolute 
numbers of TF expressing CD4+ T cells in BAL demonstrated that, in the presence of α-IFN-γ , SAHM1 
treatment reduced Gata3+CD4 T cells numbers, but did not affect numbers of Rorγt+ or FoxP3+CD4+ 
T cells (Figure 6F). We observed that total serum IgE levels were increased in HDM-exposed mice, 
compared with PBS control mice, but the effects of α-IFN-γ or SAHM1 treatment in HDM-exposed mice 
were limited (Figure 6G). SAHM1-treated HDM/α-IFN-γ -exposed mice showed some reduction of serum 
IgE levels compared with those in diluent-treated control mice, but this did not reach significance 
(Figure 6G). 
From these experiments we conclude that SAHM1 treatment reduces AAI, even in the setting of 
α-IFN-γ -induced asthma exacerbation. Furthermore, these findings indicate that Notch signaling 
in the HDM-mediated airway inflammation model does not only function to counteract inhibitory 
effects of IFN-γ on Th2 differentiation. 
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myeloid DCs through thymic stromal lymphopoietin, which resulted in myeloid 
DC-driven Th2 responses220. These findings indicate that environmental factors, 
including air pollution, influence Notch signaling. 
Although Notch activation in epithelial cells is sufficient to induce mucous 
metaplasia, which is a hallmark of asthma, the lack of Notch signaling 
seems to be beneficial427. In this context Notch and STAT6 signaling operate in 
parallel and independent pathways to regulate mucous metaplasia191. Thus, 
pharmacological targeting of Notch signaling in epithelial cells, such as by 
SAHM1, can be considered in patients with airway diseases associated with 
mucous metaplasia191. It is very well possible that in our HDM-driven AAI model, 
topical intratracheal application of SAHM1 also beneficially targeted epithelial 
or endothelial cells. Neutralization of Notch2 reverses established goblet 
cell formation in an IL-13-induced mouse model of mucus hypersecretion423, 
428. Taken together, these effects on the airway epithelium could be seen as a 
bonus of SAHM1 topical therapy in the airways targeting inflammatory cells. 
Nevertheless, our previous finding that HDM-driven airway inflammation 
is diminished in mice with conditional RBPJ deletion exclusively in the T cell 
lineage demonstrated the critical role of Notch signaling in T cells419. 
Our study has implications for the therapeutic use of peptidomimetic 
compounds in general. Although stapled peptides have been used in vivo and 
several of these are in human clinical testing, this is the first report of topical 
delivery. This suggests the potential to use this class of inhibitor for localized 
delivery in patients with asthma and other indications. 
In conclusion, we demonstrate that the Notch pathway is important for an in vivo 
type 2 immune response. Importantly, targeting the NICD-MAML-RBPJ complex 
by SAHM1 reduced Th2 inflammation during ongoing HDM challenge and 
enhanced recovery after established asthma. Therefore SAHM1 might represent a 
novel therapeutic opportunity to abrogate both airway inflammation and BHR in 
patients with allergic asthma. 
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Discussion
The Notch signaling pathway has been implicated in asthma pathogenesis. Here we show that the 
cell-permeable, hydrocarbon-stapled peptide SAHM1 is effective in an HDM-driven model for AAI in 
mice. SAHM1 treatment reduced functional airway abnormalities: HDM-exposed mice showed all 
signs of allergic inflammation, including BHR to methacholine and eosinophilia. However, when 
they received SAHM1 therapy, they showed fewer signs of BHR and eosinophilic airway inflammation. 
Notch signaling in CD4+ T cells induces the formation of a nuclear complex containing NICD, RBPJ and 
MAML. When RBPJ is deleted in CD4+ T cells, this complex cannot be formed, and the Notch pathway 
is blunted93, 419. SAHM1 binds this nuclear complex at the MAML interface and thereby functions as 
a competitor. Because an RBPJ-binding site is present in the Gata3 upstream promoter (exon 1a) and 
because we found that Gata3 expression is reduced by SAHM1, it is conceivable that this drug dampens 
AAI by inhibiting the expression of Gata3 from the upstream promoter. Direct therapeutic targeting 
of Gata3 is challenging, although recently, improvements in both early and late asthmatic responses 
after allergen provocation were demonstrated in patients after treatment with a DNAzyme that 
specifically targets Gata3 mRNA420. Intriguingly, there are differences in the regulation of Il4 gene 
transcription (which is partly Notch dependent) and Il5 and Il13 gene transcription (which is Gata3 and 
IL-4R/signal transducer and activator of transcription 6 (STAT6) dependent)39, 93. This might implicate 
that when Notch signaling is inhibited in a strong asthma protocol, initial production of IL-4 can 
still induce IL-4R/STAT6-dependent transcription of Gata3 from the exon 1b promoter and thus 
transcription of the Il5 and Il13 genes. 
GSIs, which act as Notch inhibitors, were used successfully in models of AAI, showing the importance 
of the Notch pathway in IL-4-producing CD4+ T cells208, 421, 422. The finding that Notch inhibition is 
effective during both the primary and secondary immune response illustrated the ongoing need of 
the Notch pathway for maintenance of Th2 responses208, 421. Unfortunately, GSI show significant side 
effects and are not specific. Here we demonstrate that in HDM-driven AAI, which is an acute and short 
T cell-dependent asthma model, Notch signaling is important during allergen challenge, which is in 
agreement with earlier findings that Notch is required for maintaining the Th2 program135. Several 
features of SAHM1 are of significant interest in the context of its application as a new treatment 
strategy in asthmatic patients. We observed that SAHM1 is effective in dampening HDM-induced AAI 
and α-IFN-γ -induced exacerbation of allergic inflammation. Moreover, SAHM1 was potent in reducing 
inflammation in mice with established AAI and to enhance and accelerate recovery. Furthermore, 
these findings indicate that Notch signaling in the HDM-mediated airway inflammation model 
does not only function to counteract inhibitory effects of IFN-γ on Th2 differentiation. In addition, 
the Notch signaling pathway is not only critical for T cells, but also for other cells involved in AAI, 
including epithelial cells and DCs423. Because in endothelial cells the Il33 gene is a Notch target424, 
SAHM1 treatment can result in impaired IL-33 responses. Of note, IL-33 production by airway 
epithelial cells plays an important role in patients with AAI425. Notch is a common differentiation 
signal for T cell priming of CD11b+ DC subsets in the spleen and intestine178, and deletion of RBPJ 
resulted in a reduced capacity of DCs to activate T cells426. Human bronchial epithelial cells treated 
with diesel exhaust particles generate oxidative stress and upregulate Jagged1 and OX40 ligand in 
4
Chapter 8
Notch signaling in T helper 
cell subsets: instructor or 
unbiased amplifier?
Irma Tindemans
Marlies J.W. Peeters
Rudi W. Hendriks
Published in; 
Frontiers in Immunology 2017; 8, 419
Summary 168
Introduction 168
The Notch signaling pathway 169
Induction of Notch ligands on APCs 170
The role of Notch ligands in Th2  170
and Th1 differentiation and function 
“Instructive” versus “unbiased amplifier” model     175
Conclusions and future directions 176
Funding 177
169168
An accumulating number of studies suggest that the Notch signaling pathway, which also plays 
a crucial role in early hematopoietic development and at multiple steps of T lineage development, 
is essential for Th cell differentiation (for recent review: REF 207). Currently, two opposing models 
have been proposed that explain how Notch ligands can influence Th subset differentiation. 
According to the ‘instructive’ model, Jagged and Delta-like ligands (DLL) on APCs induce Th2 and Th1 
differentiation, respectively93. Alternatively, the ‘unbiased amplifier’ model proposes that Notch 
ligands are not instructive but rather function to generally amplify Th cell responses135. In this review, 
we will discuss these two contrasting hypotheses on the role of Notch signaling. We will focus both on 
Notch receptor expressing T cells and on Notch ligand-expressing cells.
The Notch signaling pathway
There are five Notch ligands: two Jagged (Jagged1 and Jagged2) and three Delta-like ligands (DLL1, 
DLL3 and DLL4), which are bound by four receptors, Notch1-4. For these ligands to be functional 
their ubiquitination by Mindbomb1 or Neuralized within the cell is required500. Details of the Notch 
signaling pathway are discussed in various excellent reviews444, 459. Briefly, following ligand-receptor 
binding, the Notch intracellular domain (NICD) is cleaved by a γ-secretase complex and translocates 
to the nucleus and binds to the transcription factor RBPJk (recombination signal binding protein for 
immunoglobulin Jk region; Figure 1). Finally, additional co-activating proteins are recruited, such 
as mastermind-like proteins (MAML1-3) and p300 to induce transcription of target genes. Notch 
signaling does not only induce Th lineage-defining transcription factors and cytokines (described 
below), but also general pathways critical for T cell activation, including IL-2 production, upregulation 
of the IL-2 receptor and glucose uptake107-110. Notch signaling potentiates phosphatidylinositol 
3-kinase-dependent signaling downstream of the T cell receptor (TCR) and CD28 by inducing 
activation of Akt kinase and mammalian target of rapamycin, which enhances T cell effector 
functions and survival and allows them to respond to lower antigen doses108, 111, 112. Notch signaling can 
be enhanced by the protein kinase PKCθ, which is crucial for TCR and CD28 signaling and regulation 
of the actin cytoskeleton113. Moreover, upon TCR stimulation NICD interacts with other proteins in the 
cell in a non-canonical, RBPJκ-independent pathway that leads to NFκB activation114, 115. 
Summary 
For protection against pathogens, it is essential that naïve CD4+ T cells differentiate into specific effector 
T helper (Th) cell subsets following activation by antigen presented by dendritic cells (DCs). Next to T cell 
receptor and cytokine signals, membrane-bound Notch ligands have an important role in orchestrating 
Th cell differentiation. Several studies provided evidence that DC activation is accompanied by surface 
expression of Notch ligands. Intriguingly, DCs that express the Delta-like or Jagged Notch ligands gain 
the capacity to instruct Th1 or Th2 cell polarization, respectively. However, in contrast to this model 
it has also been hypothesized that Notch signaling acts as a general amplifier of Th cell responses 
rather than an instructive director of specific T cell fates. In this alternative model Notch enhances 
proliferation, cytokine production and anti-apoptotic signals or promotes co-stimulatory signals in T 
cells. An instructive role for Notch ligand expressing DCs in the induction of T helper cell differentiation 
is further challenged by evidence for the involvement of Notch signaling in differentiation of Th9, Th17, 
regulatory T cells and follicular T helper cells. In this review, we will discuss the two opposing models, 
referred to as the ‘instructive’ and the ‘unbiased amplifier’ model. We highlight both the function of 
different Notch receptors on CD4+ T cells and the impact of Notch ligands on antigen-presenting cells.
Introduction
Following signals from both antigen presenting cells (APCs) and the micro-environment, activated CD4+ 
T cells are triggered to initiate secretion of specific effector cytokines. Since the original observation 
in 1986 that upon antigenic stimulation naïve CD4+ T cells can differentiate into T helper 1 (Th1) or Th2 
effector T cells depending on polarizing cytokine signals23, various additional Th subsets have been 
recognized. These include Th9, Th17, Th22, follicular T helper cells (Tfh) and regulatory T cells (Tregs), 
each characterized by a unique cytokine production profile and a key transcription factor (see for recent 
review: REF 24). These Th subsets play a crucial role in appropriate immune responses during host 
defense, but are also involved in the pathogenesis of inflammatory diseases25, 26. 
Th1 cells mainly produce IFN-γ and TNF-α and are associated with the elimination of intracellular 
pathogens. Th1 development is facilitated by either IL-12 and STAT4 or by IFN-γ, STAT1 and the key 
Th1 transcriptional regulator T-box-containing protein (T-bet), encoded by Tbx2128. Th2 cells control 
helminth infections and are implicated in allergic immune responses such as allergic asthma. They are 
potent producers of Th2 cytokines that induce IgE synthesis (IL-4), recruit eosinophils (IL-5) and cause 
smooth muscle hyperreactivity and goblet cell hyperplasia (IL-13). Therefore, Th2 cells are central in the 
orchestration and amplification of inflammatory events in allergic asthma. The master transcription 
factor Gata3 is necessary and sufficient for Th2 cytokine gene expression in Th2 cells409. Because Th2 
differentiation is driven by IL-4, this raises the paradox that IL-4 is required to generate the cell type 
that is its major producer. But, the origin of the first IL-4 required for Th2 cell induction remains 
unclear. While a range of cell types are able to produce IL-4, Th2 cell responses can still be generated 
when only T cells can make IL-4, arguing against an essential role for an external source of IL-441, 42. 
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with a DC-specific conditional deficiency of both Jagged1 and Jagged2 developed normal AAI following 
in vivo HDM-exposure (Chapter 3). Although most studies using bmDCs would support an instructive 
role for Jagged in the induction of Th2 cell differentiation and function (Table 1), our studies indicate 
that induction of Th2 responses in HDM-driven AAI is dependent on Jagged expression on other cell 
types than DCs or alternatively on cooperation between Jagged and DLL on DCs. 
Taken together, although several lines of evidence indicate that DCs use the Notch pathway to 
instruct Th cell fates, Notch may also act as an unbiased amplifier of Th cell differentiation.
Induction of Notch ligands on APCs
Th2-promoting stimuli including helminth eggs, prostaglandin E2, cholera toxin and allergens 
such as house dust mite (HDM), birch pollen and cockroach allergens were shown to induce Jagged 
expression on APCs, as summarized in Table 1. Conversely, microbial Th1-inducing stimuli, e.g. 
dengue virus, respiratory syncytial virus (RSV), bacterial LPS and the TRL9 ligand CpG, upregulate 
the Notch ligands DLL1/DLL4 on APCs (Table 1). Other studies, however, do not show exclusive 
upregulation of either DLL or Jagged molecules, but rather upregulation of Notch ligands of both 
families upon stimulation93, 205, 208, 214, 215, 217, 221, 222, 227, 419, 501. Interestingly, whereas surface induction of DLL 
requires MyD88, this is not the case for Jagged induction93, 210, 216, 223-225. LPS can promote both Th1 and 
Th2 responses, which are MyD88-dependent and Myd88-independent, respectively, but the molecular 
mechanisms responsible for Jagged induction by LPS are unknown502-504. Together, although there 
is also evidence that particular stimuli can induce both Th1 and Th2 differentiation, many studies 
support an instructive role of DLL and Jagged expression on APCs.
The role of Notch ligands in Th2 and Th1 differentiation 
and function
Th2 cells
Notch signaling can initiate Th2 cell differentiation by direct activation of (i) a 3’ enhancer of the 
Il4 gene, and (ii) an upstream promoter of Gata339, 93, 129, 130. Several studies using mice expressing a 
dominant negative (DN) MAML transgene have demonstrated that Notch signaling is essential for 
Th2 cell differentiation and function130, 131. When γ-secretase inhibitors (GSI) were used to block Notch 
signaling in OVA-induced asthma or food allergy models, Th2 cytokine production by T cells was 
inhibited while IFN-γ production was increased132-134. Moreover, upon gene ablation of Notch1/Notch2 
or RBPJk, IL-4 production was abrogated and functional responses against parasitical pathogens were 
reduced93. At the same time, IFN-γ expression was unaffected, supporting an instructive role for Notch 
signaling. In line with an instructive model, DLL4 was demonstrated to have a regulatory role in Th2 
responses to cockroach allergen, OVA, RSV or Schistosoma Mansoni egg antigen (Table 1) and in an 
experimental autoimmune encephalomyelitis (EAE) model212. A protective Th1 response to RSV in the 
lungs was converted into an allergic Th2 response by DLL4-neutralization in vivo216.
However, defective Th2 responses against the intestinal helminth Trichuris muris in DN-MAML 
transgenic mice were restored when mice received anti-IFN-γ antibodies, indicating that Notch 
functions to optimize rather than to initiate the Th2 response135. Moreover, decreased Th2 
responses were found when DLL4 was blocked in a mouse model for RSV-mediated allergic asthma 
exacerbations406. Finally, we very recently found that whereas mice with RBPJk-deficient T cells failed 
to develop HDM-driven allergic airway inflammation (AAI) and airway hyperreactivity (AHR), mice 
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Instructive model Unbiased amplifier model
T cell
Th1 stimuli Th2 stimuli
Jagged1/2DLL1/4
Tbx21, Ifng
Notch receptorNotch receptor
RBPJ-κ
MAML
p300
Gata3, Il4
RBPJ-κ
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p300
APC?
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p300
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↑Co-stimulation
↑Transcription factors 
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 ?
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Figure 1: Schematic overview of the two models describing the role of Notch signaling in Th cell differentiation. 
(A) According to the instructive model, Th1-stimuli and Th2-stimuli induce DLL and Jagged ligand expression on APCs, respectively. Upon 
receptor-ligand binding, Th1 differentiation is induced by Notch intracellular domain (NICD) binding and activating transcription of the Th1 
transcription factor gene Tbx21 and signature cytokine Ifng. For Th2 differentiation, Notch induces transcription of Gata3 and Il4. 
(B) Notch ligands act as an unbiased amplifier, thereby sensitizing cells to the environment to ensure that activated CD4+ T cells overcome 
a Th cell commitment threshold. Notch induces activation, proliferation, enhance anti-apoptotic signals and is simultaneously recruited to 
Th1, Th2 and Th17 genes. So, in this hypothesis Notch acts as an enabler of differentiation, whereby the outcome depends on signals of the 
environment, such as cytokines.
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“Instructive” versus “unbiased amplifier” model 
As summarized in Table 1, considerable evidence supports an “instructive model” whereby pathogens 
direct Th1 and Th2 differentiation via upregulation of DLL or Jagged ligands on DCs, respectively (Figure 
1). This implies that different Notch ligands induce distinct cellular responses in T cells, largely by 
the same signaling components. Although it has been speculated that different ligands might induce 
qualitatively different signals, e.g. RBPJk-dependent or independent, or signals that differ in strength 
or kinetics524, the molecular mechanisms involved are currently unknown. 
It has been shown that DLL4 induces a stronger Notch signal than DLL1 or Jagged1516. Also, the ability 
of ligands to induce Notch signaling is dependent on the glycosylation status of the extracellular 
domain of Notch: Notch receptors carrying N-acetylglucosamine preferentially signal via Delta 
ligands, while Jagged binding is inhibited99. Absence or overexpression of Fringe glycosyltransferase 
proteins alters Th1 and Th2 differentiation406, 422. Another possibility would be that different ligands 
preferentially activate different Notch receptors, which may each have unique downstream nuclear 
targets to induce distinct cellular programs. Indeed, it has been reported that whereas Notch1 and 
Notch2 activate Th2 differentiation, Notch3 promotes Th1 differentiation and IFN-γ production129, 388. 
The expression of all these Notch receptors is induced on T cells upon TCR stimulation137, 151, 461. Because 
different NICDs have different target gene preferences525, distinct ligand-receptor combinations 
may produce quantitatively or qualitatively distinct signals526. However, this is not supported by the 
findings that both Th1 and Th2 differentiation is affected in T cells that are Notch1/Notch2 double-
deficient129, 137 and that retroviral expression of Notch1 as well as Notch3 was associated with increased 
Th1 responses136, 388. This issue is further complicated by the observation that individual Notch 
receptors are upregulated with different kinetics527. It is therefore conceivable that they have distinct 
functions depending on the phase of the response.
Several studies are in apparent conflict with the “instructive model”. For example, DLL ligands were 
reported to promote Th2 responses or Jagged ligands were implicated in Th1 induction406, 528. Neither 
Jagged1 or DLL1 could instruct Th2 or Th1 cytokine differentiation in vitro in the absence of polarizing 
cytokines150. Importantly, Bailis et al. showed that Notch signaling simultaneously induced Th1, Th2 
and Th17 gene transcription, also under polarizing conditions that were described to favor only one 
of the differentiation outcomes135. In addition, Notch signaling via DLL4 was shown to boost antigen 
sensitivity of CD4+ T cells via promoting co-stimulatory signals in T cells108. Together, this would 
suggest that Notch acts as a co-stimulating factor that orchestrates multiple Th cell programs by 
sensitizing cells to exogenous cytokines, thereby ensuring that activated CD4+ T cells overcome a Th 
cell commitment threshold. In support of a role for Notch as an unbiased amplifier (Figure 1), Notch 
signaling was shown to be required for optimal T cell expansion, CD25 and IL-2 induction in vitro of 
both Th1 and Th2 cells107, 108, 110, 150. Finally, Notch signals promote survival by enhancing anti-apoptotic 
signals and glucose uptake109, 149. 
It is conceivable that minor differences in experimental design or conditions form the basis of the 
discrepant results that support one of the two opposing models for Notch function in Th differentiation. 
Many studies on Notch ligands on APCs have employed GM-CSF cultured bmDCs (Table 1), 
Th1 cells
The signature Th1 genes Ifng and Tbx21 were identified as direct Notch targets135, 136. Mice in which T 
cells were Notch1/Notch2 double-deficient showed impaired IFN-γ secretion by Th1 cells during in vivo 
Leishmania major parasite infection, but reports employing DN-MAML transgenic or conditional 
RBPJκ knockout mice, demonstrated that Th1 cell function was unaffected129-131, 137, 419. Therefore, these 
findings suggest that signals that regulate Th1 differentiation involve RBPJκ-independent functions of 
Notch. Studies using GSI showed that Th1 differentiation was impaired in an in vivo EAE model135, 136. By 
contrast, an increase in Th1 differentiation (and a concomitant decrease in Th2 cytokine production) 
was seen in an OVA-driven AAI model133. The interpretation of these apparently conflicting findings 
remains complicated, because effects of GSI are not limited to Notch signaling and e.g. also involve 
HLA-A2 expression and cadherins198.
The capacity of DLL1/DLL4 to induce Th1 cell differentiation is supported by many in vitro and in vivo 
experiments, as outlined in Table 1. For example, anti-DLL4 antibodies reduced IFN-γ and TNF-α 
secretion by T cells in vivo211-213. DLL1-blockade decreased Th1 cell numbers in an allograft model152. 
Conversely, Jagged1-Fc had no effect and anti-Jagged1 antibodies worsened EAE disease205, 226. Gene 
ablation of Jagged1 or Mindbomb1, which is critical for expression of functional Notch ligands, did not 
affect Th1 differentiation in vitro208, 222. 
In conclusion, although most studies would support an instructive role for DLL1/DLL4 in Th1 
induction, the role of Notch signaling in Th1 cell differentiation remains incompletely understood.
Other T helper cell subsets
Given the increasing complexity of T cell subset biology, it is not unexpected that the bipotential 
instructional model is not sufficient to fully explain the function of Notch signaling in Th cell 
differentiation. For example, Notch signaling cooperates with TGF-β to induce Th9 cell differentiation 
and IL-9 expression via Jagged2 ligation138. The Rorc, Il17 and Il23r gene promoters are direct Notch targets 
and, accordingly, Th17 cell differentiation is impaired when Notch signaling is blocked139-143. Hereby, 
DLL1, DLL3 and DLL4 ligands were found to be essential212, 213, 230, 406, 505, but a role for Jagged1 remains 
controversial506-508. Remarkably, addition of DLL3 enhanced Th17 differentiation in vitro509, although it 
was shown that DLL3 cannot activate Notch in adjacent cells, but inhibits signaling when expressed 
in the same cell as the Notch receptor510. Differentiation and function of Tregs requires Notch 
signaling in T cells105, 144-146, whereby both DLL and Jagged ligands can promote Treg expansion511-518. 
Although the key Treg transcription factor Foxp3 is a direct Notch target519, the role of Notch in Tregs 
seems rather complex, because targeting of DLL4 or Treg-specific components of the Notch pathway 
was associated with an increase of Tregs in in vivo autoimmune models212, 520, 521. Moreover, hepatocytes 
and plasmacytoid DCs can induce IL-10 production in T cells via Jagged1 and DLL4, respectively515, 522, 523. 
Finally, the finding that the absence of Notch receptors on T cells or DLL4 on lymph node stromal cells, 
resulted in a deficiency of Tfh cells147, 148, implicates Notch signaling in Tfh cell differentiation.
8
177176
Since Notch signaling is involved in the differentiation of basically all Th subsets, 
it could serve as a potential therapeutic target, for example by inhibiting Th2 
responses in allergies or Th1/Th17 responses in autoimmune diseases. However, 
because effects of GSI are not limited to Notch signaling, it will be valuable 
to develop more specific compounds targeting Notch signaling components. 
Indeed synthetic, cell-permeable stabilized peptides that target a critical 
protein-protein interface in the Notch transactivation complex199-201, as well as 
specific antibodies that target Notch receptors202-204 or Notch ligands205, 206 have 
been designed. Promising results were obtained with Notch pathway blocking 
antibodies in cancer patients534 and future studies should explore whether these 
antibodies are beneficial for allergic or autoimmune patients.
Interestingly, GSI administration during only the challenge in asthma models 
was sufficient to decrease Th2 cytokine production132, 133. These findings imply that 
Notch signaling is not likely critical to initiate IL-4 production in activated T cells 
and thus the initial source of IL-4, for example in AAI, remains unclear. While 
several cells including basophils, Tfh cells, NKT cells and ILC2 are capable of 
producing IL-433-40, mice deficient for NKT cells, ILC2 or basophils are still capable 
of inducing Th2 responses385, 535, 536, suggesting that IL-4 production by Tfh cells 
could be crucial for Th2 cell induction. Nevertheless, the finding that in animal 
models allergic disease symptoms are reduced by GSI administration during 
challenge only, indicates that Notch signaling is important in maintaining 
rather than inducing Th2 cell responses. This makes Notch signaling an 
interesting target for development of therapeutic strategies in allergic asthma. 
Funding
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which were recently shown to contain not only DCs, but also monocyte-derived macrophages400. In 
our own studies, we found that Jagged expression was required for the induction of a Th2 response 
in the lung when in vitro HDM-pulsed bmDCs were used for allergen sensitization, but not when mice 
were in vivo sensitized by endogenous airway DCs (Chapter 3). Moreover, studies are complicated by the 
finding that Notch ligands are not only induced on DCs, but also on macrophages, B and T cells or 
lymph node stromal cells148, 205, 460, 461. Stimulation via CD46 and CD3 was shown to upregulate Jagged1 
on human T cells462, suggesting that T cells can provide Notch signals to each other. However, it is 
of note that normally several mechanisms, including lateral inhibition, are used to regulate Notch 
activity when similar cell types express both ligand and receptor. By lateral inhibition signal-sending 
cells actively repress their Notch signaling pathway529 which would hamper concerted Notch-
mediated differentiation and polarization of adjacent T helper cells. Finally, Notch receptors can 
become activated independent of ligand binding471. Indeed, spontaneous Notch cleavage has been 
observed upon TCR triggering107, 110, 114. Ligand-independent Notch signaling would also be supported 
by the recent identification of a PKCθ-dependent mechanism that enhances Notch activation113. More 
experiments targeting Notch ligands in various cells types are required to determine how the Notch 
signaling pathway is activated in T cell subsets in vivo. 
Another concern is that some gain-of-function approaches, involving overexpression of Notch 
receptors or ligands, may be associated with strong or prolonged, less physiological Notch signals. 
In this context, it is interesting that variable Notch signal strength allows induction of distinct 
responses by the same signaling pathway530, 531, paralleling previous experiments demonstrating 
Th1 or Th2 cells are induced by strong or weak TCR signals, respectively532, 533. Therefore, in studies on 
the effects of Notch ligands on Th differentiation, it may be critical to use a range of antigen doses. 
Finally, since it has recently been shown that Th2 inflammation also crucially involves IL-4-producing 
Tfh cells34, 68, findings of impaired in vivo Th2 cell differentiation may point at Tfh rather than Th2 
defects and should therefore be interpreted with care.
Conclusions and future directions
Given the increasing number of characterized Th subsets, it is unlikely that Notch signaling simply 
acts as a bimodal molecular switch for the induction of either Th1 and Th2 differentiation, based on 
DLL and Jagged expression on DCs, respectively. Nevertheless, many studies described above support 
the notion that individual Notch ligands have differential effects on T helper cell differentiation, 
which cannot be explained by the unbiased amplifier model. The two models, however, may not 
necessarily be mutually exclusive. Effects of Notch signaling could be quite different during induction 
and during maintenance of Th subset differentiation. Moreover, the finding that there is quite some 
plasticity between Th subsets24 and that Th2 differentiation may involve a Tfh phase has further 
complicated the role of Notch signaling in Th differentiation. We also conclude that the elucidation 
of the role of Notch ligands on particular cell types requires comprehensive in vivo studies, using cell-
specific knockout of individual Notch ligands or combinations. 
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What ligand on which cell type is required for Notch-mediated Th2 cell
inflammation in an HDM-mediated model for allergic airway inflammation? 
A noticeable amount of evidence supports an instructive model whereby allergens direct 
differentiation of Th1 and Th2 cells via upregulation of DLL or Jagged ligands on APCs, respectively 
(Chapter 8). Nevertheless, we did not find any evidence for a role for the Notch ligand Jagged on DCs, 
alveolar macrophages, fibroblastic reticular cells, B cells and T cells (Chapter 3 and 6), although we 
found considerable Jagged expression on DCs and lymph node fibroblastic reticular cells. This suggests 
redundancy of Notch ligand expression on other cell types or redundancy with other Notch ligands. 
Given the increasing number of characterized Th subsets and the increasing number of studies that 
show plasticity of these T helper subsets455, it seems unlikely that Notch signaling just acts as a 
bimodal instructor of either Th1 and Th2 differentiation based on the presented ligand. Our findings 
that Notch signaling has a function during a later phase in the Th2 cell response and that Notch 
mediates cytokine responsiveness of Th2 cells, add to the hypothesis that Notch acts as a unbiased 
amplifier of T helper cell responses in which Notch together with environmental triggers steers T 
helper cell differentiation. Finding which ligands on which cell types are involved in the Th2 response 
will be crucial to understand the mechanism of Notch-driven Th2 cell inflammation.
What distinct cellular responses are mediated by the different Notch ligands 
and how do different Notch ligands and Notch receptors induce distinct 
cellular responses in T cells, largely by the same signaling components?
The Notch signaling pathway is a relatively simple pathway containing a limited amount of signaling 
components. As described in chapter 8, little is known about how the 5 different Notch ligands in 
combination with the 4 different Notch receptors induce distinct cellular responses in T cells, largely 
by the same signaling components. In addition, it is unclear how the distribution of expression of 
different Notch ligands and receptors on different cell types and tissue compartments contributes to 
the type of interactions and cellular responses. The instructive model implies that different Notch 
ligands induce distinct cellular responses in T cells while the unbiased amplifier simply suggests that 
all ligands can induce T helper cell differentiation. Evidence suggests that different ligands might 
induce qualitatively different signals or signals that differ in strength or kinetics524. Also, ligands 
might preferentially bind to Notch receptors depending on the glycosylation status of the extracellular 
domain of the Notch receptor99. In addition, different Notch intracellular domains (NICDs) might 
have different target gene preferences525. It is therefore not unlikely that distinct ligand-receptor 
combinations can produce quantitatively or qualitatively distinct signals526 and could therefore have 
distinct functions. A better understanding of the molecular mechanisms involved in the different 
ligand-receptor interactions in various T cell subsets will contribute to the understanding of the 
function of the different ligands during Notch signaling-mediated T helper cell differentiation and 
activation. 
In this thesis we showed that Notch signaling is required for Th2 cell-mediated allergic airway 
inflammation (AAI). We demonstrated this in mice lacking either RBPJκ or both Notch1 and Notch2 
specifically in T cells and by using the synthetic, cell-permeable stabilized peptide SAHM1 to target 
protein-protein interfaces in the Notch transactivation complex (Chapter 3-5). In addition, we found 
that AAI, induced by HDM, develops independently of the Notch ligand Jagged on DCs, alveolar 
macrophages, fibroblastic reticular cells, B cells and T cells (Chapter 3 and 6). Our experiments further 
provide evidence that Notch signaling was not required for the initiation of Th2 cell differentiation 
or proliferation during the sensitization phase, but was needed to promote or maintain Th2 cell-
mediated inflammation upon repeated exposure to house-dust mite (HDM). Transcriptional as 
well as flow cytometric analyses of Th2 cells from WT and Notch-deficient mice revealed that Notch 
signaling has a function in lymphocyte adhesion and responsiveness to cytokines (Chapter 5). Lastly, 
we characterized Th2 cells from asthmatic patients and healthy subjects in detail. We found that 
frequencies of Notch1 and Notch2 positive memory T cells were increased in peripheral blood from 
asthma patients with low asthma control. This correlated with the expression of the prostaglandin 
DP2 receptor CRTH2 on Th2 cells (Chapter 7). The data described in this thesis do not only indicate that 
targeting of the Notch signaling pathway is a promising therapeutic approach for asthma patients, 
but also provide new questions for future research on the function of Notch signaling during Th2 cell-
mediated inflammation in allergic asthma. 
Outstanding questions
- What ligand on which cell type is required for Notch-mediated Th2 cell inflammation in an HDM-mediated 
model for allergic airway inflammation?
- What distinct cellular responses are mediated by the different Notch ligands and how do different Notch 
ligands and Notch receptors induce distinct cellular responses in T cells, largely by the same signaling 
components?
- Via what mechanism does Notch signaling support migration of Th2 cells from the lymph nodes to the 
lungs?
- In which phase of HDM-mediated allergic airway inflammation is Notch signaling required most?
- Via which mechanisms does Notch signaling enhance differentiation and inflammation of other (non-
Th2) T helper cell subsets?
- Can the Notch inhibitor SAHM1 reduce airway inflammation and alleviate symptoms in patients with 
allergic asthma?
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Can the Notch inhibitor SAHM1 reduce airway inflammation 
and alleviate symptoms in patients with allergic asthma?
Assembly of the NICD-MAML-RBPJκ nuclear complex can effectively be 
prevented by the synthetic Notch inhibitor SAHM1. We found that treating mice 
intranasally with the Notch inhibitor SAHM1 during only the challenge phase 
of our HDM-driven model for AAI is sufficient to abolish Th2 cell inflammation, 
eosinophilia and bronchial hyperreactivity (Chapter 4). Importantly, our finding 
that inhibiting Notch signaling can reduce already established AAI is a strong 
indicator that patients with allergic asthma could benefit from an inhaled 
Notch inhibitor such as SAHM1. We found increased proportions of Notch1+ 
and Notch2+ memory CD4+ T cells and Th2 cells in peripheral blood from asthma 
patients (Chapter 7). Herein, we did not find differences between allergic and non-
allergic asthma patients. Since the percentage of Notch positive T cells was low 
and highly variable between patients it would be helpful to obtain information 
about Notch expression on CD4+ T cells in lungs or lymph nodes, which may be 
higher than in peripheral blood CD4+ T cells. In addition, when SAHM1 or other 
inhibitors of the Notch pathway would be tested as a therapeutic agent in asthma 
patients, the therapeutic effects in patients with high and low Notch expression 
should be compared. Such an analysis would reveal whether or not only patients 
with high Notch expression on CD4+ T cells would benefit from Notch inhibitors. 
In addition, since Notch signaling is a general pathway and not specific for T 
cells, the effects of SAHM1 on other cell types should be evaluated.
Altogether, we showed that Notch signaling is crucial during Th2 cell-mediated 
AAI in an HDM-driven model for AAI and we found increased proportions of 
Notch1+ and Notch2+ cells in the memory CD4+ T cell and Th2 cell populations from 
asthmatic patients. Therefore, we conclude that the Notch signaling pathway is 
a promising therapeutic target for patients with asthma.
Via what mechanism does Notch signaling support migration of Th2 cells 
from the lymph nodes to the lungs and in which phase of HDM-mediated 
allergic airway inflammation is Notch signaling required most?
Previous in vitro experiments have shown that Notch signaling can directly induce transcription of 
the Il4 and Gata3 genes93, 129, 130. In contrast, our experiments indicate that there is no crucial role for 
Notch signaling during the induction of proliferation or cytokine production of Th2 cells, although 
Gata3 expression was reduced in the absence of Notch signaling. Moreover, Notch signaling was 
necessary during the challenge phase of AAI and mediated lymph node egress of Th2 cells, adhesion 
and cytokine responsiveness (Chapter 4 and 5). Together, these data provide a new perspective on the 
role of Notch signaling in T helper differentiation. Our findings suggest that Notch signaling does 
not induce Th2 cell differentiation independent of STAT6, but instead steers Th2 cell differentiation 
together with cytokines and mediates lymph node egress of Th2 cells. Investigating which factors 
(cytokines or Notch signaling) induce Th2 cell differentiation requires a range of complex experiments 
that comprises experiments that block Notch signaling together with IL-4 during the priming of Th2 
cells. In addition, it would be helpful to measure a range of time points after one or multiple allergen 
challenges to find at what time point Notch signaling is most required for which processes during the 
Th2 cell lifespan. This is complex, since it is well possible that the function of Notch signaling during 
Th2 cell differentiation differs per type of model and stimulus and whether experiments are performed 
in vitro or in vivo.
Via which mechanisms does Notch signaling enhance differentiation and 
inflammation of other (non-Th2) T helper cell subsets?
Notch signaling was not only described to induce differentiation of Th2 cells, but also for the 
differentiation of multiple T helper cell subsets (as described in detail in Chapters 1 and 8). These include 
Th1 cells, since the Th1 genes Ifng and Tbx21 were identified as direct Notch targets135, 136. Moreover, 
Notch signaling cooperates with TGF-β to induce Th9 cell differentiation and IL-9 expression138 and 
the promoter regions of the Th17 cell-associated Rorc, Il17 and Il23r genes are identified as direct 
Notch targets139-143. Also, the key Treg transcription factor Foxp3 is a direct Notch target. Lastly, 
Notch signaling is required for the differentiation of Tfh cells147, 148. To our knowledge, it has not 
been established if Notch signaling is actually required for the early transcriptional program during 
initiation of differentiation of Th1 cells, Th9 cells, Th17 cells, Tregs and Tfh cells. Since we found that 
Notch signaling is mainly required during a later phase of the Th2 cell response, it is possible that the 
Notch function is similar during immune responses mediated by other T helper cell subsets. Since 
Notch signaling could be a potential therapeutic target in many CD4+ T cell-driven diseases, it would 
be helpful to better understand the mechanisms involved in function or control of Notch signaling in 
these cells.
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Asthma is a chronic heterogeneous respiratory disease characterized by episodes of airway inflammation, 
bronchoconstriction, airway hyperreactivity and increased mucus production. It is estimated that 
worldwide over 300 million people have asthma. Since a major subgroup of asthma patients do not 
establish disease control using the currently prescribed medical treatment, it is important to develop 
new therapeutic approaches to treat patients. Allergic asthma is the most prevalently occurring type of 
asthma and is typically characterized by eosinophilia and T helper 2 (Th2) cell-mediated inflammation. 
Allergic asthma is triggered by inhaled allergens such as house-dust mite (HDM) that activate dendritic 
cells (DCs). These cells present the allergens to naïve T cells in the draining lymph nodes, which initiates 
Th2 cell differentiation. Th2 cells have a central role in the development of allergic asthma, since they 
typically produce the cytokines IL-4, IL-5 and IL-13 that explain many hallmarks of allergic asthma by 
inducing IgE production by plasma cells, eosinophilia and smooth muscle hyperreactivity and mucus 
production by goblet cells, respectively. Moreover, type 2 innate lymphoid cells (ILC2) contribute to the 
Th2 response in allergic asthma by producing IL-5 and IL-13 in response to epithelial pro-inflammatory 
cytokines such as TSLP, IL-25 and IL-33 (Chapter 1). 
It was observed that depending on cytokine signals naïve T helper cells can differentiate into multiple T 
helper cell lineages including - in addition to Th2 cells - Th1, Th2, Th9, Th17, T follicular helper (Tfh) and 
T regulatory (Treg) cells. Each T helper cell subset is identified by a unique cytokine production profile 
and a key transcription factor (Chapter 1). Th2 cells express the key transcription factor Gata3, which 
controls expression of IL-4, IL-5 and IL-13. Moreover, Gata3 is required for T cell development as well as 
ILC2 development and function (Chapter 2). While Th2 cells are the main producers of IL-4, these cells are 
induced in response to IL-4 via signal transducer and activator of transcription 6 (STAT6) signaling. The 
initiation of Th2 cell differentiation via the IL-4/STAT6 axis is therefore suggestive of an autocrine loop and 
the origin of the initial IL-4 that induces Th2 cell differentiation remains unclear.
It was shown that expression of Gata3 and IL-4 can be directly regulated by Notch signaling. The highly 
conserved Notch signaling pathway mediates cell-cell contact-dependent signaling that regulates 
cell proliferation, apoptosis and a broad array of cell fate decisions in immune cell development and 
differentiation. Differentially expressed Notch ligands endow differentiation of naïve CD4+ T helper cells: 
Delta-like (DLL) and Jagged ligands were shown to induce Th1 and Th2 differentiation, respectively. Notch 
signaling leads to the activation of a nuclear DNA-binding complex that contains recombination-signal-
binding protein for immunoglobulin Jκ region (RBPjκ). In chapter 3 of this thesis, we investigated the role 
of Notch signaling and Jagged ligands in allergic asthma using mice lacking Jagged ligands on DCs or mice 
lacking RBPJκ specifically in T cells. We induced allergic airway inflammation (AAI) by sensitizing and 
challenging mice intranasally with HDM. We show that HDM exposure promoted the expression of Jagged1, 
but not Jagged2, on DCs. Mice lacking Jagged1, Jagged2 or both of these Notch ligands specifically in 
DCs developed AAI characterized by eosinophilia and Th2 cell activation that was not different from the 
eosinophilic airway inflammation in wild-type (WT) control littermates. Importantly, RBPJκ-deficient 
mice failed to develop AAI and airway hyperreactivity. Therefore, our results demonstrate that the Notch 
signaling pathway in T cells is essential for inducing Th2-mediated AAI in a HDM-driven asthma model, 
while the expression of the Notch ligands Jagged1 and Jagged2 on DCs is dispensable.
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required for Th2 cell mediated inflammation, or alternatively other Notch ligands 
such as DLL1 have the capacity to support Th2 cell-mediated responses.
A subgroup of asthma patients is unable to control their disease using 
corticosteroids. It is therefore important to obtain knowledge about the 
immunological differences between steroid-controlled and uncontrolled asthmatic 
patients to develop additional therapeutic approaches for asthma. Because of 
the evidence that Notch signaling is required during Th2 inflammation in AAI in 
mice, we questioned whether Notch expression is altered on Th2 cells in allergic 
asthma patients. In chapter 7, we performed flow-cytometry on peripheral blood 
mononuclear cells from asthmatic patients and healthy subjects. We found 
increased proportions of Notch1 and Notch2 expressing cells especially within the 
population of memory CD4+ T cells from asthma patients with low asthma control. In 
addition, we performed genome-wide expression profiling of Th2 cells and identified 
several genes involved in lymphocyte activation that were higher expressed in Th2 
cells from asthma patients than in healthy controls. Moreover, we identified many 
genes that were expressed at a lower level in Th2 cells from asthma patients than 
in healthy individuals, including genes involved in the activation of JUN kinase and 
in apoptosis. A fraction of these genes correlated with lung function (Chapter 7). 
The differentially expressed genes that we identified, together with the clinical 
phenotype of patients, may be useful in the future to classify patients and to predict 
the type of therapy they might respond to.
In summary, we found that Notch signaling is required for Th2 cell-mediated AAI in 
an HDM-driven model for AAI. Also, we showed that Notch expression was increased 
on memory T cells from asthmatic patients, which suggests that targeting the 
Notch signaling pathway is a promising therapeutic approach for asthma patients.
Our findings that Notch signaling via RBPJκ in T cells is crucial for the induction of AAI, indicates that the 
Notch signaling pathway is a potential therapeutic target in allergic asthma. To investigate this, we treated 
HDM-exposed mice with the cell-permeable inhibitor stapled α-helical peptide derived from mastermind-
like 1 (SAHM1) to target protein-protein interfaces in the Notch transactivation complex. Also, we 
investigated whether blocking Notch signaling is essential during the sensitization or during the challenge 
phase. Interestingly, SAHM1 treatment during only the challenge phase significantly reduced eosinophil 
numbers and decreased Th2 cell-mediated AAI in bronchoalveolar lavage, compared with control peptide-
treated mice (Chapter 4). Also, SAHM1 therapy reduced serum IgE levels. Therapeutic intervention of Notch 
signaling by SAHM1 is therefore an appealing new topical treatment opportunity for asthmatic patients.
Since we found that inhibiting Notch signaling was mainly effective during the challenge phase, we wanted 
to further explore the function of the Notch receptors in Th2 cell inflammation. In chapter 5, we therefore 
exposed mice lacking either Notch1 or Notch2 or both receptors on T cells to acute and chronic house-
dust mite (HDM)-driven models, as well as ovalbumine (OVA)-mediated models for AAI. Also, we assessed 
whether the lack of Notch1 and/or Notch2 can be rescued by enforced expression of Gata3. Although 
HDM exposure induced AAI in wild-type (WT) animals, conditional deletion of both Notch1 and Notch2 
in T helper cells prevented development of eosinophilic airway inflammation, Th2 cytokine production, 
induction of serum IgE levels and airway hyperreactivity. Surprisingly, Gata3 overexpression in Notch-
deficient T cells only partially rescued HDM-driven Th2 cell-driven AAI. Therefore, we questioned what 
other functions Notch signaling has during Th2 cell-mediated inflammation beyond the induction of 
Gata3. We found that Th2 cell polarization following sensitization to OVA and HDM was independent of 
Notch signaling. In contrast, Notch-deficient OVA-specific Th2 cells polarized in vitro showed reduced 
accumulation in the lung following transfer into wild-type mice that were subsequently exposed to OVA. 
Instead, we observed retention of Th2 cells in lung draining lymph nodes. We performed transcriptome 
analyses to identify genes that are controlled by Notch signaling in the context of AAI. Transcriptome 
comparisons of Notch-deficient and WT Th2 cells from lymph nodes revealed 692 differentially expressed 
genes, including genes encoding adhesion molecules, cytokines and cytokine receptors. Therefore we 
conclude that in a HDM-driven asthma model, Notch signaling in T cells is essential in AAI for efficient 
cytokine responsiveness, cell adhesion and migration of Th2 cells, in particular for lymph node egress. 
We have shown that mice lacking RBPjκ or the Notch1 and Notch2 receptors or mice that were treated 
with the inhibitory peptide SAHM1 to target the Notch transactivation complex failed to generate Th2 
responses or eosinophilia in acute and chronic HDM-driven AAI mouse models (AAI) (Chapter 3-5). In 
contrast, we showed that mice lacking Jagged expression specifically on DCs still developed Th2 cell-
mediated AAI (Chapter 3). In chapter 6 we therefore investigated the role and function of the expression of 
the Jagged1 and jagged2 Notch ligands on B cells, lymph node follicular reticular cells (FRCs) and T cells. 
We demonstrated that although Notch ligand expression is induced in FRCs in the lymph nodes upon HDM 
stimulation, neither Jagged1 nor Jagged2 expressed on CCL19+ FRC is required for the induction of AAI 
(Chapter 6). Also, Notch ligand expression on CD4+ T cells was low and not required for the induction of AAI. 
We therefore conclude that the expression of the Notch ligands Jagged1 and Jagged2 on FRC, DCs or T 
cells is not critical for HDM-driven AAI in vivo. Lastly, intranasal blockade of DLL4 did not alter eosinophilia 
or Th2 cell-driven airway inflammation. We therefore hypothesize that either Jagged on other cells is 
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Astma is een heterogene chronische longziekte die gepaard gaat met ontsteking van de luchtwegen, 
luchtwegvernauwing, hyperreactiviteit van de luchtwegen en verhoogde slijmproductie. Wereldwijd zijn er 
ongeveer 300 miljoen mensen die lijden aan astma. Een deel van deze patiënten heeft nog steeds klachten 
ondanks het gebruik van ontstekingsremmende medicatie. Daarom is het nodig om op zoek te gaan naar 
nieuwe manieren om astmapatiënten te behandelen. Allergische astma is de meest voorkomende vorm 
van astma en wordt veroorzaakt doordat dendritische cellen allergenen zoals huisstofmijt herkennen in 
de luchtwegen en hiermee T cellen activeren. Na activatie door dendritische cellen ontwikkelen T cellen 
zich tot een specifieke soort T cellen, de zogenaamde T helper 2 (Th2) cellen. Th2 cellen produceren 
ontstekingsbevorderende eiwitten (cytokines IL-4, IL-5 en IL-13) die verantwoordelijk zijn voor het 
aantrekken van eosinofielen (een type ontstekingscellen dat kenmerkend is voor allergische astma), het 
verhogen van de slijmproductie door slijmbekercellen en hyperreactiviteit van glad spierweefsel (Hoofdstuk 1). 
Er bestaan ook andere soorten T cellen, namelijk Th1 cellen, Th9 cellen, Th17 cellen, T folliculaire helper 
cellen en regulatoire T cellen. Iedere soort T helper cel heeft een specifieke functie en wordt gekarakteriseerd 
door de productie van een uniek profiel van cytokines, dat gereguleerd wordt door een zogenaamde 
transcriptiefactor (Hoofdstuk 1). Th2 cellen hebben de belangrijke transcriptiefactor Gata3 die cruciaal is 
voor de ontwikkeling van T cellen en ook voor de productie van de cytokines IL-4, IL-5 en IL-13. In hoofdstuk 2 
hebben we literatuuronderzoek gedaan naar de functie van Gata3 in de ontwikkeling en het functioneren van 
het afweersysteem. Terwijl Th2 cellen de voornaamste cellen zijn die IL-4 produceren is IL-4 ook nodig voor 
de ontwikkeling van Th2 cellen zelf. Dit betekent dat de ontwikkeling van Th2 cellen afhankelijk is van een stof 
die deze cellen zelf produceren. Het is onduidelijk wat de bron is van de initiële IL-4 die de ontwikkeling van 
Th2 cellen induceert.
Onderzoekers hebben gevonden dat signalering via Notch receptoren op T cellen direct kan leiden tot 
verhoging van Gata3 in T helper cellen en de productie van IL-4. De Notch signaleringsroute is een evolutionair 
geconserveerde route die belangrijk is voor de ontwikkeling van veel soorten afweercellen. Als een ligand 
voor Notch aan de Notch receptor bindt dan ontstaat er een reactie waarbij er in de T cel een eiwitcomplex 
wordt gevormd dat zorgt voor een verhoging van de aanmaak van diverse eiwitten waaronder Gata3 en IL-4. 
Dit eiwitcomplex bevat de transcriptie regulator RBPJκ. Wij hebben onderzocht wat de functie is van Notch 
signalering tijdens het ontstaan van astma door muizen te genereren die specifiek de RBPJκ regulator 
missen in T cellen. Hierdoor zijn er in deze T cellen geen effecten meer van Notch signalering. Deze muizen 
hebben we in een astmamodel herhaaldelijk blootgesteld aan huisstofmijt. Hierdoor ontstaat normaal 
gesproken een allergische ontsteking in de longen en luchtwegvernauwing, maar muizen zonder RBPJκ in T 
cellen ontwikkelen geen van deze astma verschijnselen (Hoofdstuk 3). Er bestaan twee verschillende soorten 
liganden voor Notch receptoren, namelijk Delta en Jagged. In de literatuur is beschreven dat het ligand Delta 
kan zorgen dat T cellen zich kunnen ontwikkelen tot Th1 cellen, terwijl Jagged ervoor zorgt dat T cellen zich 
kunnen ontwikkelen tot Th2 cellen. Deze bevindingen waren vooral gebaseerd op celkweek experimenten 
en de rol van deze verschillenden liganden bij allergische astma was onduidelijk. Wij hebben in hoofdstuk 3 
onderzocht of Jagged op dendritische cellen belangrijk is voor de ontwikkeling van allergische astma. In ons 
astma muismodel vonden we dat de expressie van Jagged op het celopperval van dendritische cellen omhoog 
ging nadat muizen werden blootgesteld aan huisstofmijt. Door gebruik te maken van muizen zonder Jagged 
Ne
de
rla
nd
se
 
sa
m
en
va
tt
in
g
211210
SAHM1 nauwelijks astma ontwikkelen. Maar, we vonden ook dat muizen zonder het 
Notch ligand Jagged op dendritische cellen wel nog steeds astma ontwikkelden. 
Daarom onderzochten we de mogelijkheid dat Jagged belangrijk zou kunnen zijn op 
andere cellen dan dendritische cellen (Hoofdstuk 6). We vonden dat stromale cellen 
(steuncellen) in de lymfeklieren Jagged tot expressie brengen en dat de hoeveelheid 
Jagged verhoogd was als muizen werden blootgesteld aan huisstofmijt. Maar we 
vonden dat Jagged op deze lymfeklier stromale cellen niet noodzakelijk was voor de 
ontwikkeling van allergisch astma in de muis. Daarnaast hebben we aanwijzingen 
verkregen dat Jagged ook niet belangrijk is op alveolaire macrofagen, T cellen of 
B cellen. Deze uitkomsten suggereren dat de liganden die nodig zijn om Notch 
signalering in T cellen aan te zetten zich bevinden op andere cellen of dat het ligand 
Delta belangrijk is voor het aanzetten van de Notch signaleringsroute in T cellen.
Een subgroep van allergische astmapatiënten blijft klachten houden ondanks 
het gebruik van ontstekingsremmende medicatie. Daarom is de bevinding in 
ons muismodel dat een specifieke Notch remmer verschijnselen van allergische 
ontsteking kan verminderen, met name werkt als muizen al allergische 
luchtwegontsteking hebben ontwikkeld, van groot belang. Het maakt het namelijk 
aannemelijk dat het blokkeren van de Notch signaleringsroute ook bij astmapatiënten 
zou kunnen leiden tot een vermindering van astmasymptomen. Daarom hebben we T 
cellen in bloed onderzocht op de aanwezigheid van Notch receptoren. Hierbij vonden 
we dat het percentage van de T helper cellen dat Notch receptoren op hun oppervlak 
heeft bij astmapatiënten hoger is dan bij gezonde mensen. Daarnaast was de fractie 
Notch-positieve T helper cellen meer verhoogd in patiënten die slecht reageren op 
ontstekingsremmende medicatie dan bij patiënten waarbij de astmaverschijnselen 
goed onder controle te houden zijn met medicatie (Hoofdstuk 7). We hebben de 
Th2 cellen van astmapatiënten ook genoom-wijd in detail gekarakteriseerd om 
te onderzoeken of er nog meer verschillen zijn in Th2 cellen van astmapatiënten 
vergeleken met gezonde mensen. Hierbij hebben we verschillende genen gevonden 
die in sterkere mate actief zijn in Th2 cellen van astmapatiënten. Een aantal van deze 
genen is betrokken bij de activatie van T helper cellen en sommige van deze genen 
correleerden met een verminderde longfunctie. Toekomstig onderzoek moet uitwijzen 
of deze genen een voorspellende waarde kunnen hebben voor het ziektebeloop 
van astmapatiënten of dat deze genen een aanknopingspunt kunnen zijn voor de 
ontwikkeling van nieuwe medicijnen tegen astma. 
Samenvattend hebben we gevonden dat de Notch signaleringsroute belangrijk is bij 
een Th2 cel-afhankelijk muismodel voor allergische astma gebaseerd op herhaalde 
blootstelling aan huisstofmijt. Daarnaast hebben we gevonden dat bij astmapatiënten 
de fractie van Notch-positieve T helper cellen in het bloed verhoogd is. Daarom is de 
Notch signaleringsroute een potentieel aangrijpingspunt voor toekomstige therapie.
op het celoppervlak van hun dendritische cellen, konden we echter aantonen dat Jagged op dendritische 
cellen niet nodig is voor het ontstaan van een ontstekingsreactie in de longen. We vonden namelijk in 
deze muizen vergelijkbare aantallen ontstekingscellen in de longen als in muizen die wel Jagged op hun 
dendritische cellen hadden. Onze resultaten laten daarom zien dat de Notch signaleringsroute in T cellen 
cruciaal is voor de ontwikkeling van allergische astma in muizen, terwijl het ligand Jagged op dendritische 
cellen hiervoor niet nodig is.
Onze bevinding dat de Notch signaleringsroute in T cellen nodig is voor het ontstaan van allergische astma 
in muizen suggereert dat Notch een aangrijpingspunt kan zijn voor de behandeling van allergische astma. 
Om dit te testen hebben we muizen behandeld met SAHM1, een remmer van RBPJκ, waardoor de Notch 
signaleringsroute niet meer effectief is. We vonden dat muizen die behandeld waren met SAHM1 geen astma 
meer ontwikkelden. We konden namelijk vaststellen dat het aantal eosinofielen en Th2 cellen in de longen 
verlaagd was en dat deze muizen verminderde IgE antistoffen in hun serum hadden. Deze antistoffen zijn 
kenmerkend voor een allergische immuunreactie. Het effect van het behandelen van de muizen met de 
Notch remmer was het sterkst tijdens herhaalde blootstelling aan huisstofmijt en niet in een vroege fase 
van de opbouw van allergie na de eerste blootstelling (Hoofdstuk 4). De bevindingen dat de Notch remmer 
met name werkt als muizen al astmaverschijnselen hebben, betekent dat het blokkeren van Notch ook bij 
astmapatiënten zou kunnen leiden tot een vermindering van astmasymptomen.
Omdat we hadden gevonden dat het blokkeren van de Notch signaleringsroute in allergische astma vooral 
effectief was tijdens een latere fase van de ziekte, na herhaaldelijke blootstelling aan huisstofmijt allergeen, 
wilden we vervolgens weten wat het onderliggende mechanisme is. Om dit te onderzoeken hebben we gebruik 
gemaakt van muizen die geen Notch receptoren op hun T cellen hebben. Deze muizen werden blootgesteld 
aan astmamodellen met huisstofmijt of het eiwit ovalbumine als allergeen. Daarnaast hebben we Notch-
deficiënte muizen gekruist met muizen die verhoogd Gata3 eiwit in hun T cellen hebben, om te onderzoeken 
of verhoogde expressie van Gata3 het effect van verminderde Notch expressie op kan heffen. We vonden dat 
muizen zonder expressie van Notch receptoren op T cellen - net als RBPJκ deficiënte muizen - geen astma 
ontwikkelen. Muizen zonder Notch receptoren op T cellen maar met verhoogd Gata3 in T cellen hadden maar 
een lichte verhoging van allergische ontsteking in de longen. Dit betekent dat Notch signalering tijdens 
Th2 cel-gemedieerd astma niet alleen werkt via verhoging van de hoeveelheid Gata3, maar ook via andere 
mechanismes. In verder onderzoek vonden we dat Notch signalering niet nodig is voor de initiële activatie 
van T cellen bij de eerste allergeenblootstelling, maar dat Notch signalering wel nodig is tijdens een latere 
fase van de afweerreactie (wanneer allergische symptomen zichtbaar worden na herhaaldelijke allergeen 
blootstelling). We hebben namelijk gemeten dat de afwezigheid van Notch bij al geactiveerde Th2 cellen 
leidt tot een ophoping van Th2 cellen in de lymfeklieren en een verminderde hoeveelheid Th2 cellen in de 
longen. Dit is een sterke aanwijzing dat Th2 cellen die gevormd worden in de lymfeklier afhankelijk zijn van 
Notch signalering om op een efficiënte manier de lymfeklier te verlaten. Met een uitgebreide analyse van 
de verschillen tussen Th2 cellen met Notch receptoren en Th2 cellen zonder Notch receptoren hebben 
we gevonden dat Notch ervoor zorgt dat Th2 cellen beter kunnen reageren op cytokines en beter kunnen 
migreren naar andere weefsels (Hoofdstuk 5). 
In hoofdstuk 3 tot en met 5 hebben we aangetoond dat muizen die Notch receptoren of de Notch-
geassocieerde transcriptiefactor RBPJκ missen in hun T cellen of muizen die behandeld worden met 
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AAI Allergic airway inflammation
ACQ Asthma control questionaire
ADAM A disintegrin and metalloproteinases
AHR Airway hyperreactivity
AGM Aorta-gonad-mesonephros
APC Antigen presenting cell
BAL Bronchoalveolar lavage
BATF3 Basic Leucine Zipper ATF-Like Transcription Factor 3
BCL B-cell lymphoma protein
BEC Blood endothelial cells
BHR Bronchial hyperreactivity
BM Bone marrow
bmDCs Bone marrow-derived dendritic cells
CA Controlled asthma
CCL Chemokine (C-C motif) ligand
CCR C-C chemokine receptor
CD Cluster of differentiation
cDC Conventional DC
CFSE Carboxyfluorescein succinimidyl ester
Chd4 Chromodomain helicase DNA binding protein 4
Chip Chromatin immunoprecipitation
CLP Common lymphoid progenitor
CMP Common myeloid progenitor
CRTH2 Chemoattractant homologous receptor expressed on TH2 cells
CTCF CCCTC-binding factor
CXCR C-X-C chemokine receptor
DC Dendritic cell
DE Differentially expressed
Derp Dermatophagoides pteronyssinus
DHS DNAse I hypersensitive site
DLL Delta-like ligand
DMSO Dimethylsulfoxide
DN Double-negative
DNA Deoxyribonucleic acid
DP Double-positive
DTR Diphtheria toxin receptor
EAE Experimental autoimmune encephalomyelitis
Ebf1 Early B cell factor-1
ELISA Enzyme-linked immunoasorbent assay
Eomes Eomesodermin
ETP Early thymic progenitors
EYFP Enhanced yellow fluorescent protein
FACS Fluorescence-activated cell sorting
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Nfil3 Nuclear-factor interleukin-3 related
NICD Notch intracellular domain
NK Natural killer
NO Nitric Oxide
OVA Ovalbumin
PA Partly controlled asthma
PAS Periodic acid-Schiff
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
pDC Plasmacytoid DC
PGD2 Prostaglandin D2
PI3K Phosphatidylinositol 3-kinase
PMA Phorbol 12-myristate 13-acetate
qRT-PCR Quantitative real-time PCR
RBPjκ  Recombination-signal-binding protein for immunoglobulin Jκ region
RELB V-rel avian reticuloendotheliosis viral oncogene homolog B
RNA Ribonucleic acid
Rorγt  Retinoic acid receptor-related orphan nuclear receptor gamma 
RPKM Reads Per Kilobase Million
RSV Respiratory syncytial virus
S1P Sphingosine-1-phosphate
S1PR Sphingosine-1-phosphate receptor
SATB Special AT-rich binding protein
Seq Sequencing
STAT Signal transducer and activator of transcription 
T-ALL T cell acute lymphoblastic leukemia
T-bet T-box-containing protein
TCR T cell receptor
TF Transcription factor
Tfh T follicular helper
Tg Transgene
Th T helper
TGF-β  Transforming growth factor beta 
TLR Toll-like receptor
TNF-α Tumor Necrosis Factor alpha 
TNP-KLH Tri-nitrophenol keyhole limpet hemagglutinin
Treg Regulatory T cell
TSLP Thymic stromal lymphopoietin
UA Uncontrolled asthma
WT Wild-type
YFP Yellow fluorescent protein
FeNO Exhaled nitric oxide
FEV1 Forced Expiratory Volume in the first second
Flt3L  FMS-like tyrosine kinase 3 ligand
Fog Friend of GATA
Foxp3 Forkhead box P3
FRC Fibroblastic reticular cells
GINA Global Initiative for Asthma
GM-CSF Granulocyte-macrophage colony-stimulating factor
GSI γ-secretase inhibitors
GWAS Genome-wide association studies
HAT Histone acetyltransferease
HC Healthy control
HDAC Histone deacetylase
HDM House-dust mite
HE Haematoxylin/eosin
Hes Hairy enhancer of split
HSC Hematopoietic stem cell
ICOS Inducible costimulatory
Id2 DNA-binding 2
IFA Incomplete Freund’s Adjuvant
Ig Immunoglobulin
IL Interleukin
ILC Innate lymphoid cells
i.n.  Intranasal
i.p. Intraperitoneal
i.t.  Intratracheal
i.v.  Intravenously
IFN Interferon
IRF Interferon-regulatory factor
Jg Jagged
LCMV Lymphocytic choriomeningitis virus
LCR Locus control region
LEC Lymphatic endothelial cells
LPS Lipopolysaccharide
LTi Lymphoid tissue-inducer
MAML1 Mastermind-like 1 
MAPK Mitogen-activated protein kinase
MedLN Mediastinal lymph node
MFI Mean fluorescent intensity
Mib Mindbomb
MoDC Monocyte-derived DC
MPP Multipotent progenitor
mTOR Mammalian target of rapamycin
N Notch
NECD Notch extracellular domain
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Irma Tindemans was born on November 7th 1989 in Breda, the Netherlands, and grew up in Mierlo. After 
completing her secondary education at the Strabrecht College in Geldrop in 2007, she studied Applied 
Sciences at Fontys University for Applied Sciences in Eindhoven. During her bachelor, she did an internship 
in the group of prof. Chris Franco at the Department of Medical Biotechnology at Flinders University of 
South Australia. Here she studied the production of antibiotics by actinobacteria isolated from barley and 
wheat. She performed her second internship in the Department of Pediatrics at Maastricht University in 
the group of prof. Boris Kramer, where she worked on the damaging effects of chorioamnionitis on the 
developing gut of preterm sheep. After obtaining her Bachelor of Applied Sciences degree in 2011, she 
was admitted to the research master program Infection and Immunity at Erasmus University Rotterdam. 
During the master program, she performed an internship in the Department of Immunology at Erasmus 
MC Rotterdam in the group of dr. Wim Dik. In this internship she studied interactions between mast 
cells and orbital fibroblasts in Graves’ Ophthalmopathy. She did her second internship in the group of dr. 
Janneke Samsom in the Laboratory of Pediatric Gastroenterology and Nutrition where she studied the 
immunological function of myofibroblasts in celiac disease. After her graduation in 2013, she started 
her PhD project in the group of prof. Rudi Hendriks in the Department of Pulmonary Medicine, Erasmus 
MC Rotterdam. In these PhD studies she investigated the function of Notch signaling in house-dust 
mite-driven T helper 2 cell-mediated allergic airway inflammation in mice as well as in peripheral blood T 
cells from allergic asthma patients. The results of her PhD project are described in this thesis and will be 
defended in May of 2018. In October of 2017, Irma returned to the laboratory of Pediatric Gastroenterology 
and Nutrition to work as a postdoc focusing on inflammatory markers in pediatric patients with 
inflammatory bowel disease.
Cu
rr
ic
ul
um
 
vi
ta
e
N
otch signaling during T helper 2 cell-m
ediated inflam
m
ation in allergic asthm
a - Irm
a Tindem
ans
Irma Tindemans
